Sila Realty Trust (SILA) 10-K 24 Mar 21 2020 FY Annual report Financial data

Cover

Cover - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Mar. 19, 2021	Jun. 30, 2020
Document Type	10-K
Document Annual Report	true
Current Fiscal Year End Date	--12-31
Document Period End Date	Dec. 31, 2020
Document Transition Report	false
Entity File Number	000-55435
Entity Registrant Name	SILA REALTY TRUST, INC.
Entity Incorporation, State or Country Code	MD
Entity Tax Identification Number	46-1854011
Entity Address, Address Line One	4890 West Kennedy Blvd.
Entity Address, Address Line Two	Suite 650
Entity Address, City or Town	Tampa
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33609
City Area Code	813
Local Phone Number	287-0101
Title of 12(g) Security	Common stock, par value $0.01 per share
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Documents Incorporated by Reference	Portions of Registrant’s proxy statement for the 2021 annual stockholders meeting, which is expected to be filed no later than April 30, 2021, are incorporated by reference in Part III. Items 10, 11, 12, 13 and 14.
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Central Index Key	0001567925
No Trading Symbol Flag	true
Class A
Entity Public Float			$ 1,433,644
Entity Common Stock, Shares Outstanding (in shares)		166,838
Class I
Entity Public Float			108,053
Entity Common Stock, Shares Outstanding (in shares)		12,766
Class T
Entity Public Float			337,933
Entity Common Stock, Shares Outstanding (in shares)		39,682
Class T2
Entity Public Float			$ 29,952
Entity Common Stock, Shares Outstanding (in shares)		3,427

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Real estate:
Land	$ 335,678	$ 343,444
Buildings and improvements, less accumulated depreciation of $197,134 and $128,304, respectively	2,338,914	2,422,102
Construction in progress	19,232	2,916
Total real estate, net	2,693,824	2,768,462
Cash and cash equivalents	53,174	69,342
Acquired intangible assets, less accumulated amortization of $90,730 and $64,164, respectively	246,761	285,459
Goodwill	39,529	0
Right-of-use assets - operating leases	29,751	29,537
Right-of-use assets - finance leases	2,527	0
Notes receivable, net	31,262	2,700
Other assets, net	108,461	84,034
Total assets	3,205,289	3,239,534
Liabilities:
Notes payable, net of deferred financing costs of $1,805 and $2,500, respectively	451,617	454,845
Credit facility, net of deferred financing costs of $5,900 and $7,385, respectively	932,100	900,615
Accounts payable due to affiliates	0	9,759
Accounts payable and other liabilities	80,246	45,354
Acquired intangible liabilities, less accumulated amortization of $13,924 and $12,332, respectively	52,560	59,538
Operating lease liabilities	32,050	31,004
Finance lease liabilities	2,843	0
Total liabilities	1,551,416	1,501,115
Stockholders’ equity:
Preferred stock, $0.01 par value per share, 100,000,000 shares authorized; none issued and outstanding	0	0
Common stock, $0.01 par value per share, 510,000,000 shares authorized; 234,957,801 and 231,416,123 shares issued, respectively; 222,045,522 and 221,912,714 shares outstanding, respectively	2,220	2,219
Additional paid-in capital	1,983,361	1,981,848
Accumulated distributions in excess of earnings	(311,264)	(240,946)
Accumulated other comprehensive loss	(20,444)	(4,704)
Total stockholders’ equity	1,653,873	1,738,417
Noncontrolling interests	0	2
Total equity	1,653,873	1,738,419
Total liabilities and stockholders’ equity	$ 3,205,289	$ 3,239,534

CONSOLIDATED BALANCE SHEETS (PA

CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Buildings and improvements, accumulated depreciation	$ 197,134	$ 128,304
Acquired intangible assets, accumulated amortization	90,730	64,164
Notes payable, deferred financing costs	1,805	2,500
Credit facility, deferred financing costs	5,900	7,385
Acquired intangible liabilities, accumulated amortization	$ 13,924	$ 12,332
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	100,000,000	100,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	510,000,000	510,000,000
Common stock, shares issued (in shares)	234,957,801	231,416,123
Common stock, shares outstanding (in shares)	222,045,522	221,912,714

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenue:
Rental revenue	$ 276,536	$ 210,901	$ 177,333
Expenses:
Rental expenses	43,533	40,984	37,327
General and administrative expenses	16,681	8,421	5,396
Internalization transaction expenses	3,640	0	0
Asset management fees	17,914	16,475	13,114
Depreciation and amortization	105,483	74,104	58,258
Impairment loss on real estate	0	21,000	0
Total expenses	187,251	160,984	114,095
Gain on real estate dispositions	3,142	79	0
Income from operations	92,427	49,996	63,238
Interest and other expense, net	55,651	47,214	34,365
Net income attributable to common stockholders	36,776	2,782	28,873
Other comprehensive (loss) income:
Unrealized (loss) income on interest rate swaps, net	(15,740)	(10,907)	2,390
Other comprehensive (loss) income	(15,740)	(10,907)	2,390
Comprehensive income (loss) attributable to common stockholders	$ 21,036	$ (8,125)	$ 31,263
Weighted average number of common shares outstanding:
Basic (in shares)	221,436,617	157,247,345	131,040,645
Diluted (in shares)	221,622,444	157,271,668	131,064,388
Net income per common share attributable to common stockholders:
Basic (in dollars per share)	$ 0.17	$ 0.02	$ 0.22
Diluted (in dollars per share)	$ 0.17	$ 0.02	$ 0.22

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-in Capital	Accumulated Distributions in Excess of Earnings	Accumulated Distributions in Excess of EarningsCumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive (Loss) Income	Accumulated Other Comprehensive (Loss) IncomeCumulative Effect, Period of Adoption, Adjustment	Total Stockholders’ Equity	Total Stockholders’ EquityCumulative Effect, Period of Adoption, Adjustment	Noncontrolling Interests
Balance, (in shares) at Dec. 31, 2017			124,327,777
Balance, beginning at Dec. 31, 2017	$ 990,551		$ 1,243	$ 1,084,905	$ (99,309)		$ 3,710		$ 990,549		$ 2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under the distribution reinvestment plan (in shares)			4,453,653
Issuance of common stock under the distribution reinvestment plan	40,938		$ 44	40,894					40,938
Issuance of common stock (in shares)			12,376,366
Issuance of common stock	118,605		$ 124	118,481					118,605
Issuance of common stock in connection with the REIT Merger	0
Vesting of restricted stock (in shares)			9,000
Common stock underlying awards	90			90					90
Commissions on sale of common stock and related dealer-manager fees	(4,836)			(4,836)					(4,836)
Distribution and servicing fees	(368)			(368)					(368)
Other offering costs	(3,643)			(3,643)					(3,643)
Repurchase of common stock (in shares)			(4,700,554)
Repurchase of common stock	(43,230)		$ (47)	(43,183)					(43,230)
Issuance of noncontrolling interests	0
Distributions to common stockholders	(81,985)				(81,985)				(81,985)
Other comprehensive (loss) income	2,390						2,390		2,390
Net income	28,873				28,873				28,873
Balance, (in shares) at Dec. 31, 2018			136,466,242
Balance, ending at Dec. 31, 2018	1,047,385	$ 0	$ 1,364	1,192,340	(152,421)	$ (103)	6,100	$ 103	1,047,383	$ 0	2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under the distribution reinvestment plan (in shares)			4,317,245
Issuance of common stock under the distribution reinvestment plan	39,934		$ 43	39,891					39,934
Issuance of common stock in connection with the REIT Merger (in shares)			83,676,775
Issuance of common stock in connection with the REIT Merger	774,010		$ 837	773,173					774,010
Vesting of restricted stock (in shares)			9,750
Common stock underlying awards	89			89					89
Distribution and servicing fees	563			563					563
Other offering costs	(578)			(578)					(578)
Repurchase of common stock (in shares)			(2,557,298)
Repurchase of common stock	(23,655)		$ (25)	(23,630)					(23,655)
Issuance of noncontrolling interests	1										1
Distributions to noncontrolling interests	(1)								0		(1)
Distributions to common stockholders	(91,204)				(91,204)				(91,204)
Other comprehensive (loss) income	(10,907)						(10,907)		(10,907)
Net income	$ 2,782				2,782				2,782
Balance, (in shares) at Dec. 31, 2019	221,912,714		221,912,714
Balance, ending at Dec. 31, 2019	$ 1,738,419		$ 2,219	1,981,848	(240,946)		(4,704)		1,738,417		2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under the distribution reinvestment plan (in shares)			3,531,178
Issuance of common stock under the distribution reinvestment plan	30,553		$ 35	30,518					30,553
Issuance of common stock in connection with the REIT Merger	0
Vesting of restricted stock (in shares)			10,500
Common stock underlying awards	437			437					437
Purchase of noncontrolling interest	(2)								0		(2)
Distribution and servicing fees	51			51					51
Other offering costs	(40)			(40)					(40)
Repurchase of common stock (in shares)			(3,408,870)
Repurchase of common stock	(29,487)		$ (34)	(29,453)					(29,487)
Issuance of noncontrolling interests	0
Distributions to common stockholders	(107,094)				(107,094)				(107,094)
Other comprehensive (loss) income	(15,740)						(15,740)		(15,740)
Net income	$ 36,776				36,776				36,776
Balance, (in shares) at Dec. 31, 2020	222,045,522		222,045,522
Balance, ending at Dec. 31, 2020	$ 1,653,873		$ 2,220	$ 1,983,361	$ (311,264)		$ (20,444)		$ 1,653,873		$ 0

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net income attributable to common stockholders	$ 36,776	$ 2,782	$ 28,873
Adjustments to reconcile net income attributable to common stockholders to net cash provided by operating activities:
Depreciation and amortization	105,476	74,104	58,258
Amortization of deferred financing costs	3,884	2,825	2,810
Amortization of above-market leases	2,467	1,013	552
Amortization of below-market leases	(7,147)	(5,261)	(4,832)
Amortization of origination fee	166	0	0
Amortization of discount of deferred liability	54	0	0
Reduction in the carrying amount of right-of-use assets - operating leases, net	963	577	0
Reduction in the carrying amount of right-of-use assets - finance lease, net	7	0	0
Gain on real estate dispositions	(3,142)	(79)	0
Impairment loss on real estate	0	21,000	0
Straight-line rent	(21,161)	(14,047)	(13,364)
Stock-based compensation	437	89	90
Ineffectiveness of interest rate swaps	0	0	98
Changes in operating assets and liabilities:
Accounts payable and other liabilities	(607)	2,214	5,151
Accounts payable due to affiliates	(3,350)	1,151	413
Other assets	(1,985)	(6,259)	(3,838)
Net cash provided by operating activities	112,838	80,109	74,211
Cash flows from investing activities:
Investment in real estate	(16,135)	(528,259)	(217,332)
Investment in the internalization transaction	(25,000)	0	0
Proceeds from real estate dispositions	28,542	2,882	0
Capital expenditures	(28,797)	(12,841)	(15,583)
Payments of deal costs	(126)	0	0
Real estate deposits, net	100	(100)	100
Net cash used in investing activities	(41,416)	(538,318)	(232,815)
Cash flows from financing activities:
Proceeds from issuance of common stock	0	0	118,605
Payments on notes payable	(3,923)	(10,441)	(349)
Proceeds from credit facility	140,000	605,000	155,000
Payments on credit facility	(110,000)	(52,000)	(20,000)
Payments of deferred financing costs	(715)	(6,351)	(4,958)
Repurchase of common stock	(29,487)	(23,655)	(43,230)
Offering costs on issuance of common stock	(3,099)	(4,146)	(12,388)
Distributions to common stockholders	(76,517)	(49,494)	(40,296)
Distributions to noncontrolling interests	0	(1)	0
Purchase of noncontrolling interests	(2)	0	0
Net cash (used in) provided by financing activities	(83,743)	458,912	152,384
Net change in cash, cash equivalents and restricted cash	(12,321)	703	(6,220)
Cash, cash equivalents and restricted cash - Beginning of year	80,230	79,527	85,747
Cash, cash equivalents and restricted cash - End of year	67,909	80,230	79,527
Supplemental cash flow disclosure:
Interest paid, net of interest capitalized of $669, $142 and $1,179, respectively	55,129	43,132	32,503
Supplemental disclosure of non-cash transactions:
Common stock issued through distribution reinvestment plan	30,553	39,934	40,938
Equity consideration transferred in the REIT Merger	0	774,010	0
Net assets assumed in the REIT Merger	0	778	0
Issuance of noncontrolling interests	0	1	0
Credit facility revolving loan to term loan conversion	0	30,000	0
Accrued capital expenditures	2,875	126	0
Accrued deal costs	0	139	0
Deferred internalization transaction purchase price	14,674	0	0
Right-of-use assets in exchange for lease liability - operating leases	1,060	22,266	0
Right-of-use assets in exchange for lease liability - finance lease	2,854	0	0
Origination of note receivable related to real estate disposition	$ 28,000	$ 0	$ 0

CONSOLIDATED STATEMENTS OF CA_2

CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICAL) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement of Cash Flows [Abstract]
Interest capitalized	$ 669	$ 142	$ 1,179

Organization and Business Opera

Organization and Business Operations	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Operations	Organization and Business Operations Sila Realty Trust, Inc., formerly known as Carter Validus Mission Critical REIT II, Inc., or the Company, is a Maryland corporation that was formed on January 11, 2013. The Company elected, and currently qualifies, to be taxed as a real estate investment trust, or a REIT, under the Internal Revenue Code of 1986, as amended, or the Code, for federal income tax purposes. Substantially all of the Company’s business is conducted through Sila Realty Operating Partnership, LP f/k/a Carter Validus Operating Partnership II, LP, a Delaware limited partnership, or the Operating Partnership, formed on January 10, 2013. The Company is the sole general partner and, prior to the completion of the Internalization Transaction (as defined herein) on September 30, 2020, Carter Validus Advisors II, LLC, or the Former Advisor, was the special limited partner of the Operating Partnership. As of the closing of the Internalization Transaction, the Company owns directly or indirectly, all of the interests in the Operating Partnership. Prior to September 30, 2020, the Former Advisor was responsible for managing the Company’s affairs on a day-to-day basis and for identifying and making investments on the Company’s behalf pursuant to an advisory agreement among the Company, the Operating Partnership and the Former Advisor. On July 28, 2020, the Company and the Operating Partnership, entered into a Membership Interest Purchase Agreement, or the Purchase Agreement, to provide for the internalization of the external management functions previously performed for the Company and the Operating Partnership by the Former Advisor and its affiliates, or the Internalization Transaction. On September 30, 2020, the Company closed the Internalization Transaction. Effective September 30, 2020, as a result of the Internalization Transaction, the Former Advisor is no longer affiliated with the Company. Upon completion of the Internalization Transaction, the Company’s 76 employees, who were previously employed by an affiliate of the Former Advisor, became employees of the Company and the functions previously performed by the Former Advisor were internalized by the Company. As an internally managed company, the Company no longer pays the Former Advisor and its affiliates any fees or expense reimbursements arising from the advisory agreement. In addition, on September 30, 2020, the Operating Partnership redeemed the Former Advisor’s limited partner interest (including special limited partner interest) in the Operating Partnership in connection with the Internalization Transaction. On September 30, 2020, the Company and Sila REIT, LLC, f/k/a Carter Validus Mission Critical REIT II, LLC, a Maryland limited liability company that is the sole limited partner of the Operating Partnership, entered into the Third Amended and Restated Agreement of Limited Partnership of the Operating Partnership, or the Third A&R LP Agreement, in order to reflect the completion of the Internalization Transaction. On September 30, 2020, Articles of Amendment changing the Company’s name from “Carter Validus Mission Critical REIT II, Inc.” to “Sila Realty Trust, Inc.” were filed and accepted for record by the State Department of Assessment and Taxation of the State of Maryland, and thereby became effective as part of the Company’s charter. The Company was formed to invest primarily in quality income-producing commercial real estate, with a focus on data centers and healthcare properties, preferably with long-term leases to creditworthy tenants, as well as to make other real estate-related investments in such property types, which may include equity or debt interests in other real estate entities. During the year ended December 31, 2020, the Company acquired three real estate properties and sold two real estate properties. See Note 4—"Acquisitions and Dispositions" for additional information. As of December 31, 2020, the Company owned 153 real estate properties. The Company raised the equity capital for its real estate investments through two public offerings, or the Offerings, from May 2014 through November 2018, and the Company has offered shares pursuant to its distribution reinvestment plan, or the DRIP, pursuant to two Registration Statements on Form S-3, or each, a DRIP Offering and together the DRIP Offerings, since November 2017. Except as the context otherwise requires, the “Company” refers to Sila Realty Trust, Inc., the Operating Partnership and all wholly-owned subsidiaries.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies The summary of significant accounting policies presented below is designed to assist in understanding the Company’s consolidated financial statements. Such consolidated financial statements and the accompanying notes thereto are the responsibility of management. These accounting policies conform to United States generally accepted accounting principles, or GAAP, in all material respects, and have been consistently applied in preparing the consolidated financial statements. Principles of Consolidation and Basis of Presentation The accompanying consolidated financial statements include the accounts of the Company, the Operating Partnership, and all wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements and accompanying notes in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates are made and evaluated on an ongoing basis using information that is currently available as well as various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates. Restricted Cash Restricted cash consists of restricted cash held in escrow and restricted bank deposits. Restricted cash held in escrow includes cash held by lenders in escrow accounts for tenant and capital improvements, taxes, repairs and maintenance and other lender reserves for certain properties, in accordance with the respective lender’s loan agreement. Restricted bank deposits consist of tenant receipts for certain properties which are required to be deposited into lender-controlled accounts in accordance with the respective lender's loan agreement. Restricted cash held in escrow and restricted bank deposits are reported in other assets, net, in the accompanying consolidated balance sheets. See Note 9—"Other Assets, Net." The following table presents a reconciliation of the beginning of year and end of year cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the totals shown in the consolidated statements of cash flows (amounts in thousands): Year Ended 2020 2019 2018 Beginning of year: Cash and cash equivalents 69,342 68,360 74,803 Restricted cash 10,888 11,167 10,944 Cash, cash equivalents and restricted cash $ 80,230 $ 79,527 $ 85,747 End of year: Cash and cash equivalents 53,174 69,342 68,360 Restricted cash 14,735 10,888 11,167 Cash, cash equivalents and restricted cash $ 67,909 $ 80,230 $ 79,527 Investment in Real Estate Real estate costs related to the acquisition, development, construction and improvement of properties are capitalized. Repair and maintenance costs are expensed as incurred and significant replacements and betterments are capitalized. Repair and maintenance costs include all costs that do not extend the useful life of the real estate asset. The Company considers the period of future benefit of an asset in determining the appropriate useful life. Real estate assets, other than land, are depreciated or amortized on a straight-line basis over each asset’s useful life. The Company anticipates the estimated useful lives of its assets by class as follows: Buildings and improvements 15 – 40 years Tenant improvements Shorter of lease term or expected useful life Furniture, fixtures, and equipment 3 – 10 years Allocation of Purchase Price of Real Estate Upon the acquisition of real properties, the Company evaluates whether the acquisition is a business combination or an asset acquisition. For both business combinations and asset acquisitions the Company allocates the purchase price of properties to acquired tangible assets, consisting of land, buildings and improvements, and acquired intangible assets and liabilities, consisting of the value of above-market and below-market leases and the value of in-place leases. For asset acquisitions, the Company capitalizes transaction costs and allocates the purchase price using a relative fair value method allocating all accumulated costs. For business combinations, the Company expenses transaction costs incurred and allocates the purchase price based on the estimated fair value of each separately identifiable asset and liability. During the year ended December 31, 2020, the Company acquired three real estate properties that were determined to be asset acquisitions. See Note 4—"Acquisitions and Dispositions" for additional information. Acquisition fees and costs associated with transactions determined to be asset acquisitions are capitalized in total real estate, net, acquired intangible assets and acquired intangible liabilities in the accompanying consolidated balance sheets. The fair values of the tangible assets of an acquired property (which includes land, buildings and improvements) are determined by valuing the property as if it were vacant, and the “as-if-vacant” value is then allocated to land and buildings and improvements based on management’s determination of the relative fair value of these assets. Management determines the as-if-vacant fair value of a property using methods similar to those used by independent appraisers. Factors considered by management in performing these analyses include an estimate of carrying costs during the expected lease-up periods considering current market conditions and costs to execute similar leases, including leasing commissions and other related costs. In estimating carrying costs, management includes real estate taxes, insurance, and other operating expenses during the expected lease-up periods based on current market conditions. The fair values of above-market and below-market in-place leases are recorded based on the present value (using an interest rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to the in-place leases and (ii) an estimate of fair market lease rates for the corresponding in-place leases, measured over a period equal to the remaining non-cancelable term of the lease including any fixed rate bargain renewal periods, with respect to a below-market lease. The above-market and below-market lease values are capitalized as intangible lease assets or liabilities. Above-market lease values are amortized as an adjustment of rental revenue over the remaining terms of the respective leases. Below-market leases are amortized as an adjustment of rental revenue over the remaining terms of the respective leases, including any fixed rate bargain renewal periods. If a lease were to be terminated prior to its stated expiration, all unamortized amounts of above-market and below-market in-place lease values related to that lease would be recorded as an adjustment to rental revenue. The fair values of in-place leases include an estimate of direct costs associated with obtaining a new tenant and opportunity costs associated with lost rentals that are avoided by acquiring an in-place lease. Direct costs associated with obtaining a new tenant include commissions, tenant improvements, and other direct costs and are estimated based on management’s consideration of current market costs to execute a similar lease. The value of opportunity costs is calculated using the contractual amounts to be paid pursuant to the in-place leases over a market absorption period for a similar lease. These lease intangibles are amortized to depreciation and amortization expense over the remaining terms of the respective leases. If a lease were to be terminated prior to its stated expiration, all unamortized amounts of in-place lease assets relating to that lease would be expensed. Impairment of Long-Lived Assets The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of its real estate and related intangible assets may not be recoverable. When indicators of potential impairment suggest that the carrying value of real estate and related intangible assets may not be recoverable, the Company assesses the recoverability of the asset group by estimating whether the Company will recover the carrying value of the asset group through its undiscounted future cash flows and their eventual disposition. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of the asset group, the Company will record an impairment loss to the extent that the carrying value exceeds the estimated fair value of the asset group. When developing estimates of expected future cash flows, the Company makes certain assumptions regarding future market rental rates subsequent to the expiration of current lease arrangements, property operating expenses, terminal capitalization and discount rates, probability weighting of the potential re-lease of the property versus sales scenarios, sale prices of comparable properties, required tenant improvements and the number of years the property will be held for investment. The use of alternative assumptions in the future cash flow analysis could result in a different determination of the property’s future cash flows and a different conclusion regarding the existence of an impairment, the extent of such loss, if any, as well as the carrying value of the real estate and related assets. In addition, the Company estimates the fair value of the assets by applying a market approach using comparable sales for certain properties. The use of alternative assumptions in the market approach analysis could result in a different determination of the property’s estimated fair value and a different conclusion regarding the existence of an impairment, the extent of such loss, if any, as well as the carrying value of the real estate and related assets. Impairment of Real Estate During the year ended December 31, 2020, no impairment losses were recorded on real estate assets. During the third quarter ended September 30, 2019, real estate assets related to one healthcare property were determined to be impaired due to a tenant of the property experiencing financial difficulty and vacating its space, and a second tenant indicating its desire to terminate its lease early, which the Company determined would be consistent with its strategic plans for the property. On November 8, 2019, the Company terminated the lease with the second tenant. The aggregate carrying amount of the assets of $40,266,000 exceeded their fair value. The carrying value of the property was reduced to its estimated fair value of $27,266,000, resulting in an impairment charge of $13,000,000, which is included in impairment loss on real estate in the consolidated statements of comprehensive income (loss). In addition, during the fourth quarter ended December 31, 2019, real estate assets related to another healthcare property with an aggregate carrying amount of $30,412,000 were reduced to their estimated fair value of $22,412,000, resulting in an impairment charge of $8,000,000 based on a letter of intent from a prospective buyer to purchase the property. Impairment charges are recorded as impairment loss on real estate in the consolidated statements of comprehensive income (loss). During the year ended December 31, 2018, no impairment losses were recorded on real estate assets. Impairment of Acquired Intangible Assets and Acquired Intangible Liabilities During the year ended December 31, 2020, the Company recognized impairments of three in-place lease intangible assets in the amount of approximately $4,693,000 and one above-market lease intangible asset in the amount of approximately $344,000, by accelerating the amortization of the acquired intangible assets. Of the $4,693,000 in-place lease intangible assets written off, $3,189,000 related to a tenant in a data center property of the Company that was experiencing financial difficulty due to deteriorating economic conditions driven by the impact of COVID-19 and the pandemic’s acceleration of the tenant’s modification of work strategy to a remote environment, $1,484,000 related to one healthcare tenant of the Company that was experiencing financial difficulties and vacated the property on June 19, 2020 and $20,000 as a result of a lease termination at a healthcare property. During year ended December 31, 2020, the Company wrote off one below-market lease intangible liability in the amount of approximately $1,974,000, by accelerating the amortization of the acquired intangible liability related to one tenant of the data center property discussed above. During the year ended December 31, 2019, the Company recognized impairments of in-place lease intangible assets in the amount of approximately $3,195,000, by accelerating the amortization of the acquired intangible assets related to two tenants of a healthcare property. During the year ended December 31, 2019, the Company wrote off one below-market lease intangible liability in the amount of approximately $212,000, by accelerating the amortization of the acquired intangible liability related to one tenant of a healthcare property. During the year ended December 31, 2018, no impairment losses were recorded on acquired intangible assets or intangible liabilities. Goodwill Goodwill represents the excess of the amount paid over the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed in a business combination and is allocated to an entity's reporting units. The Company's reporting unit represents each individual operating real estate property. Goodwill has an indefinite life and is not amortized. On September 30, 2020, the Company recorded $39,529,000 of goodwill related to the Internalization Transaction. See Note 3—"Internalization Transaction" for details. The Company evaluates goodwill for impairment when an event occurs or circumstances change that indicate the carrying value may not be recoverable, or at least annually. Unless circumstances otherwise dictate, the annual impairment test is performed as of the last date of each year. The Company evaluates potential triggering events that may affect the estimated fair value of the Company’s reporting units to assess whether any goodwill impairment exists. Deteriorating or adverse market conditions for certain reporting units may have a significant impact on the estimated fair value of these reporting units and could result in future impairments of goodwill. If the carrying value of a reporting unit exceeds its estimated fair value, then an impairment charge is recorded in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. The Company adopted the annual impairment test and performed a qualitative analysis of each reporting unit as of December 31, 2020. The Company concluded, based on the qualitative assessment, that it is not more likely than not that the fair value of each reporting unit is less than its carrying amount. As of December 31, 2020, no impairment losses on goodwill have been recognized. Notes Receivable Notes receivable are recorded at their outstanding principal balance, net of any unearned income, unamortized deferred fees and costs and allowances for loan losses. The Company defers notes receivable origination costs and fees and amortizes them as an adjustment of yield over the term of the related note receivable. Amortization of the notes receivable origination costs and fees are recorded in interest and other expense, net, in the accompanying consolidated statements of comprehensive income (loss). During the year ended December 31, 2020, in connection with the sale of a healthcare property, a wholly-owned subsidiary of the Company issued a note receivable in the principal amount of $28,000,000. See Note 8—"Notes Receivable, Net" for further discussion. The Company evaluates the collectability of both interest and principal on each note receivable to determine whether it is collectible, primarily through the evaluation of credit quality indicators, such as the tenant's financial condition, collateral, evaluations of historical loss experience, current economic conditions and other relevant factors, including contractual terms of repayments. Evaluating a note receivable for potential impairment requires management to exercise judgment. The use of alternative assumptions in evaluating a note receivable could result in a different determination of the note's estimated fair value and a different conclusion regarding the existence of an impairment, the extent of such loss, if any, as well as the carrying value of the note receivable. See "Recently Adopted Accounting Pronouncements—Measurement of Credit Losses on Financial Instruments" section below for further discussion. Deferred Financing Costs Deferred financing costs are loan fees, legal fees and other third-party costs associated with obtaining and further modifying financing. These costs are amortized over the terms of the respective financing agreements using the effective interest method. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity unless specific rules are met that would allow for the carryover of such costs to the refinanced debt. Costs incurred in seeking financing transactions that do not close are expensed in the period in which it is determined that the financing will not close. Deferred financing costs are recorded as a reduction of the related debt on the accompanying consolidated balance sheets. Deferred financing costs related to a revolving line of credit are recorded in other assets, net, in the accompanying consolidated balance sheets. Leasing Commission Fees Leasing commission fees are fees incurred for the initial lease-up, leasing-up of newly constructed properties or re-leasing to existing tenants. Leasing commission fees are capitalized in other assets, net, in the accompanying consolidated balance sheets and amortized over the terms of the related leases. Fair Value Accounting Standards Codification, or ASC, 820, Fair Value Measurements and Disclosures , or ASC 820, defines fair value, establishes a framework for measuring fair value in accordance with GAAP and expands disclosures about fair value measurements. ASC 820 emphasizes that fair value is intended to be a market-based measurement, as opposed to a transaction-specific measurement. Fair value is defined by ASC 820 as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Depending on the nature of the asset or liability, various techniques and assumptions can be used to estimate the fair value. Assets and liabilities are measured using inputs from three levels of the fair value hierarchy, as follows: Level 1—Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. An active market is defined as a market in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2—Inputs other than quoted prices for similar assets and liabilities in active markets that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data correlation or other means (market corroborated inputs). Level 3—Unobservable inputs, only used to the extent that observable inputs are not available, reflect the Company’s assumptions about the pricing of an asset or liability. The following describes the methods the Company used to estimate the fair value of the Company’s financial assets and liabilities: Cash and cash equivalents, restricted cash, tenant receivables, prepaid and other assets, accounts payable and accrued liabilities —The Company considers the carrying values of these financial instruments, assets and liabilities, to approximate fair value because of the short period of time between origination of the instruments and their expected realization. Notes payable — Fixed Rate —The fair value is estimated by discounting the expected cash flows on notes payable at current rates at which management believes similar loans would be made considering the terms and conditions of the loan and prevailing market interest rates. Credit facility — Fixed Rate —The fair value is estimated by discounting the expected cash flows on the credit facility at current rates at which management believes similar borrowings would be made considering the terms and conditions of the borrowings and prevailing market interest rates. Credit facility — Variable Rate —The fair value of the Company's variable rate credit facility is estimated based on the interest rates currently offered to the Company by financial institutions. Derivative instruments —The Company’s derivative instruments consist of interest rate swaps. These swaps are carried at fair value to comply with the provisions of ASC 820. The fair value of these instruments is determined using interest rate market pricing models. The Company incorporated credit valuation adjustments to appropriately reflect the Company’s nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements. Considerable judgment is necessary to develop estimated fair values of financial assets and liabilities. Accordingly, the estimates presented herein are not necessarily indicative of the amounts the Company could realize or be liable for on disposition of the financial assets and liabilities. See additional discussion in Note 15—"Fair Value." Revenue Recognition, Tenant Receivables and Allowance for Uncollectible Accounts Effective January 1, 2018, the Company recognizes non-rental related revenue in accordance with ASC 606, Revenue from Contracts with Customers, or ASC 606. The Company has identified its revenue streams as rental income from leasing arrangements and tenant reimbursements, which are outside the scope of ASC 606. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Non-rental revenue, subject to ASC 606, is immaterial to the Company's consolidated financial statements. The majority of the Company's revenue is derived from rental revenue, which is accounted for in accordance with ASC 842, Leases, or ASC 842. In accordance with ASC 842, minimum rental revenue is recognized on a straight-line basis over the term of the related lease (including rent holidays). For lease arrangements when it is not probable that the Company will collect all or substantially all of the remaining lease payments under the term of the lease, rental revenue is limited to the lesser of the rental revenue that would be recognized on a straight-line basis or the lease payments that have been collected from the lessee. Differences between rental income recognized and amounts contractually due under the lease agreements are credited or charged to straight-line rent receivable or straight-line rent liability, as applicable. Tenant reimbursements, which are comprised of additional amounts recoverable from tenants for common area maintenance expenses and certain other recoverable expenses, is recognized when the services are provided and the performance obligations are satisfied. Prior to the adoption of ASC 842, tenant receivables and straight-line rent receivables were carried net of the provision for credit losses. The provision for credit losses was established for estimated losses resulting from the inability of certain tenants to meet the contractual obligations under their lease agreements. The Company’s determination of the adequacy of these provisions was based primarily upon evaluations of historical loss experience, the tenant’s financial condition, security deposits, letters of credit, lease guarantees, current economic conditions and other relevant factors. Effective January 1, 2019, upon adoption of ASC 842, the Company is no longer recording a provision for credit losses but is, instead, assessing whether or not it is probable that the Company will collect all or substantially all of the remaining lease payments under the term of the lease. Where it is not probable that the Company will collect all or substantially all of the remaining lease payments under the term of the lease, rental revenue is limited to the lesser of the rental revenue that would be recognized on a straight-line basis or the lease payments that have been collected from the lessee. During the years ended December 31, 2020, 2019, and 2018, the Company recorded $126,000, $672,000 and $0, respectively, as a reduction in rental revenue in the accompanying consolidated statements of comprehensive income (loss). Concentration of Credit Risk and Significant Leases As of December 31, 2020, the Company had cash on deposit, including restricted cash, in certain financial institutions that had deposits in excess of current federally insured levels. The Company limits its cash investments to financial institutions with high credit standings; therefore, the Company believes it is not exposed to any significant credit risk on its cash deposits. To date, the Company has not experienced a loss or lack of access to cash in its accounts. As of December 31, 2020, the Company owned real estate investments in two micropolitan statistical areas and 68 metropolitan statistical areas, or MSAs, two MSAs of which accounted for 10.0% or more of rental revenue. Real estate investments located in the Atlanta-Sandy Springs-Roswell, Georgia MSA and the Houston-The Woodlands-Sugar Land, Texas MSA accounted for 11.9% and 10.3%, respectively, of rental revenue for the year ended December 31, 2020. As of December 31, 2020, the Company had one exposure to tenant concentration that accounted for 10.0% or more of rental revenue for the year ended December 31, 2020. The leases with tenants at healthcare properties under common control of Post Acute Medical, LLC accounted for 10.1% of rental revenue for the year ended December 31, 2020. Share Repurchase Program The Company’s share repurchase program, or SRP, allows for repurchases of shares of the Company’s common stock when certain criteria are met. The SRP provides that all repurchases during any calendar year, including those redeemable upon death or a Qualifying Disability of a stockholder, are limited to those that can be funded with equivalent proceeds raised from the DRIP during the prior calendar year and other operating funds, if any, as the board of directors, in its sole discretion, may reserve for this purpose. Repurchases of shares of the Company’s common stock are at the sole discretion of the Company’s board of directors, provided, however, that the Company will limit the number of shares repurchased during any calendar year to 5.0% of the number of shares of common stock outstanding as of December 31 st of the previous calendar year. Subject to the terms and limitations of the SRP, including, but not limited to, quarterly share limitations, an annual 5.0% share limitation and DRIP funding limitations and any amendments to the plan, as more fully described below, the SRP is generally available to any stockholder as a potential means of interim liquidity. In addition, the Company’s board of directors, in its sole discretion, may suspend (in whole or in part) the SRP at any time, and may amend, reduce, terminate or otherwise change the SRP upon 30 days' prior notice to the Company’s stockholders for any reason it deems appropriate. The Company generally honors valid repurchase requests approximately 30 days following the end of the applicable quarter. The Company reached the DRIP funding limitation and was not able to fully accommodate all repurchase requests for the second quarter repurchase date of 2020, which was April 30, 2020. See Part II, Item 5. "Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities" for further information for the second quarter repurchase date of 2020. On April 30, 2020, due to the uncertainty surrounding the ongoing coronavirus, or COVID-19, pandemic and any impact it may have on the Company, the Company's board of directors decided to temporarily suspend share repurchases under the SRP, effe ctive wit h repurchase requests that would otherwise be processed on the third quarter repurchase date of 2020, which was July 30, 2020. On December 11, 2020, the Company's board of directors authorized and approved the Amended and Restated Share Repurchase Program, or the A&R SRP, which applied beginning with the first quarter repurchase date of 2021, which was January 28, 2021. Under the A&R SRP, the Company will only repurchase shares due to death or involuntary exigent circumstance in accordance with the A&R SRP, subject in each case to the terms and limitations of the A&R SRP, including, but not limited to, quarterly share limitations, an annual 5.0% share limitation, and DRIP funding limitations. Under the A&R SRP, the Company may waive certain of the terms and requirements of the A&R SRP in the event of the death of a stockholder who is a natural person, including shares held through an Individual Retirement Account or other retirement or profit-sharing plan, and certain trusts meeting the requirements of the A&R SRP. The Company may also waive certain of the terms and requirements of the A&R SRP in the event of an involuntary exigent circumstance, as determined by the Company or any of the executive officers thereof, in its or their sole discretion. See Part II, Item 5. "Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities" for more information on the Company's A&R SRP. Effective as of the closing of the Internalization Transaction, the Operating Partnership redeemed the limited partner interest held by the Former Advisor for an aggregate purchase price of approximately $2,000. Additionally, the Company repurchased 29,362 Class A shares of common stock held by Carter Validus REIT Management Company II, LLC, the Former Sponsor, for an aggregate purchase price of approximately $254,000 (an average of $8.65 per share). During the year ended December 31, 2020, the Company repurchased 3,408,870 Class A shares, Class I shares, Class T shares and Class T2 shares of common stock (2,666,674 Class A shares, 408,346 Class I shares, 298,224 Class T shares and 35,626 Class T2 shares), or 1.54% of shares outstanding as of December 31, 2019, for an aggregate purchase price of approximately $29,487,000 (an average of $8.65 per share). During the year ended December 31, 2019, the Company repurchased 2,557,298 Class A shares, Class I shares, Class T shares and Class T2 shares of common stock (1,910,894 Class A shares, 189,947 Class I shares, 451,058 Class T shares and 5,399 Class T2 shares), or 1.87% of shares outstanding as of December 31, 2018, for an aggregate purchase price of approximately $23,655,000 (an average of $9.25 per share). Distribution Policy and Distributions Payable In order to maintain its status as a REIT, the Company is required to make distributions each taxable year equal to at least 90% of its REIT taxable income, computed without regard to the dividends paid deduction and excluding capital gains. To the extent funds are available, the Company intends to continue to pay regular distributions to stockholders. Distributions are paid to stockholders of record as of the applicable record dates. Distributions are payable to stockholders from legally available funds therefor. The Company declared distributions per share of common stock in the amounts of $0.48, $0.58 and $0.63 for the years ended December 31, 2020, 2019 and 2018, respectively. As of December 31, 2020, the Company had distributions payable of approximately $9,117,000. Of these distributions payable, approximately $6,574,000 was paid in cash and approximately $2,543,000 was reinvested in shares of common stock pursuant to the DRIP on January 4, 2021. Distributions to stockholders are determined by the board of directors of the Company and are dependent upon a number of factors, including funds available for the payment of distributions, financial condition, the timing of proper

Internalization Transaction

Internalization Transaction	12 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Internalization Transaction	Internalization Transaction Overview On July 28, 2020, the Company and the Operating Partnership entered into the Purchase Agreement, to effectively provide for the internalization of the Company’s external management functions. The Purchase Agreement was entered into with the Former Advisor, and various affiliates of the Former Advisor, or the Sellers, and Sila Realty Management Company, LLC, f/k/a CV Manager, LLC, a newly formed Delaware limited liability company, or Manager Sub. The Internalization Transaction closed on September 30, 2020. A special committee comprised entirely of independent and disinterested members of the Company's board of directors, negotiated the Internalization Transaction and, after consultation with its independent legal and financial advisors, determined that the Internalization Transaction is advisable, fair and reasonable to and in the Company’s best interests and on terms and conditions no less favorable to the Company than those available from unaffiliated third parties. The Company anticipates that the Internalization Transaction will provide various benefits, including cost savings, continuity of management and further alignment of interests between management and its stockholders, as well as a potential benefit for ultimate liquidity given the preference for an internal management structure in traded equity REITs. Under the Purchase Agreement and related agreements, immediately prior to the closing of the Internalization Transaction, the Sellers assigned to Manager Sub all of the assets necessary to operate the business of the Company and its subsidiaries, or the Business, and delegated all obligations of the Sellers in connection with the Business to Manager Sub pursuant to an assignment and acceptance agreement. On September 30, 2020, or the Closing, under the Purchase Agreement, the Operating Partnership (i) acquired 100% of the membership interests in Manager Sub for an aggregate cash purchase price of $40,000,000, subject to certain adjustments, or the Purchase Price, and (ii) redeemed the Former Advisor’s limited partner interest (including special limited partner interest) in the Operating Partnership. The Purchase Price will be paid as follows, subject to certain acceleration provisions: (i) $25,000,000 was paid at the closing, (ii) $7,500,000 will be due and payable on March 31, 2021, and (iii) $7,500,000 will be due and payable on March 31, 2022 and recorded at fair value, net of amortization of discount in accounts payable and other liabilities in the accompanying consolidated balance sheets. Concurrently with, and as a condition to the execution and delivery of the Purchase Agreement, the Company entered into an employment agreement with each of Michael A. Seton and Kay C. Neely, pursuant to which Mr. Seton and Ms. Neely have served from and after the closing as the Company’s Chief Executive Officer and Chief Financial Officer, respectively. Such employment agreements were effective at and upon the Closing. Allocation of Purchase Price The Internalization Transaction was accounted for as a business combination and the following table summarizes management’s allocation of the fair value of the Internalization Transaction (amounts in thousands): December 31, 2020 Goodwill $ 39,529 Right-of-use assets - operating lease 1,205 Total assets acquired 40,734 Operating lease liabilities (1,060) Deferred internalization transaction purchase price (14,674) Total liabilities acquired (15,734) Net assets allocated at acquisition $ 25,000 Pro Forma Financial Information (Unaudited) Assuming the Internalization Transaction had occurred on January 1, 2019, pro forma revenues and net income attributable to common stockholders would have been as follows for the periods presented below (amounts in thousands, except per share amounts): Year Ended 2020 2019 Pro forma basis: Revenues $ 276,536 $ 210,901 Net income attributable to common stockholders $ 56,083 $ 11,822 Net income per common share attributable to common stockholders: Basic $ 0.25 $ 0.08 Diluted $ 0.25 $ 0.08 The condensed pro forma financial statements for the years ended December 31, 2020 and 2019 include pro forma adjustments related to the Internalization Transaction during 2020 and 2019. The pro forma information for the year ended December 31, 2020, was adjusted to exclude approximately $3,640,000 of internalization transaction expenses. Internalization transaction expenses consist primarily of legal fees, as well as fees for other professional and financial advisors. The pro forma information may not be indicative of what actual results of operations would have been had the transaction occurred at the beginning of 2019, nor is it necessarily indicative of future operating results.

Acquisitions and Dispositions

Acquisitions and Dispositions	12 Months Ended
	Dec. 31, 2020
Real Estate [Abstract]
Acquisitions and Dispositions	Acquisitions and Dispositions 2020 Real Estate Property Acquisitions During the year ended December 31, 2020, the Company purchased three real estate properties, or the 2020 Acquisitions, all of which were determined to be asset acquisitions. Upon the completion of each 2020 Acquisitions, the Company allocated the purchase price of the real estate properties to acquired tangible assets, consisting of land, buildings and improvements and tenant improvements, acquired intangible assets, consisting of in-place leases, and acquired intangible liabilities, consisting of ground lease liabilities and below-market leases, based on the relative fair value method of allocating all accumulated costs. The following table summarizes the consideration transferred for the 2020 Acquisitions during the year ended December 31, 2020: Property Description Date Acquired Ownership Percentage Purchase Price Grimes Healthcare Facility 02/19/2020 100% $ 5,030 Tampa Healthcare Facility 09/08/2020 100% 11,047 Tucson Healthcare Facility IV (1) 12/22/2020 100% 58 Total $ 16,135 (1) The Tucson Healthcare Facility IV was acquired as a development healthcare property. At the closing date, the Company funded additional $849,000 for the construction of the development property. The following table summarizes the Company's purchase price allocation of the 2020 Acquisitions during the year ended December 31, 2020 (amounts in thousands): Total (1) Land $ 831 Buildings and improvements 13,524 Tenant improvements 463 In-place leases 1,748 Right-of-use assets - finance lease 2,534 Total assets acquired 19,100 Finance lease liabilities (2,854) Below-market leases (169) Total liabilities acquired (3,023) Net assets acquired $ 16,077 (1) The Tucson Healthcare Facility IV was acquired as a development healthcare property. At the closing date, the Company funded $849,000 for the construction of the development property and capitalized acquisition costs of $58,000, which are a part of construction in progress in the accompanying consolidated balance sheets as of December 31, 2020. Acquisition fees and costs associated with transactions determined to be asset acquisitions are capitalized. The Company capitalized acquisition fees and costs of approximately $310,000 related to the 2020 Acquisitions, which are included in the Company's allocation of the real estate acquisitions presented above. The total amount of all acquisition fees and costs is limited to 6.0% of the contract purchase price of a property, unless the Company’s board of directors determines a higher transaction fee to be commercially competitive, fair and reasonable to the Company. The contract purchase price is the amount actually paid or allocated in respect of the purchase, development, construction or improvement of a property exclusive of acquisition fees and costs. During the year ended December 31, 2020, acquisition fees and costs did not exceed 6.0% of the contract purchase price of the 2020 Acquisitions during such period. 2020 Real Estate Property Dispositions and Origination of Note Receivable The Company sold two healthcare properties, or the 2020 Dispositions, during the year ended December 31, 2020, for an aggregate sale price of $58,000,000 and generated net proceeds of $28,542,000. For the year ended December 31, 2020, the Company recognized an aggregate gain on sale of $3,142,000 in gain on real estate dispositions in the consolidated statements of comprehensive income (loss). The following table summarizes the 2020 Dispositions during the year ended December 31, 2020: Property Description Disposition Date Ownership Percentage Sale Price Net Proceeds San Antonio Healthcare Facility II 05/28/2020 100% $ 35,000 (1) $ 6,125 Dallas Healthcare Facility II 11/06/2020 100% 23,000 22,417 Total $ 58,000 $ 28,542 (1) The sale price of $35,000,000 consisted of $7,000,000 cash and a $28,000,000 investment in note receivable. See Note 8—"Notes Receivable, Net" for additional information.

Acquired Intangible Assets, Net

Acquired Intangible Assets, Net	12 Months Ended
	Dec. 31, 2020
Finite-Lived Intangible Assets, Net [Abstract]
Acquired Intangible Assets, Net	Acquired Intangible Assets, Net Acquired intangible assets, net, consisted of the following as of December 31, 2020 and 2019 (amounts in thousands, except weighted average remaining life amounts): December 31, 2020 December 31, 2019 In-place leases, net of accumulated amortization of $86,728 and $62,252, respectively (with a weighted average remaining life of 9.8 years and 10.4 years, respectively) $ 231,200 $ 266,856 Above-market leases, net of accumulated amortization of $4,002 and $1,912, respectively (with a weighted average remaining life of 9.9 years and 10.5 years, respectively) 15,561 18,603 $ 246,761 $ 285,459 The aggregate weighted average remaining life of the acquired intangible assets was 9.8 years and 10.4 years as of December 31, 2020 and 2019, respectively. Amortization of the acquired intangible assets was $37,637,000, $26,699,000 and $19,919,000 for the years ended December 31, 2020, 2019 and 2018, respectively. Of the $37,637,000 recorded for the year ended December 31, 2020, $5,037,000 was attributable to accelerated amortization due to the impairment of three in-place lease intangible assets and one above-market lease intangible asset. Of the $26,699,000 recorded for the year ended December 31, 2019, $3,195,000 was attributable to accelerated amortization due to the impairment of two in-place lease intangible assets. Amortization of the in-place leases is included in depreciation and amortization of the above-market leases is recorded as an adjustment to rental revenue in the accompanying consolidated statements of comprehensive income (loss). Estimated amortization expense on the acquired intangible assets as of December 31, 2020, for each of the next five years ending December 31 and thereafter, is as follows (amounts in thousands): Year Amount 2021 $ 30,597 2022 29,159 2023 28,076 2024 26,001 2025 23,018 Thereafter 109,910 $ 246,761

Acquired Intangible Liabilities

Acquired Intangible Liabilities, Net	12 Months Ended
	Dec. 31, 2020
Intangible Lease Liabilities, Net [Abstract]
Acquired Intangible Liabilities, Net	Acquired Intangible Liabilities, Net Acquired intangible liabilities, net, consisted of the following as of December 31, 2020 and 2019 (amounts in thousands, except weighted average remaining life amounts): December 31, 2020 December 31, 2019 Below-market leases, net of accumulated amortization of $13,924 and $12,332, respectively (with a weighted average remaining life of 16.2 years and 16.1 years, respectively) $ 52,560 $ 59,538 Amortization of the below-market leases was $7,147,000, $5,261,000 and $4,832,000 for the years ended December 31, 2020, 2019 and 2018, respectively. Of the $7,147,000 and $5,261,000 recorded for the years ended December 31, 2020 and 2019, respectively, $1,974,000 and $212,000, respectively, was attributable to accelerated amortization of a below-market lease intangible liability. Amortization of below-market leases is recorded as an adjustment to rental revenue in the accompanying consolidated statements of comprehensive income (loss). Estimated amortization of the acquired intangible liabilities as of December 31, 2020, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands): Year Amount 2021 $ 4,385 2022 3,873 2023 3,808 2024 3,706 2025 3,482 Thereafter 33,306 $ 52,560

Leases

Leases	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Leases	Leases Lessor Rental Revenue The Company’s real estate properties are leased to tenants under operating leases with varying terms. Typically, the leases have provisions to extend the terms of the lease agreements. The Company retains substantially all of the risks and benefits of ownership of the real estate properties leased to tenants. Future rent to be received from the Company's investments in real estate assets under the terms of non-cancellable operating leases in effect as of December 31, 2020, including optional renewal periods, when applicable, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands): Year Amount 2021 $ 224,764 2022 233,130 2023 235,913 2024 232,177 2025 223,136 Thereafter 1,434,582 Total (1) $ 2,583,702 (1) The total future rent amount of $2,583,702,000 includes approximately $59,171,000 in rent to be received in connection with two leases executed as of December 31, 2020, at two development properties with estimated lease commencement dates of April 1, 2021 and February 1, 2022. Lessee Operating Leases The Company has entered into various non-cancellable operating lease agreements for 17 ground leases and one office lease related to the Company’s principal executive office in Tampa, Florida, or the Corporate Lease. Of the 17 ground operating leases entered into, four do not have corresponding operating lease liabilities because the Company did not have future payment obligations at the acquisition of these leases. In connection with the Internalization Transaction on September 30, 2020, the Company acquired the Corporate Lease, with an operating lease liability of $1,060,000. The Corporate Lease of 24,555 square feet of office space expires on January 21, 2022. The Company incurred operating lease costs associated with its ground operating leases of $2,567,000, $1,388,000 and $134,000 for the years ended December 31, 2020, 2019 and 2018, respectively, which are recorded as rental expenses in the consolidated statements of comprehensive income (loss). The Company was reimbursed by tenants who sublease the ground leases $1,604,000, $781,000 and $94,000 for the years ended December 31, 2020, 2019 and 2018, respectively. The tenant reimbursements for ground leases are recorded as rental revenue in the consolidated statements of comprehensive income (loss). The Company incurred operating lease costs associated with its Corporate Lease of $264,000 for the year ended December 31, 2020, which is recorded as general and administrative expenses in the consolidated statements of comprehensive income (loss). The future rent payments, discounted by the Company's incremental borrowing rates, under non-cancellable operating leases, as of December 31, 2020, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands): Year Amount 2021 $ 2,464 2022 1,682 2023 1,638 2024 1,687 2025 1,688 Thereafter 135,031 Total undiscounted rental payments 144,190 Less imputed interest (112,140) Total operating lease liabilities $ 32,050 The Company's operating and finance leases do not provide an implicit interest rate. In order to calculate the present value of the remaining operating and finance lease payments, the Company used incremental borrowing rates, or IBRs, adjusted for a number of factors. The determination of an appropriate IBR involves multiple inputs and judgments. The Company determined its IBRs considering the general economic environment, the Company's credit rating and various financing and asset specific adjustments to ensure the IBRs are appropriate for the intended use of the underlying operating or finance lease. As of December 31, 2020, the IBRs ranged between 3.5% and 6.6%, with the weighted average IBR for the Company's operating leases of 5.7%. The weighted average remaining lease term for the Company's operating leases was 48.1 years and 50.7 years as of December 31, 2020 and 2019, respectively. Finance Leases During the year ended December 31, 2020, the Company entered into one non-cancellable ground lease agreement for an aggregate present value of future rent payments of $2,854,000. The ground lease obligations generally require fixed annual rental payments and may also include escalation clauses. The lease represents a finance lease, as defined in ASC 842, Leases . Ground lease expenses for finance lease payments are recognized as amortization expense of the ROU asset - finance lease and interest expense on the finance lease liability over the lease term. The Company recognized amortization expense of the ROU asset - finance lease of $7,000 for the year ended December 31, 2020, and is recorded as depreciation and amortization in the consolidated statements of comprehensive income (loss). The Company recognized interest on the finance lease liability of $47,000 for the year ended December 31, 2020, and is recorded as interest and other expense, net, in the consolidated statements of comprehensive income (loss). The future rent payments, discounted by the Company's incremental borrowing rates, under non-cancellable finance leases, as of December 31, 2020, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands): Year Amount 2021 $ 147 2022 147 2023 147 2024 152 2025 154 Thereafter 7,110 Total undiscounted rental payments 7,857 Less imputed interest (5,014) Total finance lease liabilities $ 2,843 As of December 31, 2020, the Company's IBR for its finance lease was 5.3% and a remaining lease term of 43.4 years.
Leases	Leases Lessor Rental Revenue The Company’s real estate properties are leased to tenants under operating leases with varying terms. Typically, the leases have provisions to extend the terms of the lease agreements. The Company retains substantially all of the risks and benefits of ownership of the real estate properties leased to tenants. Future rent to be received from the Company's investments in real estate assets under the terms of non-cancellable operating leases in effect as of December 31, 2020, including optional renewal periods, when applicable, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands): Year Amount 2021 $ 224,764 2022 233,130 2023 235,913 2024 232,177 2025 223,136 Thereafter 1,434,582 Total (1) $ 2,583,702 (1) The total future rent amount of $2,583,702,000 includes approximately $59,171,000 in rent to be received in connection with two leases executed as of December 31, 2020, at two development properties with estimated lease commencement dates of April 1, 2021 and February 1, 2022. Lessee Operating Leases The Company has entered into various non-cancellable operating lease agreements for 17 ground leases and one office lease related to the Company’s principal executive office in Tampa, Florida, or the Corporate Lease. Of the 17 ground operating leases entered into, four do not have corresponding operating lease liabilities because the Company did not have future payment obligations at the acquisition of these leases. In connection with the Internalization Transaction on September 30, 2020, the Company acquired the Corporate Lease, with an operating lease liability of $1,060,000. The Corporate Lease of 24,555 square feet of office space expires on January 21, 2022. The Company incurred operating lease costs associated with its ground operating leases of $2,567,000, $1,388,000 and $134,000 for the years ended December 31, 2020, 2019 and 2018, respectively, which are recorded as rental expenses in the consolidated statements of comprehensive income (loss). The Company was reimbursed by tenants who sublease the ground leases $1,604,000, $781,000 and $94,000 for the years ended December 31, 2020, 2019 and 2018, respectively. The tenant reimbursements for ground leases are recorded as rental revenue in the consolidated statements of comprehensive income (loss). The Company incurred operating lease costs associated with its Corporate Lease of $264,000 for the year ended December 31, 2020, which is recorded as general and administrative expenses in the consolidated statements of comprehensive income (loss). The future rent payments, discounted by the Company's incremental borrowing rates, under non-cancellable operating leases, as of December 31, 2020, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands): Year Amount 2021 $ 2,464 2022 1,682 2023 1,638 2024 1,687 2025 1,688 Thereafter 135,031 Total undiscounted rental payments 144,190 Less imputed interest (112,140) Total operating lease liabilities $ 32,050 The Company's operating and finance leases do not provide an implicit interest rate. In order to calculate the present value of the remaining operating and finance lease payments, the Company used incremental borrowing rates, or IBRs, adjusted for a number of factors. The determination of an appropriate IBR involves multiple inputs and judgments. The Company determined its IBRs considering the general economic environment, the Company's credit rating and various financing and asset specific adjustments to ensure the IBRs are appropriate for the intended use of the underlying operating or finance lease. As of December 31, 2020, the IBRs ranged between 3.5% and 6.6%, with the weighted average IBR for the Company's operating leases of 5.7%. The weighted average remaining lease term for the Company's operating leases was 48.1 years and 50.7 years as of December 31, 2020 and 2019, respectively. Finance Leases During the year ended December 31, 2020, the Company entered into one non-cancellable ground lease agreement for an aggregate present value of future rent payments of $2,854,000. The ground lease obligations generally require fixed annual rental payments and may also include escalation clauses. The lease represents a finance lease, as defined in ASC 842, Leases . Ground lease expenses for finance lease payments are recognized as amortization expense of the ROU asset - finance lease and interest expense on the finance lease liability over the lease term. The Company recognized amortization expense of the ROU asset - finance lease of $7,000 for the year ended December 31, 2020, and is recorded as depreciation and amortization in the consolidated statements of comprehensive income (loss). The Company recognized interest on the finance lease liability of $47,000 for the year ended December 31, 2020, and is recorded as interest and other expense, net, in the consolidated statements of comprehensive income (loss). The future rent payments, discounted by the Company's incremental borrowing rates, under non-cancellable finance leases, as of December 31, 2020, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands): Year Amount 2021 $ 147 2022 147 2023 147 2024 152 2025 154 Thereafter 7,110 Total undiscounted rental payments 7,857 Less imputed interest (5,014) Total finance lease liabilities $ 2,843 As of December 31, 2020, the Company's IBR for its finance lease was 5.3% and a remaining lease term of 43.4 years.

Notes Receivable, Net

Notes Receivable, Net	12 Months Ended
	Dec. 31, 2020
Receivables [Abstract]
Notes Receivable, Net	Notes Receivable, Net As of December 31, 2020, the Company had two notes receivable outstanding in the amount of $31,262,000 secured by real estate properties. The following summarizes the notes receivable balances as of December 31, 2020 and 2019: December 31, 2020 December 31, 2019 Interest Rate (1) Maturity Date Note receivable $ 2,700 $ 2,700 6.0% 11/05/2021 Note receivable 28,562 — 7.0% 06/01/2022 Total notes receivable $ 31,262 $ 2,700 (1) As of December 31, 2020. As described in Note 4—"Acquisitions and Dispositions", in connection with the sale of the San Antonio Healthcare Facility II on May 28, 2020, a wholly-owned subsidiary of the Company entered into a note receivable agreement in the principal amount of $28,000,000. The note receivable is secured by a first mortgage lien on San Antonio Healthcare Facility II and matures on June 1, 2022, or the Maturity Date. The interest rate of the note receivable is 7.0% per annum for the period commencing May 28, 2020 through May 31, 2021, and 8.0% per annum for the period commencing on June 1, 2021 through the Maturity Date. Monthly payments are interest only, with the outstanding principal due and payable on the Maturity Date; however, the outstanding principal and any unpaid accrued interest can be prepaid at any time without penalty or charge. In connection with the note receivable, the Company incurred a loan origination fee in the amount of $560,000, which is amortized ratably over the term of the note receivable. During the year ended December 31, 2020, the Company amortized $166,000 related to the loan origination fee, which was recorded in interest and other expense, net, in the accompanying consolidated statements of comprehensive income (loss). During the year ended December 31, 2020, the Company recognized $1,187,000 of interest income on the note receivable, which was recorded in interest and other expense, net, in the accompanying consolidated statements of comprehensive income (loss). As of December 31, 2020, the Company had an unamortized loan origination fee in the amount of $394,000, which was recorded in notes receivable, net, in the accompanying consolidated balance sheets. In connection with an outstanding note receivable in the amount of $2,700,000, on November 5, 2020, the Company entered into an amended agreement with the borrower to, among other things, change the maturity date to November 5, 2021 (the maturity date was previously November 5, 2020), or earlier, as provided in the amended agreement. On January 6, 2021, in accordance with the amended note receivable agreement, the borrower paid an amendment fee in the amount of $50,000 and paid down $500,000 in principal outstanding on the note receivable. The note receivable is secured by (i) a payment guaranty from a parent company to the borrower of the note receivable, and (ii) the equity interest in a healthcare real estate property that the Company believes has sufficient value to cover the note receivable if the Company exercises its rights to take possession of the asset. Expected Credit Losses As of December 31, 2020, the Company had two notes receivable, one of which was determined to be a collateral dependent loan and the other the Company does not expect to incur a loss because it is secured by collateral that the Company believes has sufficient value to cover the note receivable in the event of a default by the borrower. The Company's evaluation considered factors such as the potential future value of the collateral, adjustments for current conditions and supportable forecasts for the collateral. As a result of the evaluation, the Company did not record any estimated credit losses for its notes receivable for the year ended December 31, 2020, because the Company believes that the collateral for these loans was sufficient to cover its investment.

Other Assets, Net

Other Assets, Net	12 Months Ended
	Dec. 31, 2020
Other Assets [Abstract]
Other Assets, Net	Other Assets, Net Other assets, net, consisted of the following as of December 31, 2020 and 2019 (amounts in thousands): December 31, 2020 December 31, 2019 Deferred financing costs, related to the revolver portion of the credit facility, net of accumulated amortization of $6,902 and $5,696, respectively $ 1,634 $ 2,623 Leasing commissions, net of accumulated amortization of $811 and $240, respectively 11,421 10,288 Restricted cash 14,735 10,888 Tenant receivables 5,541 6,116 Straight-line rent receivable, net 69,687 48,526 Prepaid and other assets 5,443 4,709 Derivative assets — 884 $ 108,461 $ 84,034 Amortization of deferred financing costs related to the revolver portion of the credit facility for the years ended December 31, 2020, 2019 and 2018 was $1,206,000, $1,010,000 and $1,260,000, respectively, which was recorded as interest and other expense, net, in the accompanying consolidated statements of comprehensive income (loss). Amortization of leasing commissions for the years ended December 31, 2020, 2019 and 2018 was $598,000, $158,000 and $76,000, respectively, which was recorded as depreciation and amortization in the accompanying consolidated statements of comprehensive income (loss). Of the $598,000 recorded for amortization of leasing commissions for the year ended December 31, 2020, $12,000 was attributable to accelerated amortization due to the impairment of leasing commissions related to two tenants who were experiencing financial difficulties.

Accounts Payable and Other Liab

Accounts Payable and Other Liabilities	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Accounts Payable and Other Liabilities	Accounts Payable and Other Liabilities Accounts payable and other liabilities consisted of the following as of December 31, 2020 and 2019 (amounts in thousands): December 31, 2020 December 31, 2019 Accounts payable and accrued expenses $ 14,033 $ 11,448 Accrued interest expense 4,269 5,185 Accrued property taxes 2,511 3,537 Accrued personnel costs (1) 1,202 — Distribution and servicing fees 3,128 — Distributions payable to stockholders 9,117 9,093 Tenant deposits 1,047 1,500 Deferred rental income 9,767 9,003 Deferred internalization transaction liability (2) 14,728 — Derivative liabilities 20,444 5,588 $ 80,246 $ 45,354 (1) Upon completion of the Internalization Transaction on September 30, 2020, 76 individuals previously employed by an affiliate of the Former Advisor, became employees of the Company. These costs include payroll related expenses that have been earned by the Company's employees from October 1, 2020 through December 31, 2020. (2) Represents the assumed liability recorded at fair value, net of amortization of discount, as a part of the Internalization Transaction. See Note 3—"Internalization Transaction" for additional information.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Notes Payable	Notes Payable As of December 31, 2020, the Company had $453,422,000 principal outstanding in notes payable collateralized by real estate properties with a weighted average interest rate of 4.4%. The following table summarizes the notes payable balances as of December 31, 2020 and 2019 (amounts in thousands): Interest Rates December 31, 2020 December 31, 2019 Range Weighted Maturity Date Fixed rate notes payable $ 218,415 $ 219,567 4.0% - 4.8% 4.3% 12/11/2021 - 07/01/2027 Variable rate notes payable fixed through interest rate swaps 235,007 237,778 3.7% - 5.1% 4.5% 10/28/2021 - 11/16/2022 Total notes payable, principal amount outstanding 453,422 457,345 Unamortized deferred financing costs related to notes payable (1,805) (2,500) Total notes payable, net of deferred financing costs $ 451,617 $ 454,845 The Company did not enter into any notes payable during the year ended December 31, 2020. During the quarter ended June 30, 2020, the Company temporarily fell out of compliance with one of its mortgage loan agreements as a result of a covenant requiring the tenant at the property to maintain a certain rent coverage ratio. The tenant at the property is a healthcare tenant that experienced a temporary reduction in patient volume as a result of the COVID-19 pandemic but has not missed any rental payments. The lenders waived compliance with the covenant through June 30, 2020. During the quarter ended September 30, 2020, the Company amended the mortgage loan agreement to, among other things, modify the rent coverage ratio beginning with the quarter ended September 30, 2020, through the quarter ending June 30, 2021. The principal payments due on the notes payable as of December 31, 2020, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands): Year Amount 2021 (1) $ 146,026 2022 166,209 2023 2,710 2024 27,360 2025 2,195 Thereafter 108,922 $ 453,422 (1) The Company has adequate liquidity and availability under the credit facility to satisfy its outstanding debt obligations as they become due in 2021.

Credit Facility

Credit Facility	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Credit Facility	Credit Facility The Company's outstanding credit facility as of December 31, 2020 and 2019 consisted of the following (amounts in thousands): December 31, 2020 December 31, 2019 Variable rate revolving line of credit $ 138,000 $ 108,000 Variable rate term loan fixed through interest rate swaps 400,000 250,000 Variable rate term loans 400,000 550,000 Total credit facility, principal amount outstanding 938,000 908,000 Unamortized deferred financing costs related to the term loan credit facility (5,900) (7,385) Total credit facility, net of deferred financing costs $ 932,100 $ 900,615 Significant activities regarding the credit facility during the year ended December 31, 2020 include: • During the year ended December 31, 2020, the Company drew $140,000,000 on its credit facility, $20,000,000 of which was related to a property acquisition and the funding of share repurchases, $75,000,000 was drawn to provide additional liquidity due to the uncertainty in overall economic conditions created by the COVID-19 pandemic and $45,000,000 was related to another property acquisition and the Internalization Transaction. During the year ended December 31, 2020, the Company repaid $110,000,000 on its credit facility. • During the year ended December 31, 2020, three interest rate swap agreements, which the Company entered into in December 2019, with an effective date of January 1, 2020, effectively fixed London Interbank Offered Rate, or LIBOR, related to $150,000,000 of the term loans of the credit facility. • During the year ended December 31, 2020, two interest rate swap agreements, which the Company entered into in June 2020, with an effective date of July 1, 2020, effectively fixed LIBOR related to $100,000,000 of the term loans of the credit facility. • On July 10, 2020, the Company, the Operating Partnership, certain of the Company's subsidiaries, KeyBank National Association and the other lenders listed as lenders in the Company’s credit agreement and term loan agreement entered into second amendments to such agreements due to certain rent concessions provided to tenants as a result of the COVID-19 pandemic and their impact on the amount available to be drawn under the Company’s credit facility. In particular, the second amendments (i) modify the calculation of Adjusted Net Operating Income, or ANOI, such that beginning with the second quarter of 2020 and continuing thereafter, ANOI is calculated using a trailing 12 month accrual method, rather than a trailing six month annualized cash-based approach, and waives a rent coverage ratio requirement with respect to certain healthcare pool properties beginning with the quarter ended June 30, 2020 through and including the quarter ending June 30, 2021, and (ii) provide updated provisions for the conversion of the benchmark interest rate from LIBOR to an alternate index rate adopted by the Federal Reserve Board and the Federal Reserve Bank of New York following the occurrence of certain transition events. The principal payments due on the credit facility as of December 31, 2020, for each of the next five years ending December 31, are as follows (amounts in thousands): Year Amount 2022 (1) $ 138,000 2023 280,000 2024 520,000 $ 938,000 (1) Amount relates to the revolving line of credit under the credit facility. As of December 31, 2020, the maturity date of the revolving line of credit under the credit facility was April 27, 2022, subject to our right for one, 12-month extension period. The proceeds of loans made under the credit facility may be used to finance the acquisitions of real estate investments, for tenant improvements and leasing commissions with respect to real estate, for repayment of indebtedness, for capital expenditures with respect to real estate, and for general corporate and working capital purposes. The credit facility can be increased to $1,600,000,000, subject to certain conditions. The annual interest rate payable under the credit facility is, at the Company's option, either: (a) LIBOR, plus an applicable margin ranging from 1.75% to 2.25%, which is determined based on the Company's overall leverage, or (b) a base rate which means, for any day, a fluctuating rate per annum equal to the prime rate for such day plus an applicable margin ranging from 0.75% to 1.25%, which is determined based on the Company's overall leverage. As of December 31, 2020, the weighted average interest rate on the variable rate portion of the credit facility was 2.40% and the weighted average interest rate on the variable rate fixed through interest rate swap portion of the credit facility was 3.77%. In addition to interest, the Company is required to pay a fee on the unused portion of the lenders’ commitments under the credit agreement at a per annum rate equal to 0.25% if the daily amount outstanding under the credit agreement is less than 50% of the lenders’ commitments, or 0.15% if the daily amount outstanding under the credit agreement is greater than or equal to 50% of the lenders’ commitments. The unused fee is payable quarterly in arrears. The actual amount of credit available under the credit facility is a function of certain loan-to-cost, loan-to-value and debt service coverage ratios contained in the credit facility agreements. The amount of credit available under the credit facility will be a maximum principal amount of the value of the assets that are included in the pool availability. The credit facility agreements contain various affirmative and negative covenants that are customary for credit facilities and transactions of this type, including limitations on the incurrence of debt by the Company, the Operating Partnership and its subsidiaries that own properties that serve as collateral for the credit facility, limitations on the nature of the Company's business, the Operating Partnership and its subsidiaries, and limitations on distributions by the Company, the Operating

Related-Party Transactions and

Related-Party Transactions and Arrangements	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related-Party Transactions and Arrangements	Related-Party Transactions and Arrangements Prior to the closing of the Internalization Transaction, the Company had no direct employees. Substantially all of the Company's business was managed by the Former Advisor. The employees of the Former Advisor and its affiliates provided services to the Company related to acquisitions, property management, asset management, accounting, investor relations and all other administrative services. Upon completion of the Internalization, the employees of an affiliate of the Former Advisor, became employees of the Company and the functions previously performed by the Former Advisor were internalized by the Company. As an internally managed company, the Company no longer pays the Former Advisor and its affiliates any fees or expense reimbursements arising from the advisory agreement. Additionally, the Company concluded that there were no preexisting relationships between the Former Advisor and the Company that had to be settled and accounted for as separate transactions from the Internalization Transaction. Special Limited Partner Interest of Advisor Prior to the closing of the Internalization Transaction, the Former Advisor, as the special limited partner of the Operating Partnership, was entitled to: (i) certain cash distributions upon the disposition of certain of the Operating Partnership’s assets; or (ii) a one-time payment in the form of cash, shares or promissory note or a combination of the forms of payment in connection with the redemption of the special limited partnership interests upon the occurrence of a listing of the Company’s shares of common stock on a national stock exchange or certain events that result in the termination or non-renewal of the advisory agreement. The Former Advisor would only become entitled to the compensation after stockholders have, in the aggregate, cumulative distributions equal to their invested capital plus an 8.0% cumulative, non-compounded annual return on such invested capital. The Former Advisor's special limited partnership interest in the Operating Partnership was redeemed and cancelled at the closing of the Internalization Transaction and the Former Advisor did not receive any compensation as a special limited partner of the Operating Partnership. Distribution and Servicing Fees Through the termination of the Offering on November 27, 2018, the Company paid SC Distributors, LLC, an affiliate of the Former Advisor that served as the dealer manager of the Offerings, or the Dealer Manager, selling commissions and dealer manager fees in connection with the sale of shares of certain classes of common stock. The Company continues to pay the Dealer Manager a distribution and servicing fee with respect to its Class T and Class T2 shares of common stock that were sold in the Initial Offering (primary Offering only) and the Offering. Distribution and servicing fees are recorded in the accompanying consolidated statements of stockholders' equity as a reduction to equity as incurred. Effective September 30, 2020, as a result of the Internalization Transaction, the Dealer Manager is no longer a related party of the Company. Acquisition Fees and Expenses Prior to entering into the Purchase Agreement for the Internalization Transaction on July 28, 2020, the Company paid to the Former Advisor 2.0% of the contract purchase price of each property or asset acquired and 2.0% of the amount advanced with respect to loans and similar assets (including without limitation mezzanine loans). Prior to the closing of the Internalization Transaction, the Company reimbursed the Former Advisor for acquisition expenses incurred in connection with the selection and acquisition of properties or real estate-related investments (including expenses relating to potential investments that the Company did not close), such as legal fees and expenses, costs of real estate due diligence, appraisals, non-refundable option payments on properties not acquired, travel and communications expenses, accounting fees and expenses and title insurance premiums, whether or not the property was acquired. The Company reimbursed the Former Advisor expenses of approximately 0.01% of the aggregate purchase price of all properties acquired. In connection with Tampa Healthcare Facility acquired on September 8, 2020, the Company did not pay acquisition fees to its Former Advisor, in accordance with the Purchase Agreement. Acquisition fees and expenses associated with the acquisition of properties determined to be business combinations are expensed as incurred, including investment transactions that are no longer under consideration. Acquisition fees and expenses associated with transactions determined to be asset acquisitions are capitalized in total real estate, net, in the accompanying consolidated balance sheets. Asset Management Fees Prior to the closing of the Internalization Transaction, the Company paid to the Former Advisor an asset management fee calculated on a monthly basis in an amount equal to 1/12th of 0.75% of aggregate asset value, which was payable monthly, in arrears. Operating Expense Reimbursement Prior to the closing of the Internalization Transaction, the Company reimbursed the Former Advisor for all operating expenses it paid or incurred in connection with the services provided to the Company, subject to certain limitations. Expenses in excess of the operating expenses in the four immediately preceding quarters that exceeded the greater of (a) 2% of average invested assets or (b) 25% of net income, subject to certain adjustments, were not reimbursed unless the independent directors determined such excess expenses were justified. The Company did not reimburse the Former Advisor for personnel costs in connection with services for which the Former Advisor received an acquisition fee or a disposition fee. Operating expenses incurred on the Company’s behalf are recorded in general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss). Property Management Fees In connection with the rental, leasing, operation and management of the Company’s properties, prior to the closing of the Internalization Transaction, the Company paid Carter Validus Real Estate Management Services II, LLC, a wholly-owned subsidiary of the Former Sponsor, or the Former Property Manager, and its affiliates, aggregate fees equal to 3.0% of gross revenues from the properties managed, or property management fees. The Company reimbursed the Former Property Manager and its affiliates for property-level expenses that any of them paid or incurred on the Company’s behalf, including certain salaries, bonuses and benefits of persons employed by the Former Property Manager and its affiliates, except for the salaries, bonuses and benefits of persons who also served as one of its executive officers. For certain properties the Former Property Manager and its affiliates subcontracted the performance of their duties to third parties and paid all or a portion of the property management fee to the third parties with whom they contracted for those services. When the Company contracted directly with third parties for such services, it paid such third parties customary market fees and paid the Former Property Manager an oversight fee equal to 1.0% of the gross revenues of the properties managed. In no event did the Company pay the Former Property Manager or any affiliate both a property management fee and an oversight fee with respect to any particular property. Property management fees are recorded in rental expenses in the accompanying consolidated statements of comprehensive income (loss). Leasing Commission Fees Prior to the closing of the Internalization Transaction, the Company paid the Former Property Manager a separate fee in connection with leasing properties to new tenants or renewals or expansions of existing leases with existing tenants in an amount not to exceed the fee customarily charged in arm’s-length transactions by others rendering similar services in the same geographic area for similar properties as determined by a survey of brokers and agents in such area. Leasing commission fees are capitalized in other assets, net, in the accompanying consolidated balance sheets and amortized over the terms of the related leases. Construction Management Fees Prior to the closing of the Internalization Transaction, for acting as general contractor and/or construction manager to supervise or coordinate projects or to provide major repairs or rehabilitation on the Company's properties, the Company paid the Former Property Manager up to 5.0% of the cost of the projects, repairs and/or rehabilitation, as applicable, or construction management fees. Construction management fees are capitalized in real estate, net, in the accompanying consolidated balance sheets. Disposition Fees Prior to the closing of the Internalization Transaction, the Company paid its Former Advisor, or its affiliates, if the Former Advisor or its affiliates provided a substantial amount of services (as determined by a majority of the Company’s independent directors) in connection with the sale of properties, a disposition fee, equal to the lesser of 1.0% of the contract sales price or one-half of the total brokerage commission paid if a third party broker was also involved, without exceeding the lesser of 6.0% of the contract sales price or a reasonable, customary and competitive real estate commission. The following table details amounts incurred in connection with the Company's related-party transactions as described above for the years ended December 31, 2020, 2019 and 2018 (amounts in thousands): Incurred Year Ended Fee Entity 2020 2019 2018 Distribution and servicing fees (1) SC Distributors, LLC $ (65) $ (563) $ 368 Acquisition fees and costs Carter Validus Advisors II, LLC and its affiliates 97 26,072 4,272 Asset management fees Carter Validus Advisors II, LLC and its affiliates 17,914 16,475 13,114 Property management fees Carter Validus Real Estate Management Services II, LLC 5,290 5,403 4,391 Operating expense reimbursement Carter Validus Advisors II, LLC and its affiliates 3,966 4,492 2,692 Leasing commission fees Carter Validus Real Estate Management Services II, LLC 594 1,241 497 Construction management fees Carter Validus Real Estate Management Services II, LLC 435 276 243 Disposition fees Carter Validus Advisors II, LLC and its affiliates 350 — — Loan origination fees Carter Validus Advisors II, LLC and its affiliates 560 — — Total $ 29,141 $ 53,396 $ 25,577 (1) Reduction of distribution and servicing fees is a result of repurchases of Class T and Class T2 shares of common stock for the years ended December 31, 2020 and 2019. The following table details amounts payable to affiliates in connection with the Company's related-party transactions as described above as of December 31, 2020 and 2019 (amounts in thousands): Payable Fee Entity December 31, 2020 December 31, 2019 Distribution and servicing fees SC Distributors, LLC $ — $ 6,210 Asset management fees Carter Validus Advisors II, LLC and its affiliates — 2,100 Property management fees Carter Validus Real Estate Management Services II, LLC — 433 Operating expense reimbursement Carter Validus Advisors II, LLC and its affiliates — 518 Leasing commission fees Carter Validus Real Estate Management Services II, LLC — 299 Construction management fees Carter Validus Real Estate Management Services II, LLC — 199 Total $ — $ 9,759

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting Management reviews the performance of individual properties and aggregates individual properties based on operating criteria into two reportable segments—commercial real estate investments in data centers and healthcare, and makes operating decisions based on these two reportable segments. The Company’s commercial real estate investments in data centers and healthcare are based on certain underwriting assumptions and operating criteria, which are different for data centers and healthcare. The Company evaluates performance based on the net operating income of the individual properties in each segment. Net operating income, a non-GAAP financial measure, is defined as rental revenue, less rental expenses, w h ich excludes depreciation and amortization, general and administrative expenses, internalization transaction expenses, asset management fees, gain on real estate dispositions, impairment loss on real estate and interest and other expense, net. The Company believes that segment net operating income serves as a useful supplement to net income because it allows investors and management to measure unlevered property-level operating results and to compare operating results to the operating results of other real estate companies between periods on a consistent basis. Segment net operating income should not be considered as an alternative to net income determined in accordance with GAAP as an indicator of financial performance, and accordingly, the Company believes that in order to facilitate a clear understanding of the consolidated historical operating results, segment net operating income should be examined in conjunction with net income as presented in the accompanying consolidated financial statements and data included elsewhere in this Annual Report on Form 10-K. Non-segment assets primarily consist of corporate assets, including cash and cash equivalents, notes receivable, right-of-use assets - operating leases attributable to the Corporate Lease and deferred financing costs attributable to the revolving line of credit portion of the Company's credit facility not attributable to individual properties. On September 30, 2020, the Company recorded $39,529,000 of goodwill related to the Internalization Transaction that was allocated to separately identified reporting units. The Company's reporting units represent each individual operating real estate property and meet aggregation criteria to be grouped into two reportable segments- data centers and healthcare. Summary information for the reportable segments during the years ended December 31, 2020, 2019 and 2018 is as follows (amounts in thousands): Data Centers Healthcare Year Ended December 31, 2020 Revenue: Rental revenue $ 110,755 $ 165,781 $ 276,536 Expenses: Rental expenses (28,346) (15,187) (43,533) Segment net operating income $ 82,409 $ 150,594 233,003 Expenses: General and administrative expenses (16,681) Internalization transaction expenses (3,640) Asset management fees (17,914) Depreciation and amortization (105,483) Gain on real estate dispositions 3,142 Income from operations 92,427 Interest and other expense, net (55,651) Net income attributable to common stockholders $ 36,776 Data Centers Healthcare Year Ended Revenue: Rental revenue $ 109,689 $ 101,212 $ 210,901 Expenses: Rental expenses (30,270) (10,714) (40,984) Segment net operating income $ 79,419 $ 90,498 169,917 Expenses: General and administrative expenses (8,421) Asset management fees (16,475) Depreciation and amortization (74,104) Impairment loss on real estate - healthcare (21,000) Gain on real estate disposition 79 Income from operations 49,996 Interest and other expense, net (47,214) Net income attributable to common stockholders $ 2,782 Data Centers Healthcare Year Ended December 31, 2018 Revenue: Rental revenue $ 103,226 $ 74,107 $ 177,333 Expenses: Rental expenses (27,289) (10,038) (37,327) Segment net operating income $ 75,937 $ 64,069 140,006 Expenses: General and administrative expenses (5,396) Asset management fees (13,114) Depreciation and amortization (58,258) Income from operations 63,238 Interest and other expense, net (34,365) Net income attributable to common stockholders $ 28,873 There were no intersegment sales or transfers during the years ended December 31, 2020, 2019 and 2018. Assets by each reportable segment as of December 31, 2020 and 2019 are as follows (amounts in thousands): December 31, 2020 December 31, 2019 Assets by segment: Data centers $ 979,222 (1) $ 989,953 Healthcare 2,147,389 (1) 2,184,450 All other 78,678 65,131 Total assets $ 3,205,289 $ 3,239,534 (1) Includes $15,574,000 of goodwill allocated to the data centers segment and $23,955,000 of goodwill allocated to the healthcare segment acquired in the Internalization Transaction on September 30, 2020. Capital additions, acquisitions and dispositions and goodwill by reportable segments for the years ended December 31, 2020, 2019 and 2018 are as follows (amounts in thousands): Year Ended 2020 2019 2018 Capital additions by segment: Data centers $ 3,945 $ 7,004 $ 2,763 Healthcare 24,852 5,837 12,820 Total 28,797 12,841 15,583 Acquisitions by segment: Data centers — — 112,181 Healthcare 16,135 528,259 105,151 Total 16,135 528,259 217,332 Proceeds from Dispositions by segment: Data centers — — — Healthcare (28,542) (2,882) — Total (28,542) (2,882) — Net cash outflows from capital additions, acquisitions and dispositions $ 16,390 $ 538,218 $ 232,915 Goodwill allocated by segment: Data centers $ 15,574 $ — — Healthcare 23,955 — — Total $ 39,529 $ — $ —

Fair Value

Fair Value	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value	Fair Value Notes payable—Fixed Rate —The estimated fair value of notes payable — fixed rate measured using observable inputs from similar liabilities (Level 2) was approximately $229,999,000 and $222,816,000 as of December 31, 2020 and 2019, respectively, as compared to the outstanding principal of $218,415,000 and $219,567,000 as of December 31, 2020 and 2019, respectively. The estimated fair value of notes payable — variable rate fixed through interest rate swap agreements (Level 2) was approximately $234,554,000 and $237,974,000 as of December 31, 2020 and 2019, respectively, as compared to the outstanding principal of $235,007,000 and $237,778,000 as of December 31, 2020 and 2019, respectively. Credit facility — Variable Rate —The estimated fair value of the credit facility—variable rate (Level 2) was approximately $536,329,000 and $659,691,000 as of December 31, 2020 and 2019, respectively, as compared to the outstanding principal of $538,000,000 and $658,000,000 as of December 31, 2020 and 2019, respectively. Credit facility — Fixed Rate —The estimated fair value of the credit facility—variable rate fixed through interest rate swap agreements (Level 2) was approximately $398,563,000 and $250,472,000 as of December 31, 2020 and 2019, respectively, as compared to the outstanding principal of $400,000,000 and $250,000,000 as of December 31, 2020 and 2019, respectively. The fair value of the Company's debt is estimated based on the interest rates currently offered to the Company by its respective financial institution. Notes receivable —The outstanding principal balance of the notes receivable in the amount of $30,700,000 and $2,700,000 approximated the fair value as of December 31, 2020 and 2019, respectively. The fair value was determined through the evaluation of credit quality indicators such as underlying collateral and payment history and measured using significant other observable inputs (Level 2), which requires certain judgments to be made by management. Derivative instruments —Considerable judgment is necessary to develop estimated fair values of financial instruments. Accordingly, the estimates presented herein are not necessarily indicative of the amount the Company could realize, or be liable for, on disposition of the financial instruments. The Company determined that the majority of the inputs used to value its interest rate swaps fall within Level 2 of the fair value hierarchy. The credit valuation adjustments associated with these instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by the Company and the respective counterparty. However, as of December 31, 2020, the Company assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and determined that the credit valuation adjustments are not significant to the overall valuation of its interest rate swaps. As a result, the Company determined that its interest rate swaps valuation in its entirety is classified in Level 2 of the fair value hierarchy. See Note 16—"Derivative Instruments and Hedging Activities" for further discussion of the Company's derivative instruments. The following tables show the fair value of the Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of December 31, 2020 and 2019 (amounts in thousands): December 31, 2020 Fair Value Hierarchy Quoted Prices in Active Significant Other Significant Total Fair Liabilities: Derivative liabilities $ — $ 20,444 $ — $ 20,444 Total liabilities at fair value $ — $ 20,444 $ — $ 20,444 December 31, 2019 Fair Value Hierarchy Quoted Prices in Active Significant Other Significant Total Fair Assets: Derivative assets $ — $ 884 $ — $ 884 Total assets at fair value $ — $ 884 $ — $ 884 Liabilities: Derivative liabilities $ — $ 5,588 $ — $ 5,588 Total liabilities at fair value $ — $ 5,588 $ — $ 5,588

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	12 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	Derivative Instruments and Hedging Activities Cash Flow Hedges of Interest Rate Risk The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable rate amounts from a counterparty in exchange for the Company making fixed rate payments over the life of the agreements without exchange of the underlying notional amount. Changes in the fair value of derivatives designated, and that qualify, as cash flow hedges are recorded in accumulated other comprehensive (loss) income in the accompanying consolidated statements of stockholders' equity and are subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. Amounts reported in accumulated other comprehensive loss related to derivatives will be reclassified to interest and other expense, net, as interest payments are made on the Company’s variable rate debt. During the next twelve months, the Company estimates that an additional $9,486,000 will be reclassified from accumulated other comprehensive loss as an increase to interest and other expense, net. See Note 15—"Fair Value" for further discussion of the fair value of the Company’s derivative instruments. The following table summarizes the notional amount and fair value of the Company’s derivative instruments (amounts in thousands): Derivatives Balance Effective Maturity December 31, 2020 December 31, 2019 Outstanding Fair Value of Outstanding Fair Value of Asset (Liability) Asset (Liability) Interest rate swaps Other assets, net/ 11/01/2016 to 10/28/2021 to $ 635,007 $ — $ (20,444) $ 637,778 $ 884 $ (5,588) The notional amount under the agreements is an indication of the extent of the Company’s involvement in each instrument at the time, but does not represent exposure to credit, interest rate or market risks. Accounting for changes in the fair value of a derivative instrument depends on the intended use and designation of the derivative instrument. The Company designated the interest rate swaps as cash flow hedges to hedge the variability of the anticipated cash flows on its variable rate credit facility and notes payable. The change in fair value of the derivative instruments that are designated as hedges are recorded in other comprehensive (loss) income in the accompanying consolidated statements of comprehensive income (loss). The table below summarizes the amount of (loss) income recognized on the interest rate derivatives designated as cash flow hedges for the years ended December 31, 2020, 2019 and 2018 (amounts in thousands): Derivatives in Cash Flow Amount of (Loss) Income Recognized Location of (Loss) Income Amount of (Loss) Income Total Amount of Interest and Other Expense, Net Presented in Statements of Comprehensive Income (Loss) Year Ended December 31, 2020 Interest rate swaps $ (23,583) Interest and other expense, net $ (7,843) $ 55,651 Total $ (23,583) $ (7,843) Year Ended December 31, 2019 Interest rate swaps $ (9,305) Interest and other expense, net $ 1,602 $ 47,214 Total $ (9,305) $ 1,602 Year Ended December 31, 2018 Interest rate swaps $ 3,208 Interest and other expense, net $ 818 $ 34,365 Total $ 3,208 $ 818 Credit Risk-Related Contingent Features The Company has agreements with each of its derivative counterparties that contain a provision where if the Company either defaults or is capable of being declared in default on any of its indebtedness, then the Company could also be declared in default on its derivative obligations. The Company records credit risk valuation adjustments on its interest rate swaps based on the respective credit quality of the Company and the counterparty. The Company believes it mitigates its credit risk by entering into agreements with creditworthy counterparties. As of December 31, 2020, the fair value of derivatives in a net liability position was $21,901,000, inclusive of accrued interest but excluding any adjustment for nonperformance risk related to the agreement. As of December 31, 2020, there were no termination events or events of default related to the interest rate swaps. Tabular Disclosure Offsetting Derivatives The Company has elected not to offset derivative positions in its consolidated financial statements. The following tables present the effect on the Company’s financial position had the Company made the election to offset its derivative positions as of December 31, 2020 and 2019 (amounts in thousands): Offsetting of Derivative Assets Gross Amounts Not Offset in the Balance Sheet Gross Gross Amounts Net Amounts of Financial Instruments Cash Collateral Net December 31, 2019 $ 884 $ — $ 884 $ (5) $ — $ 879 Offsetting of Derivative Liabilities Gross Amounts Not Offset in the Balance Sheet Gross Gross Amounts Net Amounts of Financial Instruments Cash Collateral Net December 31, 2020 $ 20,444 $ — $ 20,444 $ — $ — $ 20,444 December 31, 2019 $ 5,588 $ — $ 5,588 $ (5) $ — $ 5,583 The Company reports derivative assets and derivative liabilities in the accompanying consolidated balance sheets as other assets, net, and accounts payable and other liabilities, respectively.

Accumulated Other Comprehensive

Accumulated Other Comprehensive (Loss) Income	12 Months Ended
	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive (Loss) Income	Accumulated Other Comprehensive (Loss) Income The following table presents a rollforward of amounts recognized in accumulated other comprehensive (loss) income by component for the years ended December 31, 2020, 2019 and 2018 (amounts in thousands): Unrealized Income (Loss) on Derivative Balance as of December 31, 2017 $ 3,710 Other comprehensive income before reclassification 3,208 Amount of income reclassified from accumulated other comprehensive income to net income (effective portion) (818) Other comprehensive income 2,390 Balance as of December 31, 2018 6,100 Cumulative effect of accounting change 103 Balance as of January 1, 2019 6,203 Other comprehensive loss before reclassification (9,305) Amount of income reclassified from accumulated other comprehensive income to net income (including missed forecast) (1,602) Other comprehensive loss (10,907) Balance as of December 31, 2019 (4,704) Other comprehensive loss before reclassification (23,583) Amount of loss reclassified from accumulated other comprehensive loss to net income 7,843 Other comprehensive loss (15,740) Balance as of December 31, 2020 $ (20,444) The following table presents reclassifications out of accumulated other comprehensive (loss) income for the years ended December 31, 2020, 2019 and 2018 (amounts in thousands): Details about Accumulated Other Amounts Reclassified from Affected Line Items in the Consolidated Statements of Comprehensive Income (Loss) Year Ended 2020 2019 2018 Interest rate swap contracts $ 7,843 $ (1,602) $ (818) Interest and other expense, net

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock-based Compensation	Stock-based Compensation Incentive Plan On May 6, 2014, the Company adopted the 2014 restricted share plan, or the Incentive Plan, pursuant to which the Company has the power and authority to grant restricted or deferred stock awards to persons eligible under the Incentive Plan. The Company authorized and reserved 300,000 shares of its Class A shares for issuance under the Incentive Plan, subject to certain adjustments. On March 6, 2020, the Company's board of directors approved the Amended and Restated 2014 restricted share plan, or the A&R Incentive Plan, pursuant to which the Company has the authority and power to grant awards of restricted shares of its Class A common stock to its directors, officers and employees. The Company's board of directors has authorized a total of 5,000,000 Class A shares of common stock for issuance under the A&R Incentive Plan on a fully diluted basis at any time. Subject to certain limited exceptions, restricted stock may not be sold, assigned, transferred, pledged, encumbered, hypothecated or otherwise disposed of and is subject to forfeiture within the vesting period. The Company uses the straight-line method to recognize expenses for service awards with graded vesting. On March 6, 2020, the Company's board of directors determined to revise the amounts of restricted Class A shares of common stock the independent directors are entitled to receive each year. On July 1, 2020, the Company granted each independent director $60,000 in restricted shares of Class A common stock. Restricted shares of Class A common stock issued to the Company’s independent directors in July 2020 will vest over a three-year period following the first anniversary of the date of grant in increments of 33.34% per annum. The fair value of each share of restricted common stock was estimated at the date of grant at $8.65 per share. The Company’s board of directors determined that, effective upon the closing of the Internalization Transaction, the independent directors are entitled to receive $70,000 each year in restricted shares of Class A common stock of the Company at the most recently determined estimated net asset value per share (the 2020 grant was prorated through June 30, 2021), which were issued pursuant to the Company’s A&R Incentive Plan. Restricted shares of Class A common stock issued to the independent directors will vest over a one-year period. On October 1, 2020, the Company granted each independent director $7,500 in restricted shares of Class A common stock, which will vest over a one-year period. The fair value of each share of restricted common stock was estimated at the date of grant at $8.65 per share. Executive Awards Concurrently with, and as a condition to the execution and delivery of the Purchase Agreement on July 28, 2020, the Company entered into an employment agreement with each of Michael A. Seton and Kay C. Neely, or the Executives, pursuant to which Mr. Seton and Ms. Neely have served from and after the closing of the Internalization Transaction as the Company’s Chief Executive Officer and Chief Financial Officer, respectively. Such employment agreements became effective on September 30, 2020. Subject to each Executive’s continued employment through the grant date, in the first quarter of calendar year 2021, each Executive will receive an award of time-based restricted shares of Class A common stock, or the Time-Based 2021 Award, and an award of performance-based restricted stock units, or the Performance-Based 2021 Award, and together with the Time-Based 2021 Award, the “2021 Awards”, each to be granted under and subject to the terms of the Company’s A&R Incentive Plan and award agreements. In the case of Mr. Seton, the combined value of the shares of the Company’s common stock underlying the 2021 Awards on the grant date will be $1,800,000, with 50% of the grant date value of the 2021 Awards consisting of the Performance-Based 2021 Award and 50% consisting of the Time-Based 2021 Award. In the case of Ms. Neely, the combined value of the shares of the Company’s common stock underlying the 2021 Awards will be $700,000, with 50% of the grant date value of the 2021 Awards consisting of the Performance-Based 2021 Award and 50% consisting of the Time-Based 2021 Award. The performance objectives and other terms and conditions of the Performance-Based 2021 Award were determined by the Company's compensation committee, which was established and effective upon the closing of the Internalization Transaction. The Time-Based 2021 Award will vest ratably over four years following the grant date, subject to the Executive’s continued employment through the applicable vesting dates, with certain exceptions. The Performance-Based 2021 Award will vest based on the level of achievement of performance over the three On October 1, 2020, Mr. Seton and Ms. Neely received a grant of 231,214 and 115,607 time-based restricted shares of Class A common stock, respectively, with a grant date fair value of $2,000,000 and $1,000,000, respectively, which, subject to the Executive’s continuous employment through the applicable vesting dates, with certain exceptions, will vest on December 31, 2024, or, if earlier, on the 15th month anniversary of the date of a “qualified event” (such as a listing of the Company’s stock on a nationally recognized stock exchange or an underwritten public offering of the Company’s stock). The awards were granted under and subject to the terms of the A&R Incentive Plan and an award agreement. Additionally, on October 1, 2020, the Company granted one-time awards of approximately 206,936 restricted shares of Class A common stock to certain employees at the date of grant fair value per share of $8.65. The granted shares will vest on December 31, 2024, or, if earlier, on the 15th month anniversary of the date of a “qualified event” defined above. The awards were granted under and subject to the terms of the A&R Incentive Plan and an award agreement. On January 8, 2021, the Company granted the Time-Based 2021 Award to Mr. Seton and Ms. Neely of 103,567 and 40,276 in restricted shares of Class A common stock, respectively. In addition, on January 8, 2021, the Company's compensation committee approved performance-based deferred stock unit awards, or Performance DSUs, to be granted for the Performance-Based 2021 Award. The Performance DSUs represent the right to receive a number of restricted shares of Class A common stock of the Company on a one-to-one basis with the number of Performance DSUs that vest. The awards were granted under and subject to the terms of the A&R Incentive Plan and an award agreement. As of December 31, 2020 and 2019, there was $4,921,000 and $215,000, respectively, of total unrecognized compensation expense related to nonvested shares of the Company’s restricted Class A common stock. This expense is expected to be recognized over a remaining weighted average period of 3.77 years. This expected expense does not include the impact of any future stock-based compensation awards. As of December 31, 2020 and 2019, the fair value of the nonvested shares of restricted Class A common stock was $5,326,336 and $240,038, respectively. A summary of the status of the nonvested shares of restricted Class A common stock as of December 31, 2019 and the changes for the year ended December 31, 2020 is presented below: Restricted Stock Shares Nonvested at December 31, 2019 27,750 Vested (10,500) Granted 595,677 Nonvested at December 31, 2020 612,927 Stock-based compensation expense for the years ended December 31, 2020, 2019 and 2018 was approximately $437,000, $89,000 and $90,000, respectively, which is reported in general and administrative costs in the accompanying consolidated statements of comprehensive income (loss).

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes As a REIT, the Company generally will not be subject to U.S. federal income tax on taxable income that it distributes to the stockholders. For U.S. federal income tax purposes, distributions to stockholders are characterized as either ordinary dividends, capital gain distributions, or nontaxable distributions. Nontaxable distributions will reduce U.S. stockholders’ respective bases in their shares. The following table shows the character of distributions the Company paid on a percentage basis during the years ended December 31, 2020, 2019 and 2018: Year Ended December 31, Character of Class A Distributions: 2020 2019 2018 Ordinary dividends — % 17.93 % 41.38 % Capital gain distributions — % 0.38 % — % Nontaxable distributions 100.00 % 81.69 % 58.62 % Total 100.00 % 100.00 % 100.00 % Year Ended December 31, Character of Class I Distributions: 2020 2019 2018 Ordinary dividends — % 17.93 % 41.38 % Capital gain distributions — % 0.38 % — % Nontaxable distributions 100.00 % 81.69 % 58.62 % Total 100.00 % 100.00 % 100.00 % Year Ended December 31, Character of Class T Distributions: 2020 2019 2018 Ordinary dividends — % 4.79 % 33.01 % Capital gain distributions — % 0.43 % — % Nontaxable distributions 100.00 % 94.78 % 66.99 % Total 100.00 % 100.00 % 100.00 % Year Ended December 31, Character of Class T2 Distributions: 2020 2019 2018 Ordinary dividends — % 4.79 % 33.01 % Capital gain distributions — % 0.43 % — % Nontaxable distributions 100.00 % 94.78 % 66.99 % Total 100.00 % 100.00 % 100.00 % The Company is subject to certain state and local income taxes on income, property or net worth in some jurisdictions, and in certain circumstances may also be subject to federal excise tax on undistributed income. Texas, Tennessee, California, Louisiana, North Carolina and Massachusetts are the major state and local tax jurisdictions for the Company. The Company applies the rules under ASC 740-10, Accounting for Uncertainty in Income Taxes , for uncertain tax positions using a “more likely than not” recognition threshold for tax positions. Pursuant to these rules, the financial statement effects of a tax position are initially recognized when it is more likely than not, based on the technical merits of the tax position, that such a position will be sustained upon examination by the relevant tax authorities. If the tax benefit meets the “more likely than not” threshold, the measurement of the tax benefit will be based on the Company's estimate of the ultimate tax benefit to be sustained if audited by the taxing authority. The Company concluded there was no impact related to uncertain tax positions from the results of the operations of the Company for the years ended December 31, 2020, 2019 and 2018. The earliest tax year subject to examination is 2017. The Company’s policy is to recognize accrued interest related to unrecognized tax benefits as a component of interest expense and penalties related to unrecognized tax benefits as a component of general and administrative expenses. From

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies In the ordinary course of business, the Company may become subject to litigation or claims. As of December 31, 2020, there were, and currently there are, no material pending legal proceedings to which the Company is a party. While the resolution of a lawsuit or proceeding may have an impact to the Company's financial results for the period in which it is resolved, the Company believes that the final resolution of the lawsuits or proceedings in which it is currently involved, either individually or in the aggregate, will not have a material adverse effect on its financial position, results of operations or liquidity.

Selected Quarterly Financial Da

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data (Unaudited)	Selected Quarterly Financial Data (Unaudited) Presented in the following table is a summary of the unaudited quarterly financial information for the years ended December 31, 2020 and 2019. The Company believes that all necessary adjustments, consisting only of normal recurring adjustments, have been included in the amounts stated below to present fairly, and in accordance with GAAP, the selected quarterly information (amounts in thousands, except shares and per share data): 2020 Fourth Third Second First Total revenue $ 67,809 $ 70,667 $ 68,875 $ 69,185 Total expenses (40,651) (52,119) (46,284) (48,197) Gain on real estate dispositions 439 — 2,703 — Income from operations 27,597 18,548 25,294 20,988 Interest and other expense, net (12,849) (13,284) (14,199) (15,319) Net income attributable to common stockholders $ 14,748 $ 5,264 $ 11,095 $ 5,669 Net income per common share attributable to common stockholders: Basic $ 0.07 $ 0.02 $ 0.05 $ 0.03 Diluted $ 0.07 $ 0.02 $ 0.05 $ 0.03 Weighted average number of common shares outstanding: Basic 221,863,141 221,346,730 220,992,009 221,540,890 Diluted 222,475,926 221,406,461 221,029,409 221,570,975 2019 Fourth Third Second First Total revenue $ 69,434 $ 48,063 $ 46,937 $ 46,467 Total expenses (52,160) (45,773) (30,780) (32,271) Gain on real estate disposition 79 — — — Income from operations 17,353 2,290 16,157 14,196 Interest and other expense, net (15,566) (11,920) (9,893) (9,835) Net income (loss) attributable to common stockholders $ 1,787 $ (9,630) $ 6,264 $ 4,361 Net income (loss) per common share attributable to common stockholders: Basic $ 0.01 $ (0.07) $ 0.05 $ 0.03 Diluted $ 0.01 $ (0.07) $ 0.05 $ 0.03 Weighted average number of common shares outstanding: Basic 218,928,165 137,063,509 136,135,710 136,179,343 Diluted 218,955,915 137,063,509 136,161,037 136,204,843

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Distributions Paid to Stockholders The following table summarizes the Company's distributions paid to stockholders on January 4, 2021, for the period from December 1, 2020 through December 31, 2020 (amounts in thousands): Payment Date Common Stock Cash DRIP Total Distribution January 4, 2021 Class A $ 5,489 $ 1,587 $ 7,076 January 4, 2021 Class I 325 212 537 January 4, 2021 Class T 704 679 1,383 January 4, 2021 Class T2 56 65 121 $ 6,574 $ 2,543 $ 9,117 The following table summarizes the Company's distributions paid to stockholders on February 1, 2021, for the period from January 1, 2021 through January 31, 2021 (amounts in thousands): Payment Date Common Stock Cash DRIP Total Distribution February 1, 2021 Class A $ 5,520 $ 1,586 $ 7,106 February 1, 2021 Class I 328 211 539 February 1, 2021 Class T 708 679 1,387 February 1, 2021 Class T2 56 65 121 $ 6,612 $ 2,541 $ 9,153 The following table summarizes the Company's distributions paid to stockholders on March 2, 2021, for the period from February 1, 2021 through February 28, 2021 (amounts in thousands): Payment Date Common Stock Cash DRIP Total Distribution March 2, 2021 Class A $ 4,992 $ 1,432 $ 6,424 March 2, 2021 Class I 298 191 489 March 2, 2021 Class T 642 613 1,255 March 2, 2021 Class T2 51 57 108 $ 5,983 $ 2,293 $ 8,276 Distributions Authorized The following tables summarize the daily distributions approved and authorized by the board of directors of the Company subsequent to December 31, 2020: Authorization Date (1) Common Stock Daily Distribution Rate (1) Annualized Distribution Per Share January 25, 2021 Class A $ 0.001369863 $ 0.50 January 25, 2021 Class I $ 0.001369863 $ 0.50 January 25, 2021 Class T $ 0.001131781 $ 0.41 January 25, 2021 Class T2 $ 0.001131781 $ 0.41 Authorization Date (2) Common Stock Daily Distribution Rate (2) Annualized Distribution Per Share February 25, 2021 Class A $ 0.001369863 $ 0.50 February 25, 2021 Class I $ 0.001369863 $ 0.50 February 25, 2021 Class T $ 0.001131781 $ 0.41 February 25, 2021 Class T2 $ 0.001131781 $ 0.41 Authorization Date (3) Common Stock Daily Distribution Rate (3) Annualized Distribution Per Share March 18, 2021 Class A $ 0.001369863 $ 0.50 March 18, 2021 Class I $ 0.001369863 $ 0.50 March 18, 2021 Class T $ 0.001131781 $ 0.41 March 18, 2021 Class T2 $ 0.001131781 $ 0.41 (1) Distributions approved and authorized to stockholders of record as of the close of business on each day of the period commencing on February 1, 2021 and ending on February 28, 2021. The distributions will be calculated based on 365 days in the calendar year. The distributions declared for each record date in February 2021 will be paid in March 2021. The distributions will be payable to stockholders from legally available funds therefor. (2) Distributions approved and authorized to stockholders of record as of the close of business on each day of the period commencing on March 1, 2021 and ending on March 31, 2021. The distributions will be calculated based on 365 days in the calendar year. The distributions declared for each record date in March 2021 will be paid in April 2021. The distributions will be payable to stockholders from legally available funds therefor. (3) Distributions approved and authorized to stockholders of record as of the close of business on each day of the period commencing on April 1, 2021 and ending on April 30, 2021. The distributions will be calculated based on 365 days in the calendar year. The distributions declared for each record date in April 2021 will be paid in May 2021. The distributions will be payable to stockholders from legally available funds therefor.

SCHEDULE III - REAL ESTATE ASSE

SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION	12 Months Ended
	Dec. 31, 2020
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract]
SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION	SCHEDULE III — REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION December 31, 2020 (in thousands) Initial Cost Cost Gross Amount Property Description Location Encumbrances Land Buildings and Land Buildings and Total Accumulated Year Year Date Houston Healthcare Facility Houston, TX $ — (a) $ 762 $ 2,970 $ 106 $ 762 $ 3,076 $ 3,838 $ 653 1993 — 07/31/2014 Cincinnati Healthcare Facility Cincinnati, OH — (a) 356 3,167 89 356 3,256 3,612 604 2001 — 10/29/2014 Winston-Salem Healthcare Facility Winston-Salem, NC — (a) 684 4,903 — 684 4,903 5,587 882 2004 — 12/17/2014 Stoughton Healthcare Facility Stoughton, MA — (a) 4,049 19,991 2,342 4,049 22,333 26,382 3,601 1973 1997 12/23/2014 Fort Worth Healthcare Facility Fort Worth, TX — (a) 8,297 35,615 — 8,297 35,615 43,912 5,641 2014 — 12/31/2014 Fort Worth Healthcare Facility II Fort Worth, TX — (a) 367 1,587 164 367 1,751 2,118 481 2014 — 12/31/2014 Winter Haven Healthcare Facility Winter Haven, FL — (a) — 2,805 — — 2,805 2,805 464 2009 — 01/27/2015 Overland Park Healthcare Facility Overland Park, KS — (a) 1,558 20,549 — 1,558 20,549 22,107 3,174 2014 — 02/17/2015 Indianapolis Data Center Indianapolis, IN — (a) 524 6,422 37 524 6,459 6,983 961 2000 2014 04/01/2015 Clarion Healthcare Facility Clarion, PA — (a) 462 5,377 — 462 5,377 5,839 1,008 2012 — 06/01/2015 Webster Healthcare Facility Webster, TX — (a) 1,858 20,140 — 1,858 20,140 21,998 2,927 2015 — 06/05/2015 Eagan Data Center Eagan, MN — (a) 768 5,037 — 768 5,037 5,805 861 1998 2015 06/29/2015 Houston Healthcare Facility II Houston, TX — 8,329 36,297 (17,360) 8,329 18,937 27,266 753 1950 2005/2008 06/30/2015 Augusta Healthcare Facility Augusta, ME — (a) 556 14,401 — 556 14,401 14,957 2,224 2010 — 07/22/2015 Cincinnati Healthcare Facility II Cincinnati, OH — (a) 1,812 24,382 — 1,812 24,382 26,194 3,881 1960 2014 07/22/2015 Cincinnati Healthcare Facility III Cincinnati, OH — (a) 446 10,239 4 446 10,243 10,689 1,487 2014 — 07/22/2015 Florence Healthcare Facility Florence, KY — (a) 650 9,919 — 650 9,919 10,569 1,434 2014 — 07/22/2015 Oakland Healthcare Facility Oakland, ME — (a) 229 5,416 — 229 5,416 5,645 904 2014 — 07/22/2015 Wyomissing Healthcare Facility Wyomissing, PA — (a) 1,504 20,193 — 1,504 20,193 21,697 2,978 2007 — 07/24/2015 Luling Healthcare Facility Luling, TX — (a) 824 7,530 — 824 7,530 8,354 1,104 2002 — 07/30/2015 Minnetonka Data Center Minnetonka, MN — (a) 2,085 15,099 119 1,999 15,304 17,303 2,862 1985 2001/2006 08/28/2015 Omaha Healthcare Facility Omaha, NE — (a) 1,259 9,796 — 1,259 9,796 11,055 1,341 2014 — 10/14/2015 Sherman Healthcare Facility Sherman, TX — (a) 1,679 23,926 — 1,679 23,926 25,605 3,186 2005 2010 11/20/2015 Sherman Healthcare Facility II Sherman, TX — (a) 214 3,209 — 214 3,209 3,423 431 2005 — 11/20/2015 Fort Worth Healthcare Facility III Fort Worth, TX — (a) 3,120 9,312 — 3,120 9,312 12,432 1,235 1998 2007/2015 12/23/2015 Oklahoma City Healthcare Facility Oklahoma City, OK 21,760 4,626 30,509 — 4,626 30,509 35,135 4,177 1985 1998/2003 12/29/2015 Oklahoma City Healthcare Facility II Oklahoma City, OK — (a) 991 8,366 — 991 8,366 9,357 1,218 1994 1999 12/29/2015 Waco Data Center Waco, TX — (a) 873 8,233 — 873 8,233 9,106 1,050 1956 2009 12/30/2015 Edmond Healthcare Facility Edmond, OK — (a) 796 3,199 — 796 3,199 3,995 467 2002 — 01/20/2016 Oklahoma City Healthcare Facility III Oklahoma City, OK — (a) 452 1,081 — 452 1,081 1,533 162 2006 — 01/27/2016 Oklahoma City Healthcare Facility IV Oklahoma City, OK — (a) 368 2,344 — 368 2,344 2,712 342 2007 — 01/27/2016 Alpharetta Data Center Alpharetta, GA — (a) 3,395 11,081 25 3,395 11,106 14,501 1,488 1999 — 02/02/2016 Flint Data Center Flint, MI — (a) 111 7,001 — 111 7,001 7,112 925 1989 2016 02/02/2016 Newcastle Healthcare Facility Newcastle, OK — (a) 412 1,173 — 412 1,173 1,585 174 1995 1999 02/03/2016 Oklahoma City Healthcare Facility V Oklahoma City, OK — (a) 541 12,445 — 541 12,445 12,986 1,790 2008 — 02/11/2016 Rancho Mirage Healthcare Facility Rancho Mirage, CA — 2,724 7,626 29,844 2,726 37,468 40,194 2,224 2018 — 03/01/2016 Initial Cost Cost Gross Amount Property Description Location Encumbrances Land Buildings and Land Buildings and Total Accumulated Year Year Date Oklahoma City Healthcare Facility VI Oklahoma City, OK — (a) 896 3,684 — 896 3,684 4,580 536 2007 — 03/07/2016 Franklin Data Center Franklin, TN — (a) 6,624 10,971 135 6,624 11,106 17,730 1,439 2016 2019 03/31/2016 Oklahoma City Healthcare Facility VII Oklahoma City, OK 23,988 3,203 32,380 — 3,203 32,380 35,583 3,859 2016 — 06/22/2016 Las Vegas Healthcare Facility Las Vegas, NV — (a) 2,614 639 22,091 2,895 22,449 25,344 1,801 2017 — 06/24/2016 Somerset Data Center Somerset, NJ — (a) 906 10,466 — 906 10,466 11,372 1,373 1978 2016 06/29/2016 Oklahoma City Healthcare Facility VIII Oklahoma City, OK — (a) 2,002 15,384 — 2,002 15,384 17,386 1,809 1997 2008 06/30/2016 Hawthorne Data Center Hawthorne, CA 39,749 16,498 57,312 — 16,498 57,312 73,810 6,254 1963 1983/2001 09/27/2016 McLean Data Center McLean, VA 23,460 31,554 4,930 330 31,554 5,260 36,814 616 1966 1998 10/17/2016 McLean Data Center II McLean, VA 27,540 20,392 22,727 105 20,392 22,832 43,224 2,473 1991 2019 10/17/2016 Marlton Healthcare Facility Marlton, NJ 30,471 — 57,154 5 — 57,159 57,159 5,896 1995 — 11/01/2016 Andover Data Center Andover, MA — (a) 6,566 28,072 514 6,566 28,586 35,152 3,299 2000 — 11/08/2016 Grand Rapids Healthcare Facility Grand Rapids, MI 21,381 2,533 39,487 95 2,533 39,582 42,115 4,940 2008 — 12/07/2016 Corpus Christi Healthcare Facility Corpus Christi, TX — (a) 975 4,963 698 1,002 5,634 6,636 621 1992 — 12/22/2016 Chicago Data Center Downers Grove, IL — (a) 1,329 29,940 (545) 1,358 29,366 30,724 3,024 1987 2016 12/28/2016 Blythewood Data Center Blythewood, SC — (a) 612 17,714 27 634 17,719 18,353 1,842 1983 — 12/29/2016 Tempe Data Center Tempe, AZ — (a) 2,997 11,991 132 2,997 12,123 15,120 1,262 1977 2016 01/26/2017 Aurora Healthcare Facility Aurora, IL — (a) 973 9,632 — 973 9,632 10,605 986 2002 — 03/30/2017 Norwalk Data Center Norwalk, CT 33,400 10,125 43,360 94 10,125 43,454 53,579 4,207 2013 — 03/30/2017 Allen Healthcare Facility Allen, TX 12,974 857 20,582 — 857 20,582 21,439 2,101 2007 — 03/31/2017 Austin Healthcare Facility Austin, TX 20,603 1,368 32,039 — 1,368 32,039 33,407 3,270 2012 — 03/31/2017 Beaumont Healthcare Facility Beaumont, TX 5,791 946 8,372 — 946 8,372 9,318 859 1991 — 03/31/2017 Charlotte Data Center Charlotte, NC — (a) 372 17,131 3,382 372 20,513 20,885 2,096 1989 2016 05/15/2017 Atlanta Data Center Atlanta, GA 116,200 19,159 129,778 8,435 19,159 138,213 157,372 17,357 1989 2007/2020 (e) 06/15/2017 Sunnyvale Data Center Sunnyvale, CA — (a) 10,013 24,709 — 10,013 24,709 34,722 2,252 1992 1998 06/28/2017 San Antonio Healthcare Facility San Antonio, TX 10,360 1,813 11,706 — 1,813 11,706 13,519 1,124 2012 — 06/29/2017 Cincinnati Data Center Cincinnati, OH — (a) 1,556 8,966 — 1,556 8,966 10,522 887 1985 2010 06/30/2017 Silverdale Healthcare Facility Silverdale, WA — (a) 1,530 7,506 15 1,530 7,521 9,051 776 2005 — 08/25/2017 Silverdale Healthcare Facility II Silverdale, WA — (a) 1,542 4,981 — 1,542 4,981 6,523 550 2007 — 09/20/2017 King of Prussia Data Center King of Prussia, PA 11,671 1,015 17,413 — 1,015 17,413 18,428 1,482 1960 1997 09/28/2017 Tempe Data Center II Tempe, AZ — (a) — 15,803 — — 15,803 15,803 1,361 1998 — 09/29/2017 Houston Data Center Houston, TX 48,607 10,082 101,051 — 10,082 101,051 111,133 8,011 2013 — 11/16/2017 Saginaw Healthcare Facility Saginaw, MI — (a) 1,251 15,878 235 1,251 16,113 17,364 1,747 2002 — 12/21/2017 Elgin Data Center Elgin, IL 5,467 1,067 7,861 (421) 1,067 7,440 8,507 602 2000 — 12/22/2017 Oklahoma City Data Center Oklahoma City, OK — (a) 1,868 44,253 — 1,868 44,253 46,121 3,460 2008/2016 — 12/27/2017 Rancho Cordova Data Center Rancho Cordova, CA — (a) 1,760 32,109 — 1,760 32,109 33,869 2,282 1982 2008/2010 03/14/2018 Rancho Cordova Data Center II Rancho Cordova, CA — (a) 1,943 10,340 — 1,943 10,340 12,283 750 1984 2012 03/14/2018 Carrollton Healthcare Facility Carrollton, TX — (a) 1,995 5,870 — 1,995 5,870 7,865 441 2015 — 04/27/2018 Katy Healthcare Facility Katy, TX — (a) 1,443 12,114 — 1,443 12,114 13,557 799 2015 — 06/08/2018 San Jose Data Center San Jose, CA — (a) 12,205 34,309 — 12,205 34,309 46,514 2,240 1999 2009 06/13/2018 Initial Cost Cost Gross Amount Property Description Location Encumbrances Land Buildings and Land Buildings and Total Accumulated Year Year Date Indianola Healthcare Facility Indianola, IA — (a) 330 5,698 — 330 5,698 6,028 357 2014 — 09/26/2018 Indianola Healthcare Facility II Indianola, IA — (a) 709 6,061 — 709 6,061 6,770 392 2011 — 09/26/2018 Canton Data Center Canton, OH — (a) 345 8,268 — 345 8,268 8,613 473 2008 — 10/03/2018 Benton Healthcare Facility Benton, AR — (a) — 19,048 — — 19,048 19,048 1,142 1992/1999 — 10/17/2018 Benton Healthcare Facility II Benton, AR — (a) — 1,647 — — 1,647 1,647 110 1983 — 10/17/2018 Bryant Healthcare Facility Bryant, AR — (a) 930 3,539 — 930 3,539 4,469 234 1995 — 10/17/2018 Hot Springs Healthcare Facility Hot Springs, AR — (a) 384 2,077 — 384 2,077 2,461 142 2009 — 10/17/2018 Clive Healthcare Facility Clive, IA — (a) 336 22,332 61 336 22,393 22,729 1,490 2008 — 11/26/2018 Valdosta Healthcare Facility Valdosta, GA — (a) 659 5,626 — 659 5,626 6,285 376 2004 — 11/28/2018 Valdosta Healthcare Facility II Valdosta, GA — (a) 471 2,780 — 471 2,780 3,251 189 1992 — 11/28/2018 Bryant Healthcare Facility II Bryant, AR — (a) 647 3,364 — 647 3,364 4,011 132 2016 — 08/16/2019 Laredo Healthcare Facility Laredo, TX — (a) — 12,137 — — 12,137 12,137 425 1998 — 09/19/2019 Laredo Healthcare Facility II Laredo, TX — (a) — 23,677 83 — 23,760 23,760 838 1998 — 09/19/2019 Poplar Bluff Healthcare Facility Poplar Bluff, MO — (a) — 13,515 — — 13,515 13,515 475 2013 — 09/19/2019 Tucson Healthcare Facility Tucson, AZ — (a) — 5,998 — — 5,998 5,998 212 1998 — 09/19/2019 Akron Healthcare Facility Green, OH — (a) 3,503 38,512 — 3,503 38,512 42,015 1,240 2012 — 10/04/2019 Akron Healthcare Facility II Green, OH — (a) 1,085 10,277 — 1,085 10,277 11,362 398 2013 — 10/04/2019 Akron Healthcare Facility III Akron, OH — (a) 2,206 26,044 — 2,206 26,044 28,250 811 2008 — 10/04/2019 Alexandria Healthcare Facility Alexandria, LA — (a) — 5,076 — — 5,076 5,076 158 2007 — 10/04/2019 Appleton Healthcare Facility Appleton, WI — (a) 414 1,900 — 414 1,900 2,314 79 2011 — 10/04/2019 Austin Healthcare Facility II Austin, TX — (a) 3,229 7,534 (2,807) 2,195 5,761 7,956 184 2006 — 10/04/2019 Bellevue Healthcare Facility Green Bay, WI — (a) 567 1,269 — 567 1,269 1,836 55 2010 — 10/04/2019 Bonita Springs Healthcare Facility Bonita Springs, FL — (a) 1,199 4,373 — 1,199 4,373 5,572 140 2002 2005 10/04/2019 Bridgeton Healthcare Facility Bridgeton, MO — (a) — 39,740 — — 39,740 39,740 1,232 2012 — 10/04/2019 Covington Healthcare Facility Covington, LA — (a) 2,238 16,635 — 2,238 16,635 18,873 513 1984 — 10/04/2019 Crestview Healthcare Facility Crestview, FL — (a) 400 1,536 — 400 1,536 1,936 55 2004 2010 10/04/2019 Dallas Healthcare Facility Dallas, TX — (a) 6,072 27,457 — 6,072 27,457 33,529 833 2010 — 10/04/2019 De Pere Healthcare Facility De Pere, WI — (a) 615 1,596 — 615 1,596 2,211 66 2005 — 10/04/2019 Denver Healthcare Facility Thornton, CO — (a) 3,586 32,363 — 3,586 32,363 35,949 1,012 1962 2018 10/04/2019 El Segundo Healthcare Facility El Segundo, CA — (a) 2,659 9,016 — 2,659 9,016 11,675 282 2009 — 10/04/2019 Fairlea Healthcare Facility Fairlea, WV — (a) 139 1,910 — 139 1,910 2,049 63 1999 — 10/04/2019 Fayetteville Healthcare Facility Fayetteville, AR — (a) 485 24,855 — 485 24,855 25,340 766 1994 2009 10/04/2019 Fort Myers Healthcare Facility Fort Myers, FL — (a) 2,153 2,387 — 2,153 2,387 4,540 93 1999 — 10/04/2019 Fort Myers Healthcare Facility II Fort Myers, FL — (a) 3,557 11,064 — 3,557 11,064 14,621 400 2010 — 10/04/2019 Fort Walton Beach Healthcare Facility Fort Walton Beach, FL — (a) 385 3,182 — 385 3,182 3,567 104 2005 — 10/04/2019 Frankfort Healthcare Facility Frankfort, KY — (a) 342 950 — 342 950 1,292 35 1993 — 10/04/2019 Frisco Healthcare Facility Frisco, TX — (a) — 22,114 4,653 — 26,767 26,767 1,009 2010 2020 10/04/2019 Goshen Healthcare Facility Goshen, IN — (a) 383 5,355 — 383 5,355 5,738 182 2010 — 10/04/2019 Grapevine Healthcare Facility Grapevine, TX — 1,726 26,849 — 1,726 26,849 28,575 834 2007 — 10/04/2019 Hammond Healthcare Facility Hammond, LA — (a) 2,693 23,750 — 2,693 23,750 26,443 760 2006 — 10/04/2019 Hammond Healthcare Facility II Hammond, LA — (a) 950 12,147 — 950 12,147 13,097 384 2004 — 10/04/2019 Initial Cost Cost Gross Amount Property Description Location Encumbrances Land Buildings and Land Buildings and Total Accumulated Year Year Date Harlingen Healthcare Facility Harlingen, TX — — 10,628 — — 10,628 10,628 354 2007 — 10/04/2019 Henderson Healthcare Facility Henderson, NV — (a) 839 2,390 — 839 2,390 3,229 82 2000 — 10/04/2019 Houston Healthcare Facility III Houston, TX — (a) 752 5,832 — 752 5,832 6,584 181 1998 2018 10/04/2019 Howard Healthcare Facility Howard, WI — (a) 529 1,818 — 529 1,818 2,347 76 2011 — 10/04/2019 Jacksonville Healthcare Facility Jacksonville, FL — (a) 1,233 6,173 — 1,233 6,173 7,406 203 2009 — 10/04/2019 Lafayette Healthcare Facility Lafayette, LA — (a) 4,819 35,424 — 4,819 35,424 40,243 1,110 2004 — 10/04/2019 Lakewood Ranch Healthcare Facility Lakewood Ranch, FL — (a) 636 1,784 — 636 1,784 2,420 74 2008 — 10/04/2019 Las Vegas Healthcare Facility II Las Vegas, NV — (a) 651 5,323 — 651 5,323 5,974 173 2007 — 10/04/2019 Lehigh Acres Healthcare Facility Lehigh Acres, FL — (a) 441 2,956 — 441 2,956 3,397 101 2002 — 10/04/2019 Lubbock Healthcare Facility Lubbock, TX — (a) 5,210 39,939 — 5,210 39,939 45,149 1,229 2003 — 10/04/2019 Manitowoc Healthcare Facility Manitowoc, WI — (a) 257 1,733 — 257 1,733 1,990 69 2003 — 10/04/2019 Manitowoc Healthcare Facility II Manitowoc, WI — (a) 250 11,231 — 250 11,231 11,481 381 1964 2010 10/04/2019 Marinette Healthcare Facility Marinette, WI — (a) 208 1,002 — 208 1,002 1,210 41 2008 — 10/04/2019 New Bedford Healthcare Facility New Bedford, MA — (a) 2,464 26,297 — 2,464 26,297 28,761 827 1942 1995 10/04/2019 New Braunfels Healthcare Facility New Braunfels, TX — (a) 2,568 11,386 — 2,568 11,386 13,954 356 2007 — 10/04/2019 North Smithfield Healthcare Facility North Smithfield, RI — (a) 1,309 14,024 — 1,309 14,024 15,333 463 1965 2000 10/04/2019 Oklahoma City Healthcare Facility IX Oklahoma City, OK — (a) 1,316 9,822 — 1,316 9,822 11,138 350 2007 — 10/04/2019 Oshkosh Healthcare Facility Oshkosh, WI — (a) 414 2,043 — 414 2,043 2,457 79 2010 — 10/04/2019 Palm Desert Healthcare Facility Palm Desert, CA — (a) 582 5,927 — 582 5,927 6,509 206 2005 — 10/04/2019 Rancho Mirage Healthcare Facility II Rancho Mirage, CA — (a) 2,286 5,481 — 2,286 5,481 7,767 187 2008 — 10/04/2019 San Antonio Healthcare Facility III San Antonio, TX — (a) 1,824 22,809 — 1,824 22,809 24,633 698 2012 — 10/04/2019 San Antonio Healthcare Facility IV San Antonio, TX — (a) — 31,694 — — 31,694 31,694 970 1987 — 10/04/2019 San Antonio Healthcare Facility V San Antonio, TX — (a) 3,273 19,697 903 3,273 20,600 23,873 636 2017 — 10/04/2019 Santa Rosa Beach Healthcare Facility Santa Rosa Beach, FL — (a) 741 3,049 — 741 3,049 3,790 94 2003 — 10/04/2019 Savannah Healthcare Facility Savannah, GA — (a) 2,300 20,186 — 2,300 20,186 22,486 622 2014 — 10/04/2019 St. Louis Healthcare Facility Creve Coeur, MO — (a) 1,164 8,052 — 1,164 8,052 9,216 258 2005 2007 10/04/2019 Sturgeon Bay Healthcare Facility Sturgeon Bay, WI — (a) 248 700 — 248 700 948 32 2007 — 10/04/2019 Victoria Healthcare Facility Victoria, TX — (a) 328 12,908 — 328 12,908 13,236 406 2013 — 10/04/2019 Victoria Healthcare Facility II Victoria, TX — (a) 446 12,986 — 446 12,986 13,432 405 1998 — 10/04/2019 Webster Healthcare Facility II Webster, TX — (a) 7,371 243,983 4,584 7,371 248,567 255,938 7,464 2014 2019 10/04/2019 Wilkes-Barre Healthcare Facility Mountain Top, PA — (a) 821 4,139 — 821 4,139 4,960 146 2012 — 10/04/2019 Yucca Valley Healthcare Facility Yucca Valley, CA — (a) 901 4,788 — 901 4,788 5,689 175 2009 — 10/04/2019 Tucson Healthcare Facility II Tucson, AZ — — — 18,325 — 18,325 18,325 — (f) (f) 12/26/2019 Tucson Healthcare Facility III Tucson, AZ — 1,763 — 8,349 1,763 8,349 10,112 40 2020 — 12/27/2019 Grimes Healthcare Facility Grimes, IA — (a) 831 3,690 — 831 3,690 4,521 93 2018 — 02/19/2020 Tampa Healthcare Facility Tampa, FL — (a) — 10,297 — — 10,297 10,297 100 2015 — 09/08/2020 Initial Cost Cost Gross Amount Property Description Location Encumbrances Land Buildings and Land Buildings and Total Accumulated Year Year Date Tucson Healthcare Facility IV (g) Tucson, AZ — — 58 849 — 907 907 — (f) (f) 12/22/2020 $ 453,422 $ 336,437 $ 2,468,824 $ 85,697 $ 335,678 $ 2,555,280 $ 2,890,958 $ 197,134 (a) Property collateralized under the unsecured credit facility. As of December 31, 2020, 130 commercial properties were collateralized under the credit facility and the Company had $938,000,000 aggregate principal amount outstanding thereunder. (b) The reduction to costs capitalized subsequent to acquisition primarily include impairment charges, property dispositions and other adjustments. (c) The aggregated cost for federal income tax purposes is approximately $3,060,569,000 (unaudited). (d) The Company’s assets are depreciated or amortized using the straight-line method over the useful lives of the assets by class. Generally, buildings and improvements are depreciated over 15-40 years and tenant improvements are depreciated over the shorter of lease term or expected useful life. (e) Property renovation project began in 2020 with an estimated completion date in 2021. (f) As of December 31, 2020, the property was under construction; therefore, depreciation is not applicable. (g) Initial cost of buildings and improvements include capitalized acquisition costs of $58,000, which are a part of construction in progress in the accompanying consolidated balance sheets as of December 31, 2020. NOTES TO SCHEDULE III — REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION December 31, 2020 (in thousands) Year Ended December 31, 2020 2019 2018 Real Estate: Balance at beginning of year $ 2,896,766 $ 1,758,326 $ 1,551,194 Additions: Acquisitions 14,876 1,151,827 195,328 Improvements 31,260 15,084 11,804 Deductions: Impairment — (25,501) — Dispositions (51,944) (2,807) — Other adjustments — (163) — Balance at end of year $ 2,890,958 $ 2,896,766 $ 1,758,326 Accumulated Depreciation: Balance at beginning of year $ (128,304) $ (84,594) $ (45,789) Additions: Depreciation (69,623) (48,215) (38,805) Deductions: Impairment — 4,501 — Dispositions 793 4 — Balance at end of year $ (197,134) $ (128,304) $ (84,594)

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The accompanying consolidated financial statements include the accounts of the Company, the Operating Partnership, and all wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements and accompanying notes in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates are made and evaluated on an ongoing basis using information that is currently available as well as various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates.
Restricted Cash	Restricted CashRestricted cash consists of restricted cash held in escrow and restricted bank deposits. Restricted cash held in escrow includes cash held by lenders in escrow accounts for tenant and capital improvements, taxes, repairs and maintenance and other lender reserves for certain properties, in accordance with the respective lender’s loan agreement. Restricted bank deposits consist of tenant receipts for certain properties which are required to be deposited into lender-controlled accounts in accordance with the respective lender's loan agreement. Restricted cash held in escrow and restricted bank deposits are reported in other assets, net, in the accompanying consolidated balance sheets. See Note 9—"Other Assets, Net."
Investment in Real Estate	Investment in Real EstateReal estate costs related to the acquisition, development, construction and improvement of properties are capitalized. Repair and maintenance costs are expensed as incurred and significant replacements and betterments are capitalized. Repair and maintenance costs include all costs that do not extend the useful life of the real estate asset. The Company considers the period of future benefit of an asset in determining the appropriate useful life. Real estate assets, other than land, are depreciated or amortized on a straight-line basis over each asset’s useful life.
Allocation of Purchase Price of Real Estate	Allocation of Purchase Price of Real Estate Upon the acquisition of real properties, the Company evaluates whether the acquisition is a business combination or an asset acquisition. For both business combinations and asset acquisitions the Company allocates the purchase price of properties to acquired tangible assets, consisting of land, buildings and improvements, and acquired intangible assets and liabilities, consisting of the value of above-market and below-market leases and the value of in-place leases. For asset acquisitions, the Company capitalizes transaction costs and allocates the purchase price using a relative fair value method allocating all accumulated costs. For business combinations, the Company expenses transaction costs incurred and allocates the purchase price based on the estimated fair value of each separately identifiable asset and liability. During the year ended December 31, 2020, the Company acquired three real estate properties that were determined to be asset acquisitions. See Note 4—"Acquisitions and Dispositions" for additional information. Acquisition fees and costs associated with transactions determined to be asset acquisitions are capitalized in total real estate, net, acquired intangible assets and acquired intangible liabilities in the accompanying consolidated balance sheets. The fair values of the tangible assets of an acquired property (which includes land, buildings and improvements) are determined by valuing the property as if it were vacant, and the “as-if-vacant” value is then allocated to land and buildings and improvements based on management’s determination of the relative fair value of these assets. Management determines the as-if-vacant fair value of a property using methods similar to those used by independent appraisers. Factors considered by management in performing these analyses include an estimate of carrying costs during the expected lease-up periods considering current market conditions and costs to execute similar leases, including leasing commissions and other related costs. In estimating carrying costs, management includes real estate taxes, insurance, and other operating expenses during the expected lease-up periods based on current market conditions. The fair values of above-market and below-market in-place leases are recorded based on the present value (using an interest rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to the in-place leases and (ii) an estimate of fair market lease rates for the corresponding in-place leases, measured over a period equal to the remaining non-cancelable term of the lease including any fixed rate bargain renewal periods, with respect to a below-market lease. The above-market and below-market lease values are capitalized as intangible lease assets or liabilities. Above-market lease values are amortized as an adjustment of rental revenue over the remaining terms of the respective leases. Below-market leases are amortized as an adjustment of rental revenue over the remaining terms of the respective leases, including any fixed rate bargain renewal periods. If a lease were to be terminated prior to its stated expiration, all unamortized amounts of above-market and below-market in-place lease values related to that lease would be recorded as an adjustment to rental revenue. The fair values of in-place leases include an estimate of direct costs associated with obtaining a new tenant and opportunity costs associated with lost rentals that are avoided by acquiring an in-place lease. Direct costs associated with obtaining a new tenant include commissions, tenant improvements, and other direct costs and are estimated based on management’s consideration of current market costs to execute a similar lease. The value of opportunity costs is calculated using the contractual amounts to be paid pursuant to the in-place leases over a market absorption period for a similar lease. These lease intangibles are amortized to depreciation and amortization expense over the remaining terms of the respective leases. If a lease were to be terminated prior to its stated expiration, all unamortized amounts of in-place lease assets relating to that lease would be expensed.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of its real estate and related intangible assets may not be recoverable. When indicators of potential impairment suggest that the carrying value of real estate and related intangible assets may not be recoverable, the Company assesses the recoverability of the asset group by estimating whether the Company will recover the carrying value of the asset group through its undiscounted future cash flows and their eventual disposition. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of the asset group, the Company will record an impairment loss to the extent that the carrying value exceeds the estimated fair value of the asset group. When developing estimates of expected future cash flows, the Company makes certain assumptions regarding future market rental rates subsequent to the expiration of current lease arrangements, property operating expenses, terminal capitalization and discount rates, probability weighting of the potential re-lease of the property versus sales scenarios, sale prices of comparable properties, required tenant improvements and the number of years the property will be held for investment. The use of alternative assumptions in the future cash flow analysis could result in a different determination of the property’s future cash flows and a different conclusion regarding the existence of an impairment, the extent of such loss, if any, as well as the carrying value of the real estate and related assets. In addition, the Company estimates the fair value of the assets by applying a market approach using comparable sales for certain properties. The use of alternative assumptions in the market approach analysis could result in a different determination of the property’s estimated fair value and a different conclusion regarding the existence of an impairment, the extent of such loss, if any, as well as the carrying value of the real estate and related assets. Impairment of Real Estate During the year ended December 31, 2020, no impairment losses were recorded on real estate assets. During the third quarter ended September 30, 2019, real estate assets related to one healthcare property were determined to be impaired due to a tenant of the property experiencing financial difficulty and vacating its space, and a second tenant indicating its desire to terminate its lease early, which the Company determined would be consistent with its strategic plans for the property. On November 8, 2019, the Company terminated the lease with the second tenant. The aggregate carrying amount of the assets of $40,266,000 exceeded their fair value. The carrying value of the property was reduced to its estimated fair value of $27,266,000, resulting in an impairment charge of $13,000,000, which is included in impairment loss on real estate in the consolidated statements of comprehensive income (loss). In addition, during the fourth quarter ended December 31, 2019, real estate assets related to another healthcare property with an aggregate carrying amount of $30,412,000 were reduced to their estimated fair value of $22,412,000, resulting in an impairment charge of $8,000,000 based on a letter of intent from a prospective buyer to purchase the property. Impairment charges are recorded as impairment loss on real estate in the consolidated statements of comprehensive income (loss). During the year ended December 31, 2018, no impairment losses were recorded on real estate assets. Impairment of Acquired Intangible Assets and Acquired Intangible Liabilities During the year ended December 31, 2020, the Company recognized impairments of three in-place lease intangible assets in the amount of approximately $4,693,000 and one above-market lease intangible asset in the amount of approximately $344,000, by accelerating the amortization of the acquired intangible assets. Of the $4,693,000 in-place lease intangible assets written off, $3,189,000 related to a tenant in a data center property of the Company that was experiencing financial difficulty due to deteriorating economic conditions driven by the impact of COVID-19 and the pandemic’s acceleration of the tenant’s modification of work strategy to a remote environment, $1,484,000 related to one healthcare tenant of the Company that was experiencing financial difficulties and vacated the property on June 19, 2020 and $20,000 as a result of a lease termination at a healthcare property. During year ended December 31, 2020, the Company wrote off one below-market lease intangible liability in the amount of approximately $1,974,000, by accelerating the amortization of the acquired intangible liability related to one tenant of the data center property discussed above. During the year ended December 31, 2019, the Company recognized impairments of in-place lease intangible assets in the amount of approximately $3,195,000, by accelerating the amortization of the acquired intangible assets related to two tenants of a healthcare property. During the year ended December 31, 2019, the Company wrote off one below-market lease intangible liability in the amount of approximately $212,000, by accelerating the amortization of the acquired intangible liability related to one tenant of a healthcare property. During the year ended December 31, 2018, no impairment losses were recorded on acquired intangible assets or intangible liabilities.
Goodwill	Goodwill Goodwill represents the excess of the amount paid over the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed in a business combination and is allocated to an entity's reporting units. The Company's reporting unit represents each individual operating real estate property. Goodwill has an indefinite life and is not amortized. On September 30, 2020, the Company recorded $39,529,000 of goodwill related to the Internalization Transaction. See Note 3—"Internalization Transaction" for details. The Company evaluates goodwill for impairment when an event occurs or circumstances change that indicate the carrying value may not be recoverable, or at least annually. Unless circumstances otherwise dictate, the annual impairment test is performed as of the last date of each year. The Company evaluates potential triggering events that may affect the estimated fair value of the Company’s reporting units to assess whether any goodwill impairment exists. Deteriorating or adverse market conditions for certain reporting units may have a significant impact on the estimated fair value of these reporting units and could result in future impairments of goodwill. If the carrying value of a reporting unit exceeds its estimated fair value, then an impairment charge is recorded in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. The Company adopted the annual impairment test and performed a qualitative analysis of each reporting unit as of December 31, 2020. The Company concluded, based on the qualitative assessment, that it is not more likely than not that the fair value of each reporting unit is less than its carrying amount. As of December 31, 2020, no impairment losses on goodwill have been recognized.
Notes Receivable	Notes Receivable Notes receivable are recorded at their outstanding principal balance, net of any unearned income, unamortized deferred fees and costs and allowances for loan losses. The Company defers notes receivable origination costs and fees and amortizes them as an adjustment of yield over the term of the related note receivable. Amortization of the notes receivable origination costs and fees are recorded in interest and other expense, net, in the accompanying consolidated statements of comprehensive income (loss). During the year ended December 31, 2020, in connection with the sale of a healthcare property, a wholly-owned subsidiary of the Company issued a note receivable in the principal amount of $28,000,000. See Note 8—"Notes Receivable, Net" for further discussion. The Company evaluates the collectability of both interest and principal on each note receivable to determine whether it is collectible, primarily through the evaluation of credit quality indicators, such as the tenant's financial condition, collateral, evaluations of historical loss experience, current economic conditions and other relevant factors, including contractual terms of repayments. Evaluating a note receivable for potential impairment requires management to exercise judgment. The use of alternative assumptions in evaluating a note receivable could result in a different determination of the note's estimated fair value and a different conclusion regarding the existence of an impairment, the extent of such loss, if any, as well as the carrying value of the note receivable. See "Recently Adopted Accounting Pronouncements—Measurement of Credit Losses on Financial Instruments" section below for further discussion.
Deferred Financing Costs	Deferred Financing Costs Deferred financing costs are loan fees, legal fees and other third-party costs associated with obtaining and further modifying financing. These costs are amortized over the terms of the respective financing agreements using the effective interest method. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity unless specific rules are met that would allow for the carryover of such costs to the refinanced debt. Costs incurred in seeking financing transactions that do not close are expensed in the period in which it is determined that the financing will not close. Deferred financing costs are recorded as a reduction of the related debt on the accompanying consolidated balance sheets. Deferred financing costs related to a revolving line of credit are recorded in other assets, net, in the accompanying consolidated balance sheets.
Leasing Commission Fees	Leasing Commission Fees Leasing commission fees are fees incurred for the initial lease-up, leasing-up of newly constructed properties or re-leasing to existing tenants. Leasing commission fees are capitalized in other assets, net, in the accompanying consolidated balance sheets and amortized over the terms of the related leases.
Fair Value	Fair Value Accounting Standards Codification, or ASC, 820, Fair Value Measurements and Disclosures , or ASC 820, defines fair value, establishes a framework for measuring fair value in accordance with GAAP and expands disclosures about fair value measurements. ASC 820 emphasizes that fair value is intended to be a market-based measurement, as opposed to a transaction-specific measurement. Fair value is defined by ASC 820 as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Depending on the nature of the asset or liability, various techniques and assumptions can be used to estimate the fair value. Assets and liabilities are measured using inputs from three levels of the fair value hierarchy, as follows: Level 1—Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. An active market is defined as a market in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2—Inputs other than quoted prices for similar assets and liabilities in active markets that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data correlation or other means (market corroborated inputs). Level 3—Unobservable inputs, only used to the extent that observable inputs are not available, reflect the Company’s assumptions about the pricing of an asset or liability. The following describes the methods the Company used to estimate the fair value of the Company’s financial assets and liabilities: Cash and cash equivalents, restricted cash, tenant receivables, prepaid and other assets, accounts payable and accrued liabilities —The Company considers the carrying values of these financial instruments, assets and liabilities, to approximate fair value because of the short period of time between origination of the instruments and their expected realization. Notes payable — Fixed Rate —The fair value is estimated by discounting the expected cash flows on notes payable at current rates at which management believes similar loans would be made considering the terms and conditions of the loan and prevailing market interest rates. Credit facility — Fixed Rate —The fair value is estimated by discounting the expected cash flows on the credit facility at current rates at which management believes similar borrowings would be made considering the terms and conditions of the borrowings and prevailing market interest rates. Credit facility — Variable Rate —The fair value of the Company's variable rate credit facility is estimated based on the interest rates currently offered to the Company by financial institutions. Derivative instruments —The Company’s derivative instruments consist of interest rate swaps. These swaps are carried at fair value to comply with the provisions of ASC 820. The fair value of these instruments is determined using interest rate market pricing models. The Company incorporated credit valuation adjustments to appropriately reflect the Company’s nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements. Considerable judgment is necessary to develop estimated fair values of financial assets and liabilities. Accordingly, the estimates presented herein are not necessarily indicative of the amounts the Company could realize or be liable for on disposition of the financial assets and liabilities. See additional discussion in Note 15—"Fair Value."
Revenue Recognition, Tenant Receivables and Allowance for Uncollectible Accounts	Revenue Recognition, Tenant Receivables and Allowance for Uncollectible Accounts Effective January 1, 2018, the Company recognizes non-rental related revenue in accordance with ASC 606, Revenue from Contracts with Customers, or ASC 606. The Company has identified its revenue streams as rental income from leasing arrangements and tenant reimbursements, which are outside the scope of ASC 606. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Non-rental revenue, subject to ASC 606, is immaterial to the Company's consolidated financial statements. The majority of the Company's revenue is derived from rental revenue, which is accounted for in accordance with ASC 842, Leases, or ASC 842. In accordance with ASC 842, minimum rental revenue is recognized on a straight-line basis over the term of the related lease (including rent holidays). For lease arrangements when it is not probable that the Company will collect all or substantially all of the remaining lease payments under the term of the lease, rental revenue is limited to the lesser of the rental revenue that would be recognized on a straight-line basis or the lease payments that have been collected from the lessee. Differences between rental income recognized and amounts contractually due under the lease agreements are credited or charged to straight-line rent receivable or straight-line rent liability, as applicable. Tenant reimbursements, which are comprised of additional amounts recoverable from tenants for common area maintenance expenses and certain other recoverable expenses, is recognized when the services are provided and the performance obligations are satisfied. Prior to the adoption of ASC 842, tenant receivables and straight-line rent receivables were carried net of the provision for credit losses. The provision for credit losses was established for estimated losses resulting from the inability of certain tenants to meet the contractual obligations under their lease agreements. The Company’s determination of the adequacy of these provisions was based primarily upon evaluations of historical loss experience, the tenant’s financial condition, security deposits, letters of credit, lease guarantees, current economic conditions and other relevant factors. Effective January 1, 2019, upon adoption of ASC 842, the Company is no longer recording a provision for credit losses but is, instead, assessing whether or not it is probable that the Company will collect all or substantially all of the remaining lease payments under the term of the lease. Where it is not probable that the Company will collect all or substantially all of the remaining lease payments under the term of the lease, rental revenue is limited to the lesser of the rental revenue that would be recognized on a straight-line basis or the lease payments that have been collected from the lessee. During the years ended December 31, 2020, 2019, and 2018, the Company recorded $126,000, $672,000 and $0, respectively, as a reduction in rental revenue in the accompanying consolidated statements of comprehensive income (loss).
Concentration of Credit Risk and Significant Leases	Concentration of Credit Risk and Significant Leases As of December 31, 2020, the Company had cash on deposit, including restricted cash, in certain financial institutions that had deposits in excess of current federally insured levels. The Company limits its cash investments to financial institutions with high credit standings; therefore, the Company believes it is not exposed to any significant credit risk on its cash deposits. To date, the Company has not experienced a loss or lack of access to cash in its accounts. As of December 31, 2020, the Company owned real estate investments in two micropolitan statistical areas and 68 metropolitan statistical areas, or MSAs, two MSAs of which accounted for 10.0% or more of rental revenue. Real estate investments located in the Atlanta-Sandy Springs-Roswell, Georgia MSA and the Houston-The Woodlands-Sugar Land, Texas MSA accounted for 11.9% and 10.3%, respectively, of rental revenue for the year ended December 31, 2020. As of December 31, 2020, the Company had one exposure to tenant concentration that accounted for 10.0% or more of rental revenue for the year ended December 31, 2020. The leases with tenants at healthcare properties under common control of Post Acute Medical, LLC accounted for 10.1% of rental revenue for the year ended December 31, 2020.
Share Repurchase Program	Share Repurchase Program The Company’s share repurchase program, or SRP, allows for repurchases of shares of the Company’s common stock when certain criteria are met. The SRP provides that all repurchases during any calendar year, including those redeemable upon death or a Qualifying Disability of a stockholder, are limited to those that can be funded with equivalent proceeds raised from the DRIP during the prior calendar year and other operating funds, if any, as the board of directors, in its sole discretion, may reserve for this purpose. Repurchases of shares of the Company’s common stock are at the sole discretion of the Company’s board of directors, provided, however, that the Company will limit the number of shares repurchased during any calendar year to 5.0% of the number of shares of common stock outstanding as of December 31 st of the previous calendar year. Subject to the terms and limitations of the SRP, including, but not limited to, quarterly share limitations, an annual 5.0% share limitation and DRIP funding limitations and any amendments to the plan, as more fully described below, the SRP is generally available to any stockholder as a potential means of interim liquidity. In addition, the Company’s board of directors, in its sole discretion, may suspend (in whole or in part) the SRP at any time, and may amend, reduce, terminate or otherwise change the SRP upon 30 days' prior notice to the Company’s stockholders for any reason it deems appropriate. The Company generally honors valid repurchase requests approximately 30 days following the end of the applicable quarter. The Company reached the DRIP funding limitation and was not able to fully accommodate all repurchase requests for the second quarter repurchase date of 2020, which was April 30, 2020. See Part II, Item 5. "Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities" for further information for the second quarter repurchase date of 2020. On April 30, 2020, due to the uncertainty surrounding the ongoing coronavirus, or COVID-19, pandemic and any impact it may have on the Company, the Company's board of directors decided to temporarily suspend share repurchases under the SRP, effe ctive wit h repurchase requests that would otherwise be processed on the third quarter repurchase date of 2020, which was July 30, 2020. On December 11, 2020, the Company's board of directors authorized and approved the Amended and Restated Share Repurchase Program, or the A&R SRP, which applied beginning with the first quarter repurchase date of 2021, which was January 28, 2021. Under the A&R SRP, the Company will only repurchase shares due to death or involuntary exigent circumstance in accordance with the A&R SRP, subject in each case to the terms and limitations of the A&R SRP, including, but not limited to, quarterly share limitations, an annual 5.0% share limitation, and DRIP funding limitations. Under the A&R SRP, the Company may waive certain of the terms and requirements of the A&R SRP in the event of the death of a stockholder who is a natural person, including shares held through an Individual Retirement Account or other retirement or profit-sharing plan, and certain trusts meeting the requirements of the A&R SRP. The Company may also waive certain of the terms and requirements of the A&R SRP in the event of an involuntary exigent circumstance, as determined by the Company or any of the executive officers thereof, in its or their sole discretion. See Part II, Item 5. "Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities" for more information on the Company's A&R SRP. Effective as of the closing of the Internalization Transaction, the Operating Partnership redeemed the limited partner interest held by the Former Advisor for an aggregate purchase price of approximately $2,000. Additionally, the Company repurchased 29,362 Class A shares of common stock held by Carter Validus REIT Management Company II, LLC, the Former Sponsor, for an aggregate purchase price of approximately $254,000 (an average of $8.65 per share). During the year ended December 31, 2020, the Company repurchased 3,408,870 Class A shares, Class I shares, Class T shares and Class T2 shares of common stock (2,666,674 Class A shares, 408,346 Class I shares, 298,224 Class T shares and 35,626 Class T2 shares), or 1.54% of shares outstanding as of December 31, 2019, for an aggregate purchase price of
Distribution Policy and Distributions Payable	Distribution Policy and Distributions Payable In order to maintain its status as a REIT, the Company is required to make distributions each taxable year equal to at least 90% of its REIT taxable income, computed without regard to the dividends paid deduction and excluding capital gains. To the extent funds are available, the Company intends to continue to pay regular distributions to stockholders. Distributions are paid to stockholders of record as of the applicable record dates. Distributions are payable to stockholders from legally available funds therefor. The Company declared distributions per share of common stock in the amounts of $0.48, $0.58 and $0.63 for the years ended December 31, 2020, 2019 and 2018, respectively. As of December 31, 2020, the Company had distributions payable of approximately $9,117,000. Of these distributions payable, approximately $6,574,000 was paid in cash and approximately $2,543,000 was reinvested in shares of common stock pursuant to the DRIP on January 4, 2021. Distributions to stockholders are determined by the board of directors of the Company and are dependent upon a number of factors, including funds available for the payment of distributions, financial condition, the timing of property acquisitions, capital expenditure requirements, and annual distribution requirements in order to maintain the Company’s status as a REIT under the Code. See Note 22—"Subsequent Events" for further discussion.
Stock-based Compensation	Stock-based Compensation On March 6, 2020, the Company's board of directors approved the Amended and Restated 2014 Restricted Share Plan, or the A&R Incentive Plan, pursuant to which the Company has the authority and power to grant awards of restricted shares of its Class A common stock to its directors, officers and employees. The Company accounts for its stock awards in accordance with ASC 718-10, Compensation—Stock Compensation . ASC 718-10 requires that compensation cost for all stock awards be calculated and amortized over the service period (generally equal to the vesting period). For performance-based awards, compensation costs are recognized over the service period if it is probable that the performance condition will be satisfied, with changes of the assessment at each reporting period and recording the effect of the change in the compensation cost as a cumulative catch-up adjustment. The compensation costs for restricted stock are recognized based on the fair value of the restricted stock awards at grant date less forfeitures (if applicable). See Note 18—"Stock-based Compensation" for further information on the Company's stock-based compensation.
Earnings Per Share	Earnings Per Share The Company calculates basic earnings per share by dividing net income attributable to common stockholders for the period by the weighted average shares of its common stock outstanding for that period. Diluted earnings per share are computed based on the weighted average number of shares outstanding and all potentially dilutive securities. Shares of non-vested restricted common stock give rise to potentially dilutive shares of common stock. During the years ended December 31, 2020, 2019 and 2018 diluted earnings per share reflected the effect of approximately 186,000, 24,000 and 24,000 of non-vested shares of restricted common stock that were outstanding as of each period, respectively.
Reportable Segments	Reportable Segments ASC, 280, Segment Reporting , establishes standards for reporting financial and descriptive information about an enterprise’s reportable segments. As of December 31, 2020 and 2019, the Company operated through two reportable business segments—real estate investments in data centers and healthcare. Segregation of the Company’s operations into two reportable segments is useful in assessing the performance of the Company’s business in the same way that management reviews performance and makes operating decisions. See Note 14—"Segment Reporting" for further discussion on the reportable segments of the Company.
Derivative Instruments and Hedging Activities	Derivative Instruments and Hedging Activities As required by ASC 815, Derivatives and Hedging , or ASC 815, the Company records all derivative instruments at fair value as assets and liabilities on its consolidated balance sheets. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the income or loss is recognized in the consolidated statements of comprehensive income (loss) during such period. In accordance with the fair value measurement guidance ASU 2011-04, Fair Value Measurement , the Company made an accounting policy election to measure the credit risk of its derivative financial instruments that are subject to master netting agreements on a net basis by counterparty portfolio. The Company is exposed to variability in expected future cash flows that are attributable to interest rate changes in the normal course of business. The Company’s primary strategy in entering into derivative contracts is to add stability to future cash flows by managing its exposure to interest rate movements. The Company utilizes derivative instruments, including interest rate swaps, to effectively convert some of its variable rate debt to fixed rate debt. The Company does not enter into derivative instruments for speculative purposes. In accordance with ASC 815, the Company designates interest rate swap contracts as cash flow hedges of floating-rate borrowings. For derivative instruments that are designated and qualify as cash flow hedges, the gains or losses on the derivative instruments are reported as a component of other comprehensive (loss) income in the consolidated statements of comprehensive income (loss) and are reclassified into earnings in the same line item associated with the forecasted transaction in the same period during which the hedged transactions affect earnings. See additional discussion in Note 16—"Derivative Instruments and Hedging Activities."
Income Taxes	Income Taxes The Company currently qualifies and is taxed as a REIT under Sections 856 through 860 of the Code. Accordingly, it will generally not be subject to corporate U.S. federal or state income tax to the extent that it makes qualifying distributions to stockholders, and provided it satisfies, on a continuing basis, through actual investment and operating results, the REIT requirements, including certain asset, income, distribution and stock ownership tests. If the Company fails to qualify as a REIT, and does not qualify for certain statutory relief provisions, it would be subject to U.S. federal, state and local income taxes and may be precluded from qualifying as a REIT for the subsequent four taxable years following the year in which it lost its REIT qualification, unless the Internal Revenue Service grants the Company relief under certain statutory provisions. Accordingly, failure to qualify as a REIT could have a material adverse impact on the results of operations and amounts available for distribution to stockholders. The dividends paid deduction of a REIT for qualifying dividends paid to its stockholders is computed using the Company’s taxable income as opposed to net income reported in the consolidated financial statements. Taxable income, generally, will differ from net income reported in the consolidated financial statements because the determination of taxable income is based on tax provisions and not financial accounting principles. The Company has concluded that there was no impact related to uncertain tax positions from results of operations of the Company for the years ended December 31, 2020, 2019 and 2018. The United States of America is the jurisdiction for the Company, and the earliest tax year subject to examination is 2017.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements Leases—Rent Concessions The ongoing COVID-19 pandemic has forced the temporary closure, changes to the operating hours or other temporary changes to the business of certain tenants in healthcare and data center properties of the Company. As a result of the impact of the pandemic on their businesses, certain tenants sought rent concessions, including decreased rent and rent deferrals. To provide operational clarity, on April 8, 2020, the Financial Accounting Standards Board, or FASB, issued practical expedients to the lease modification guidance in ASC 842, Leases , in the context of COVID-19 for leases where the total lease cash flows will remain substantially the same or less than those after the COVID-19 related effects. Entities may choose to forgo the evaluation of the enforceable rights and obligations of the original lease agreements in accordance with ASC 842, Leases . An entity may elect to account for rent concessions either: • as if they are part of the enforceable rights and obligations of the parties under the existing lease contracts; or • as a lease modification. As a lessor, for leases impacted by COVID-19, the Company elected to account for any rent concessions as if they were part of the enforceable rights and obligations under the existing lease. During the year ended December 31, 2020, the Company granted rent deferrals to a limited number of tenants significantly impacted by COVID-19, with immaterial impact on the Company's consolidated financial statements and on the collectability of tenant receivables over the respective term of the lease. During the year ended December 31, 2020, the Company entered into 30 rent concessions and lease modifications due to the impact of COVID-19 on its tenants and collected approximately 99% of rental revenue related to these lease concessions and lease modifications for such period. As a lessee, the Company did not elect the practical expedient and will apply the lease modification guidance in accordance with ASC 842, Leases , if changes to ground lease agreements occur. The Company had not modified any of its ground lease agreements as of December 31, 2020. Measurement of Credit Losses on Financial Instruments On January 1, 2020, the Company adopted ASU 2016-13, Financial Instruments-Credit Losses , or ASU 2016-13. ASU 2016-13 requires a new model for estimating credit losses for certain types of financial instruments, including loans receivable, held-to-maturity debt securities and net investments in direct financing leases, among other financial instruments. Other than a few narrow exceptions, ASU 2016-13 requires that all financial instruments subject to the estimated credit loss model have some amount of credit loss reserve. The reserve is to reflect the GAAP principle underlying the estimated credit loss model that all loans, debt securities, and similar assets have an inherent risk of loss, regardless of credit quality, subordinate capital or other mitigating factors. ASU 2016-13 also expands the disclosure requirements regarding an entity’s assumptions, models and methods for estimating the allowance for credit losses. The new model for estimated credit losses is applicable to the Company's notes receivable and tenant reimbursements related to the finance lease. The standard does not apply to receivables arising from operating leases, which are within the scope of ASC 842, Leases . The adoption of ASU 2016-13 did not have any impact to the Company’s consolidated financial statements. Reference Rate Reform In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (ASC 848), or ASU 2020-04 . ASU 2020-04 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU 2020-04 is optional and may be elected over time through December 31, 2022, as reference rate reform activities occur. During the year ended December 31, 2020, the Company has elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The Company continues to evaluate the impact the guidance may have on its consolidated financial statements and may apply other elections, as applicable, as additional changes in the market occur.
Reclassifications	Reclassifications Certain prior period amounts have been reclassified to conform to the current financial statement presentation, with no effect on the Company’s consolidated financial position or results of operations. Amounts related to notes receivable, net, previously classified in other assets, net, as of December 31, 2019, are now presented separately as notes receivable, net, on the consolidated balance sheets.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Reconciliation of Cash, Cash Equivalents and Restricted Cash	The following table presents a reconciliation of the beginning of year and end of year cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the totals shown in the consolidated statements of cash flows (amounts in thousands): Year Ended 2020 2019 2018 Beginning of year: Cash and cash equivalents 69,342 68,360 74,803 Restricted cash 10,888 11,167 10,944 Cash, cash equivalents and restricted cash $ 80,230 $ 79,527 $ 85,747 End of year: Cash and cash equivalents 53,174 69,342 68,360 Restricted cash 14,735 10,888 11,167 Cash, cash equivalents and restricted cash $ 67,909 $ 80,230 $ 79,527
Schedule of Estimated Useful Lives of Assets by Class	The Company anticipates the estimated useful lives of its assets by class as follows: Buildings and improvements 15 – 40 years Tenant improvements Shorter of lease term or expected useful life Furniture, fixtures, and equipment 3 – 10 years

Internalization Transaction (Ta

Internalization Transaction (Tables)	12 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Schedule of Allocation of Purchase Price	The Internalization Transaction was accounted for as a business combination and the following table summarizes management’s allocation of the fair value of the Internalization Transaction (amounts in thousands): December 31, 2020 Goodwill $ 39,529 Right-of-use assets - operating lease 1,205 Total assets acquired 40,734 Operating lease liabilities (1,060) Deferred internalization transaction purchase price (14,674) Total liabilities acquired (15,734) Net assets allocated at acquisition $ 25,000
Schedule of Pro Forma Financial Information	Assuming the Internalization Transaction had occurred on January 1, 2019, pro forma revenues and net income attributable to common stockholders would have been as follows for the periods presented below (amounts in thousands, except per share amounts): Year Ended 2020 2019 Pro forma basis: Revenues $ 276,536 $ 210,901 Net income attributable to common stockholders $ 56,083 $ 11,822 Net income per common share attributable to common stockholders: Basic $ 0.25 $ 0.08 Diluted $ 0.25 $ 0.08

Acquisitions and Dispositions (

Acquisitions and Dispositions (Tables)	12 Months Ended
	Dec. 31, 2020
Real Estate [Abstract]
Schedule of Consideration Transferred for Properties Acquired	The following table summarizes the consideration transferred for the 2020 Acquisitions during the year ended December 31, 2020: Property Description Date Acquired Ownership Percentage Purchase Price Grimes Healthcare Facility 02/19/2020 100% $ 5,030 Tampa Healthcare Facility 09/08/2020 100% 11,047 Tucson Healthcare Facility IV (1) 12/22/2020 100% 58 Total $ 16,135 (1) The Tucson Healthcare Facility IV was acquired as a development healthcare property. At the closing date, the Company funded additional $849,000 for the construction of the development property.
Schedule of Allocation of Acquisitions	The following table summarizes the Company's purchase price allocation of the 2020 Acquisitions during the year ended December 31, 2020 (amounts in thousands): Total (1) Land $ 831 Buildings and improvements 13,524 Tenant improvements 463 In-place leases 1,748 Right-of-use assets - finance lease 2,534 Total assets acquired 19,100 Finance lease liabilities (2,854) Below-market leases (169) Total liabilities acquired (3,023) Net assets acquired $ 16,077 (1) The Tucson Healthcare Facility IV was acquired as a development healthcare property. At the closing date, the Company funded $849,000 for the construction of the development property and capitalized acquisition costs of $58,000, which are a part of construction in progress in the accompanying consolidated balance sheets as of December 31, 2020.
Schedule of Dispositions	The following table summarizes the 2020 Dispositions during the year ended December 31, 2020: Property Description Disposition Date Ownership Percentage Sale Price Net Proceeds San Antonio Healthcare Facility II 05/28/2020 100% $ 35,000 (1) $ 6,125 Dallas Healthcare Facility II 11/06/2020 100% 23,000 22,417 Total $ 58,000 $ 28,542 (1) The sale price of $35,000,000 consisted of $7,000,000 cash and a $28,000,000 investment in note receivable. See Note 8—"Notes Receivable, Net" for additional information.

Acquired Intangible Assets, N_2

Acquired Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Finite-Lived Intangible Assets, Net [Abstract]
Schedule of Acquired Intangible Assets, Net	Acquired intangible assets, net, consisted of the following as of December 31, 2020 and 2019 (amounts in thousands, except weighted average remaining life amounts): December 31, 2020 December 31, 2019 In-place leases, net of accumulated amortization of $86,728 and $62,252, respectively (with a weighted average remaining life of 9.8 years and 10.4 years, respectively) $ 231,200 $ 266,856 Above-market leases, net of accumulated amortization of $4,002 and $1,912, respectively (with a weighted average remaining life of 9.9 years and 10.5 years, respectively) 15,561 18,603 $ 246,761 $ 285,459
Schedule of Estimated Future Amortization Expense of Acquired Intangible Assets	Estimated amortization expense on the acquired intangible assets as of December 31, 2020, for each of the next five years ending December 31 and thereafter, is as follows (amounts in thousands): Year Amount 2021 $ 30,597 2022 29,159 2023 28,076 2024 26,001 2025 23,018 Thereafter 109,910 $ 246,761

Acquired Intangible Liabiliti_2

Acquired Intangible Liabilities, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Intangible Lease Liabilities, Net [Abstract]
Schedule of Acquired Intangible Liabilities, Net	Acquired intangible liabilities, net, consisted of the following as of December 31, 2020 and 2019 (amounts in thousands, except weighted average remaining life amounts): December 31, 2020 December 31, 2019 Below-market leases, net of accumulated amortization of $13,924 and $12,332, respectively (with a weighted average remaining life of 16.2 years and 16.1 years, respectively) $ 52,560 $ 59,538
Schedule of Estimated Future Amortization of Acquired Intangible Liabilities	Estimated amortization of the acquired intangible liabilities as of December 31, 2020, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands): Year Amount 2021 $ 4,385 2022 3,873 2023 3,808 2024 3,706 2025 3,482 Thereafter 33,306 $ 52,560

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Schedule of Future Minimum Rent to Lessor from Operating Leases	Future rent to be received from the Company's investments in real estate assets under the terms of non-cancellable operating leases in effect as of December 31, 2020, including optional renewal periods, when applicable, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands): Year Amount 2021 $ 224,764 2022 233,130 2023 235,913 2024 232,177 2025 223,136 Thereafter 1,434,582 Total (1) $ 2,583,702 (1) The total future rent amount of $2,583,702,000 includes approximately $59,171,000 in rent to be received in connection with two leases executed as of December 31, 2020, at two development properties with estimated lease commencement dates of April 1, 2021 and February 1, 2022.
Schedule of Future Minimum Rent from Lessee for Operating Leases	The future rent payments, discounted by the Company's incremental borrowing rates, under non-cancellable operating leases, as of December 31, 2020, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands): Year Amount 2021 $ 2,464 2022 1,682 2023 1,638 2024 1,687 2025 1,688 Thereafter 135,031 Total undiscounted rental payments 144,190 Less imputed interest (112,140) Total operating lease liabilities $ 32,050
Schedule of Future Minimum Rent from Lessee for Finance Lease	The future rent payments, discounted by the Company's incremental borrowing rates, under non-cancellable finance leases, as of December 31, 2020, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands): Year Amount 2021 $ 147 2022 147 2023 147 2024 152 2025 154 Thereafter 7,110 Total undiscounted rental payments 7,857 Less imputed interest (5,014) Total finance lease liabilities $ 2,843

Notes Receivable, Net (Tables)

Notes Receivable, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Receivables [Abstract]
Schedule of Notes Receivable Balance	The following summarizes the notes receivable balances as of December 31, 2020 and 2019: December 31, 2020 December 31, 2019 Interest Rate (1) Maturity Date Note receivable $ 2,700 $ 2,700 6.0% 11/05/2021 Note receivable 28,562 — 7.0% 06/01/2022 Total notes receivable $ 31,262 $ 2,700 (1) As of December 31, 2020.

Other Assets, Net (Tables)

Other Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Other Assets [Abstract]
Schedule of Other Assets, Net	Other assets, net, consisted of the following as of December 31, 2020 and 2019 (amounts in thousands): December 31, 2020 December 31, 2019 Deferred financing costs, related to the revolver portion of the credit facility, net of accumulated amortization of $6,902 and $5,696, respectively $ 1,634 $ 2,623 Leasing commissions, net of accumulated amortization of $811 and $240, respectively 11,421 10,288 Restricted cash 14,735 10,888 Tenant receivables 5,541 6,116 Straight-line rent receivable, net 69,687 48,526 Prepaid and other assets 5,443 4,709 Derivative assets — 884 $ 108,461 $ 84,034

Accounts Payable and Other Li_2

Accounts Payable and Other Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Other Liabilities	Accounts payable and other liabilities consisted of the following as of December 31, 2020 and 2019 (amounts in thousands): December 31, 2020 December 31, 2019 Accounts payable and accrued expenses $ 14,033 $ 11,448 Accrued interest expense 4,269 5,185 Accrued property taxes 2,511 3,537 Accrued personnel costs (1) 1,202 — Distribution and servicing fees 3,128 — Distributions payable to stockholders 9,117 9,093 Tenant deposits 1,047 1,500 Deferred rental income 9,767 9,003 Deferred internalization transaction liability (2) 14,728 — Derivative liabilities 20,444 5,588 $ 80,246 $ 45,354 (1) Upon completion of the Internalization Transaction on September 30, 2020, 76 individuals previously employed by an affiliate of the Former Advisor, became employees of the Company. These costs include payroll related expenses that have been earned by the Company's employees from October 1, 2020 through December 31, 2020. (2) Represents the assumed liability recorded at fair value, net of amortization of discount, as a part of the Internalization Transaction. See Note 3—"Internalization Transaction" for additional information.

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Debt	As of December 31, 2020, the Company had $453,422,000 principal outstanding in notes payable collateralized by real estate properties with a weighted average interest rate of 4.4%. The following table summarizes the notes payable balances as of December 31, 2020 and 2019 (amounts in thousands): Interest Rates December 31, 2020 December 31, 2019 Range Weighted Maturity Date Fixed rate notes payable $ 218,415 $ 219,567 4.0% - 4.8% 4.3% 12/11/2021 - 07/01/2027 Variable rate notes payable fixed through interest rate swaps 235,007 237,778 3.7% - 5.1% 4.5% 10/28/2021 - 11/16/2022 Total notes payable, principal amount outstanding 453,422 457,345 Unamortized deferred financing costs related to notes payable (1,805) (2,500) Total notes payable, net of deferred financing costs $ 451,617 $ 454,845
Schedule of Future Principal Payments Due on Debt	The principal payments due on the notes payable as of December 31, 2020, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands): Year Amount 2021 (1) $ 146,026 2022 166,209 2023 2,710 2024 27,360 2025 2,195 Thereafter 108,922 $ 453,422 (1) The Company has adequate liquidity and availability under the credit facility to satisfy its outstanding debt obligations as they become due in 2021. The principal payments due on the credit facility as of December 31, 2020, for each of the next five years ending December 31, are as follows (amounts in thousands): Year Amount 2022 (1) $ 138,000 2023 280,000 2024 520,000 $ 938,000 (1) Amount relates to the revolving line of credit under the credit facility. As of December 31, 2020, the maturity date of the revolving line of credit under the credit facility was April 27, 2022, subject to our right for one, 12-month extension period.

Credit Facility (Tables)

Credit Facility (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Credit Facility	The Company's outstanding credit facility as of December 31, 2020 and 2019 consisted of the following (amounts in thousands): December 31, 2020 December 31, 2019 Variable rate revolving line of credit $ 138,000 $ 108,000 Variable rate term loan fixed through interest rate swaps 400,000 250,000 Variable rate term loans 400,000 550,000 Total credit facility, principal amount outstanding 938,000 908,000 Unamortized deferred financing costs related to the term loan credit facility (5,900) (7,385) Total credit facility, net of deferred financing costs $ 932,100 $ 900,615
Schedule of Future Principal Payments Due on Debt	The principal payments due on the notes payable as of December 31, 2020, for each of the next five years ending December 31 and thereafter, are as follows (amounts in thousands): Year Amount 2021 (1) $ 146,026 2022 166,209 2023 2,710 2024 27,360 2025 2,195 Thereafter 108,922 $ 453,422 (1) The Company has adequate liquidity and availability under the credit facility to satisfy its outstanding debt obligations as they become due in 2021. The principal payments due on the credit facility as of December 31, 2020, for each of the next five years ending December 31, are as follows (amounts in thousands): Year Amount 2022 (1) $ 138,000 2023 280,000 2024 520,000 $ 938,000 (1) Amount relates to the revolving line of credit under the credit facility. As of December 31, 2020, the maturity date of the revolving line of credit under the credit facility was April 27, 2022, subject to our right for one, 12-month extension period.

Related-Party Transactions an_2

Related-Party Transactions and Arrangements (Tables)	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	The following table details amounts incurred in connection with the Company's related-party transactions as described above for the years ended December 31, 2020, 2019 and 2018 (amounts in thousands): Incurred Year Ended Fee Entity 2020 2019 2018 Distribution and servicing fees (1) SC Distributors, LLC $ (65) $ (563) $ 368 Acquisition fees and costs Carter Validus Advisors II, LLC and its affiliates 97 26,072 4,272 Asset management fees Carter Validus Advisors II, LLC and its affiliates 17,914 16,475 13,114 Property management fees Carter Validus Real Estate Management Services II, LLC 5,290 5,403 4,391 Operating expense reimbursement Carter Validus Advisors II, LLC and its affiliates 3,966 4,492 2,692 Leasing commission fees Carter Validus Real Estate Management Services II, LLC 594 1,241 497 Construction management fees Carter Validus Real Estate Management Services II, LLC 435 276 243 Disposition fees Carter Validus Advisors II, LLC and its affiliates 350 — — Loan origination fees Carter Validus Advisors II, LLC and its affiliates 560 — — Total $ 29,141 $ 53,396 $ 25,577 (1) Reduction of distribution and servicing fees is a result of repurchases of Class T and Class T2 shares of common stock for the years ended December 31, 2020 and 2019. The following table details amounts payable to affiliates in connection with the Company's related-party transactions as described above as of December 31, 2020 and 2019 (amounts in thousands): Payable Fee Entity December 31, 2020 December 31, 2019 Distribution and servicing fees SC Distributors, LLC $ — $ 6,210 Asset management fees Carter Validus Advisors II, LLC and its affiliates — 2,100 Property management fees Carter Validus Real Estate Management Services II, LLC — 433 Operating expense reimbursement Carter Validus Advisors II, LLC and its affiliates — 518 Leasing commission fees Carter Validus Real Estate Management Services II, LLC — 299 Construction management fees Carter Validus Real Estate Management Services II, LLC — 199 Total $ — $ 9,759

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Schedule of Information for Reportable Segments	Summary information for the reportable segments during the years ended December 31, 2020, 2019 and 2018 is as follows (amounts in thousands): Data Centers Healthcare Year Ended December 31, 2020 Revenue: Rental revenue $ 110,755 $ 165,781 $ 276,536 Expenses: Rental expenses (28,346) (15,187) (43,533) Segment net operating income $ 82,409 $ 150,594 233,003 Expenses: General and administrative expenses (16,681) Internalization transaction expenses (3,640) Asset management fees (17,914) Depreciation and amortization (105,483) Gain on real estate dispositions 3,142 Income from operations 92,427 Interest and other expense, net (55,651) Net income attributable to common stockholders $ 36,776 Data Centers Healthcare Year Ended Revenue: Rental revenue $ 109,689 $ 101,212 $ 210,901 Expenses: Rental expenses (30,270) (10,714) (40,984) Segment net operating income $ 79,419 $ 90,498 169,917 Expenses: General and administrative expenses (8,421) Asset management fees (16,475) Depreciation and amortization (74,104) Impairment loss on real estate - healthcare (21,000) Gain on real estate disposition 79 Income from operations 49,996 Interest and other expense, net (47,214) Net income attributable to common stockholders $ 2,782 Data Centers Healthcare Year Ended December 31, 2018 Revenue: Rental revenue $ 103,226 $ 74,107 $ 177,333 Expenses: Rental expenses (27,289) (10,038) (37,327) Segment net operating income $ 75,937 $ 64,069 140,006 Expenses: General and administrative expenses (5,396) Asset management fees (13,114) Depreciation and amortization (58,258) Income from operations 63,238 Interest and other expense, net (34,365) Net income attributable to common stockholders $ 28,873
Schedule of Assets by Reportable Segments	Assets by each reportable segment as of December 31, 2020 and 2019 are as follows (amounts in thousands): December 31, 2020 December 31, 2019 Assets by segment: Data centers $ 979,222 (1) $ 989,953 Healthcare 2,147,389 (1) 2,184,450 All other 78,678 65,131 Total assets $ 3,205,289 $ 3,239,534 (1) Includes $15,574,000 of goodwill allocated to the data centers segment and $23,955,000 of goodwill allocated to the healthcare segment acquired in the Internalization Transaction on September 30, 2020.
Schedule of Capital Additions, Acquisitions, Dispositions and Goodwill by Reportable Segments	Capital additions, acquisitions and dispositions and goodwill by reportable segments for the years ended December 31, 2020, 2019 and 2018 are as follows (amounts in thousands): Year Ended 2020 2019 2018 Capital additions by segment: Data centers $ 3,945 $ 7,004 $ 2,763 Healthcare 24,852 5,837 12,820 Total 28,797 12,841 15,583 Acquisitions by segment: Data centers — — 112,181 Healthcare 16,135 528,259 105,151 Total 16,135 528,259 217,332 Proceeds from Dispositions by segment: Data centers — — — Healthcare (28,542) (2,882) — Total (28,542) (2,882) — Net cash outflows from capital additions, acquisitions and dispositions $ 16,390 $ 538,218 $ 232,915 Goodwill allocated by segment: Data centers $ 15,574 $ — — Healthcare 23,955 — — Total $ 39,529 $ — $ —

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables show the fair value of the Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of December 31, 2020 and 2019 (amounts in thousands): December 31, 2020 Fair Value Hierarchy Quoted Prices in Active Significant Other Significant Total Fair Liabilities: Derivative liabilities $ — $ 20,444 $ — $ 20,444 Total liabilities at fair value $ — $ 20,444 $ — $ 20,444 December 31, 2019 Fair Value Hierarchy Quoted Prices in Active Significant Other Significant Total Fair Assets: Derivative assets $ — $ 884 $ — $ 884 Total assets at fair value $ — $ 884 $ — $ 884 Liabilities: Derivative liabilities $ — $ 5,588 $ — $ 5,588 Total liabilities at fair value $ — $ 5,588 $ — $ 5,588

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	12 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of the Notional Amount and Fair Value of Derivative Instruments	The following table summarizes the notional amount and fair value of the Company’s derivative instruments (amounts in thousands): Derivatives Balance Effective Maturity December 31, 2020 December 31, 2019 Outstanding Fair Value of Outstanding Fair Value of Asset (Liability) Asset (Liability) Interest rate swaps Other assets, net/ 11/01/2016 to 10/28/2021 to $ 635,007 $ — $ (20,444) $ 637,778 $ 884 $ (5,588)
Schedule of Income and Losses Recognized on Derivative Instruments	The table below summarizes the amount of (loss) income recognized on the interest rate derivatives designated as cash flow hedges for the years ended December 31, 2020, 2019 and 2018 (amounts in thousands): Derivatives in Cash Flow Amount of (Loss) Income Recognized Location of (Loss) Income Amount of (Loss) Income Total Amount of Interest and Other Expense, Net Presented in Statements of Comprehensive Income (Loss) Year Ended December 31, 2020 Interest rate swaps $ (23,583) Interest and other expense, net $ (7,843) $ 55,651 Total $ (23,583) $ (7,843) Year Ended December 31, 2019 Interest rate swaps $ (9,305) Interest and other expense, net $ 1,602 $ 47,214 Total $ (9,305) $ 1,602 Year Ended December 31, 2018 Interest rate swaps $ 3,208 Interest and other expense, net $ 818 $ 34,365 Total $ 3,208 $ 818
Schedule of Offsetting of Derivative Assets	The following tables present the effect on the Company’s financial position had the Company made the election to offset its derivative positions as of December 31, 2020 and 2019 (amounts in thousands): Offsetting of Derivative Assets Gross Amounts Not Offset in the Balance Sheet Gross Gross Amounts Net Amounts of Financial Instruments Cash Collateral Net December 31, 2019 $ 884 $ — $ 884 $ (5) $ — $ 879
Schedule of Offsetting of Derivative Liabilities	Offsetting of Derivative Liabilities Gross Amounts Not Offset in the Balance Sheet Gross Gross Amounts Net Amounts of Financial Instruments Cash Collateral Net December 31, 2020 $ 20,444 $ — $ 20,444 $ — $ — $ 20,444 December 31, 2019 $ 5,588 $ — $ 5,588 $ (5) $ — $ 5,583

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive (Loss) Income (Tables)	12 Months Ended
	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Amounts Recognized in Accumulated Other Comprehensive (Loss) Income	The following table presents a rollforward of amounts recognized in accumulated other comprehensive (loss) income by component for the years ended December 31, 2020, 2019 and 2018 (amounts in thousands): Unrealized Income (Loss) on Derivative Balance as of December 31, 2017 $ 3,710 Other comprehensive income before reclassification 3,208 Amount of income reclassified from accumulated other comprehensive income to net income (effective portion) (818) Other comprehensive income 2,390 Balance as of December 31, 2018 6,100 Cumulative effect of accounting change 103 Balance as of January 1, 2019 6,203 Other comprehensive loss before reclassification (9,305) Amount of income reclassified from accumulated other comprehensive income to net income (including missed forecast) (1,602) Other comprehensive loss (10,907) Balance as of December 31, 2019 (4,704) Other comprehensive loss before reclassification (23,583) Amount of loss reclassified from accumulated other comprehensive loss to net income 7,843 Other comprehensive loss (15,740) Balance as of December 31, 2020 $ (20,444)
Schedule of Reclassifications Out of Accumulated Other Comprehensive (Loss) Income	The following table presents reclassifications out of accumulated other comprehensive (loss) income for the years ended December 31, 2020, 2019 and 2018 (amounts in thousands): Details about Accumulated Other Amounts Reclassified from Affected Line Items in the Consolidated Statements of Comprehensive Income (Loss) Year Ended 2020 2019 2018 Interest rate swap contracts $ 7,843 $ (1,602) $ (818) Interest and other expense, net

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Nonvested Shares of Restricted Common Stock Activity	A summary of the status of the nonvested shares of restricted Class A common stock as of December 31, 2019 and the changes for the year ended December 31, 2020 is presented below: Restricted Stock Shares Nonvested at December 31, 2019 27,750 Vested (10,500) Granted 595,677 Nonvested at December 31, 2020 612,927

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Characterization of Distributions Paid to Stockholders	As a REIT, the Company generally will not be subject to U.S. federal income tax on taxable income that it distributes to the stockholders. For U.S. federal income tax purposes, distributions to stockholders are characterized as either ordinary dividends, capital gain distributions, or nontaxable distributions. Nontaxable distributions will reduce U.S. stockholders’ respective bases in their shares. The following table shows the character of distributions the Company paid on a percentage basis during the years ended December 31, 2020, 2019 and 2018: Year Ended December 31, Character of Class A Distributions: 2020 2019 2018 Ordinary dividends — % 17.93 % 41.38 % Capital gain distributions — % 0.38 % — % Nontaxable distributions 100.00 % 81.69 % 58.62 % Total 100.00 % 100.00 % 100.00 % Year Ended December 31, Character of Class I Distributions: 2020 2019 2018 Ordinary dividends — % 17.93 % 41.38 % Capital gain distributions — % 0.38 % — % Nontaxable distributions 100.00 % 81.69 % 58.62 % Total 100.00 % 100.00 % 100.00 % Year Ended December 31, Character of Class T Distributions: 2020 2019 2018 Ordinary dividends — % 4.79 % 33.01 % Capital gain distributions — % 0.43 % — % Nontaxable distributions 100.00 % 94.78 % 66.99 % Total 100.00 % 100.00 % 100.00 % Year Ended December 31, Character of Class T2 Distributions: 2020 2019 2018 Ordinary dividends — % 4.79 % 33.01 % Capital gain distributions — % 0.43 % — % Nontaxable distributions 100.00 % 94.78 % 66.99 % Total 100.00 % 100.00 % 100.00 %

Selected Quarterly Financial _2

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Schedule of Selected Quarterly Financial Data (Unaudited)	Presented in the following table is a summary of the unaudited quarterly financial information for the years ended December 31, 2020 and 2019. The Company believes that all necessary adjustments, consisting only of normal recurring adjustments, have been included in the amounts stated below to present fairly, and in accordance with GAAP, the selected quarterly information (amounts in thousands, except shares and per share data): 2020 Fourth Third Second First Total revenue $ 67,809 $ 70,667 $ 68,875 $ 69,185 Total expenses (40,651) (52,119) (46,284) (48,197) Gain on real estate dispositions 439 — 2,703 — Income from operations 27,597 18,548 25,294 20,988 Interest and other expense, net (12,849) (13,284) (14,199) (15,319) Net income attributable to common stockholders $ 14,748 $ 5,264 $ 11,095 $ 5,669 Net income per common share attributable to common stockholders: Basic $ 0.07 $ 0.02 $ 0.05 $ 0.03 Diluted $ 0.07 $ 0.02 $ 0.05 $ 0.03 Weighted average number of common shares outstanding: Basic 221,863,141 221,346,730 220,992,009 221,540,890 Diluted 222,475,926 221,406,461 221,029,409 221,570,975 2019 Fourth Third Second First Total revenue $ 69,434 $ 48,063 $ 46,937 $ 46,467 Total expenses (52,160) (45,773) (30,780) (32,271) Gain on real estate disposition 79 — — — Income from operations 17,353 2,290 16,157 14,196 Interest and other expense, net (15,566) (11,920) (9,893) (9,835) Net income (loss) attributable to common stockholders $ 1,787 $ (9,630) $ 6,264 $ 4,361 Net income (loss) per common share attributable to common stockholders: Basic $ 0.01 $ (0.07) $ 0.05 $ 0.03 Diluted $ 0.01 $ (0.07) $ 0.05 $ 0.03 Weighted average number of common shares outstanding: Basic 218,928,165 137,063,509 136,135,710 136,179,343 Diluted 218,955,915 137,063,509 136,161,037 136,204,843

Subsequent Events (Tables)

Subsequent Events (Tables)	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Schedule of Subsequent Events	The following table summarizes the Company's distributions paid to stockholders on January 4, 2021, for the period from December 1, 2020 through December 31, 2020 (amounts in thousands): Payment Date Common Stock Cash DRIP Total Distribution January 4, 2021 Class A $ 5,489 $ 1,587 $ 7,076 January 4, 2021 Class I 325 212 537 January 4, 2021 Class T 704 679 1,383 January 4, 2021 Class T2 56 65 121 $ 6,574 $ 2,543 $ 9,117 The following table summarizes the Company's distributions paid to stockholders on February 1, 2021, for the period from January 1, 2021 through January 31, 2021 (amounts in thousands): Payment Date Common Stock Cash DRIP Total Distribution February 1, 2021 Class A $ 5,520 $ 1,586 $ 7,106 February 1, 2021 Class I 328 211 539 February 1, 2021 Class T 708 679 1,387 February 1, 2021 Class T2 56 65 121 $ 6,612 $ 2,541 $ 9,153 The following table summarizes the Company's distributions paid to stockholders on March 2, 2021, for the period from February 1, 2021 through February 28, 2021 (amounts in thousands): Payment Date Common Stock Cash DRIP Total Distribution March 2, 2021 Class A $ 4,992 $ 1,432 $ 6,424 March 2, 2021 Class I 298 191 489 March 2, 2021 Class T 642 613 1,255 March 2, 2021 Class T2 51 57 108 $ 5,983 $ 2,293 $ 8,276 Distributions Authorized The following tables summarize the daily distributions approved and authorized by the board of directors of the Company subsequent to December 31, 2020: Authorization Date (1) Common Stock Daily Distribution Rate (1) Annualized Distribution Per Share January 25, 2021 Class A $ 0.001369863 $ 0.50 January 25, 2021 Class I $ 0.001369863 $ 0.50 January 25, 2021 Class T $ 0.001131781 $ 0.41 January 25, 2021 Class T2 $ 0.001131781 $ 0.41 Authorization Date (2) Common Stock Daily Distribution Rate (2) Annualized Distribution Per Share February 25, 2021 Class A $ 0.001369863 $ 0.50 February 25, 2021 Class I $ 0.001369863 $ 0.50 February 25, 2021 Class T $ 0.001131781 $ 0.41 February 25, 2021 Class T2 $ 0.001131781 $ 0.41 Authorization Date (3) Common Stock Daily Distribution Rate (3) Annualized Distribution Per Share March 18, 2021 Class A $ 0.001369863 $ 0.50 March 18, 2021 Class I $ 0.001369863 $ 0.50 March 18, 2021 Class T $ 0.001131781 $ 0.41 March 18, 2021 Class T2 $ 0.001131781 $ 0.41 (1) Distributions approved and authorized to stockholders of record as of the close of business on each day of the period commencing on February 1, 2021 and ending on February 28, 2021. The distributions will be calculated based on 365 days in the calendar year. The distributions declared for each record date in February 2021 will be paid in March 2021. The distributions will be payable to stockholders from legally available funds therefor. (2) Distributions approved and authorized to stockholders of record as of the close of business on each day of the period commencing on March 1, 2021 and ending on March 31, 2021. The distributions will be calculated based on 365 days in the calendar year. The distributions declared for each record date in March 2021 will be paid in April 2021. The distributions will be payable to stockholders from legally available funds therefor. (3) Distributions approved and authorized to stockholders of record as of the close of business on each day of the period commencing on April 1, 2021 and ending on April 30, 2021. The distributions will be calculated based on 365 days in the calendar year. The distributions declared for each record date in April 2021 will be paid in May 2021. The distributions will be payable to stockholders from legally available funds therefor.

Organization and Business Ope_2

Organization and Business Operations (Details)	12 Months Ended
	Dec. 31, 2020propertyregistration_statement	Sep. 30, 2020employee	Sep. 29, 2020employee	Nov. 30, 2018initial_public_offering
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of employees | employee		76	0
Number of real estate properties acquired	3
Number of real estate properties sold	2
Number of real estate properties owned	153
Number of public offerings | initial_public_offering				2
Number of registration statements on Form S-3 | registration_statement	2

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Narrative) (Details)	Mar. 18, 2021$ / shares	Mar. 02, 2021USD ($)	Feb. 25, 2021$ / shares	Feb. 01, 2021USD ($)	Jan. 25, 2021$ / shares	Jan. 04, 2021USD ($)	Jun. 19, 2020USD ($)	Nov. 08, 2019USD ($)	Dec. 31, 2019USD ($)	Sep. 30, 2019property	Dec. 31, 2020USD ($)segmentleasemetropolitanpropertytenantmicropolitan$ / sharesshares	Dec. 31, 2019USD ($)leasetenant$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Sep. 30, 2020USD ($)
Summary of Significant Accounting Policies [Line Items]
Number of real estate properties acquired | property											3
Impairment loss on real estate								$ 13,000,000	$ 8,000,000		$ 0	$ 21,000,000	$ 0
Real estate assets, carrying amount									2,768,462,000		$ 2,693,824,000	$ 2,768,462,000
Impairment of acquired intangible assets													0
Number of tenants with impaired intangible assets | tenant												2
Number of impaired intangible liabilities | lease											1	1
Accelerated amortization of below-market leases											$ 1,974,000	$ 212,000	0
Number of tenants with impaired intangible liabilities | tenant											1	1
Goodwill									0		$ 39,529,000	$ 0
Goodwill impairment loss											0
Origination of note receivable related to real estate disposition											28,000,000	0	0
Reduction in rental revenue											$ 126,000	672,000	0
Number of micropolitan statistical areas with owned real estate investments | micropolitan											2
Number of metropolitan statistical areas with owned real estate investments | metropolitan											68
Maximum number of shares available for repurchase during any calendar year, as percentage of common stock outstanding at end of prior year											5.00%
Period of notice required for changes to share repurchase program											30 days
Purchase of noncontrolling interest											$ 2,000
Repurchase of common stock											$ 29,487,000	$ 23,655,000	$ 43,230,000
Repurchase of common stock percentage											0.0154	0.0187
Distributions declared per common share (in dollars per share) | $ / shares											$ 0.48	$ 0.58	$ 0.63
Cash paid											$ 76,517,000	$ 49,494,000	$ 40,296,000
Issuance of common stock under the distribution reinvestment plan											$ 30,553,000	$ 39,934,000	$ 40,938,000
Diluted earnings per share outstanding adjustment (in shares) | shares											186,000	24,000	24,000
Number of reportable business segments | segment											2
Impact related to uncertain tax positions from the results of operations											$ 0	$ 0	$ 0
Number of rent concessions and lease modifications | lease											30
Rental revenue from rent concessions and lease modifications, percentage collected											99.00%
Internalization Transaction
Summary of Significant Accounting Policies [Line Items]
Goodwill											$ 39,529,000			$ 39,529,000
Subsequent Event
Summary of Significant Accounting Policies [Line Items]
Distributions payable		$ 8,276,000		$ 9,153,000		$ 9,117,000
Cash paid		5,983,000		6,612,000		6,574,000
Issuance of common stock under the distribution reinvestment plan		2,293,000		2,541,000		2,543,000
Common Stock
Summary of Significant Accounting Policies [Line Items]
Repurchase of common stock (in shares) | shares											3,408,870	2,557,298	4,700,554
Repurchase of common stock											$ 34,000	$ 25,000	$ 47,000
Issuance of common stock under the distribution reinvestment plan											$ 35,000	$ 43,000	$ 44,000
Class A, I, T and T2 shares | Common Stock
Summary of Significant Accounting Policies [Line Items]
Repurchase of common stock (in shares) | shares											3,408,870	2,557,298
Repurchase of common stock											$ 29,487,000	$ 23,655,000
Repurchase of common stock, average price per share (in dollars per share) | $ / shares											$ 8.65	$ 9.25
Class A | Subsequent Event
Summary of Significant Accounting Policies [Line Items]
Distributions declared per common share (in dollars per share) | $ / shares	$ 0.001369863		$ 0.001369863		$ 0.001369863
Distributions payable		6,424,000		7,106,000		7,076,000
Cash paid		4,992,000		5,520,000		5,489,000
Issuance of common stock under the distribution reinvestment plan		1,432,000		1,586,000		1,587,000
Class A | Common Stock
Summary of Significant Accounting Policies [Line Items]
Repurchase of common stock (in shares) | shares											2,666,674	1,910,894
Class A | Common Stock | Internalization Transaction
Summary of Significant Accounting Policies [Line Items]
Purchase of noncontrolling interest											$ 2,000
Repurchase of common stock (in shares) | shares											29,362
Repurchase of common stock											$ 254,000
Repurchase of common stock, average price per share (in dollars per share) | $ / shares											$ 8.65
Class I | Subsequent Event
Summary of Significant Accounting Policies [Line Items]
Distributions declared per common share (in dollars per share) | $ / shares	0.001369863		0.001369863		0.001369863
Distributions payable		489,000		539,000		537,000
Cash paid		298,000		328,000		325,000
Issuance of common stock under the distribution reinvestment plan		191,000		211,000		212,000
Class I | Common Stock
Summary of Significant Accounting Policies [Line Items]
Repurchase of common stock (in shares) | shares											408,346	189,947
Class T | Subsequent Event
Summary of Significant Accounting Policies [Line Items]
Distributions declared per common share (in dollars per share) | $ / shares	0.001131781		0.001131781		0.001131781
Distributions payable		1,255,000		1,387,000		1,383,000
Cash paid		642,000		708,000		704,000
Issuance of common stock under the distribution reinvestment plan		613,000		679,000		679,000
Class T | Common Stock
Summary of Significant Accounting Policies [Line Items]
Repurchase of common stock (in shares) | shares											298,224	451,058
Class T2 | Subsequent Event
Summary of Significant Accounting Policies [Line Items]
Distributions declared per common share (in dollars per share) | $ / shares	$ 0.001131781		$ 0.001131781		$ 0.001131781
Distributions payable		108,000		121,000		121,000
Cash paid		51,000		56,000		56,000
Issuance of common stock under the distribution reinvestment plan		$ 57,000		$ 65,000		$ 65,000
Class T2 | Common Stock
Summary of Significant Accounting Policies [Line Items]
Repurchase of common stock (in shares) | shares											35,626	5,399
Tenant Of Data Center Property
Summary of Significant Accounting Policies [Line Items]
Number of tenants with impaired intangible assets | property											1
Tenant Of Healthcare Property
Summary of Significant Accounting Policies [Line Items]
Number of impaired properties | property										1
Number of tenants with impaired intangible assets | tenant											1
Rental Revenue | Geographic Concentration Risk
Summary of Significant Accounting Policies [Line Items]
Number of metropolitan statistical areas with owned real estate investments | metropolitan											2
Rental Revenue | Geographic Concentration Risk | Atlanta-Sandy Springs-Roswell, Georgia MSA
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage											11.90%
Rental Revenue | Geographic Concentration Risk | Houston-The Woodlands-Sugar Land, Texas MSA
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage											10.30%
Rental Revenue | Customer Concentration Risk
Summary of Significant Accounting Policies [Line Items]
Number of tenants | tenant											1
Rental Revenue | Customer Concentration Risk | Post Acute Medical LLC
Summary of Significant Accounting Policies [Line Items]
Concentration risk, percentage											10.10%
In-place leases
Summary of Significant Accounting Policies [Line Items]
Number of impaired acquired intangible assets | lease											3	2
Impairment of acquired intangible assets											$ 4,693,000	$ 3,195,000
In-place leases | Tenant Of Data Center Property
Summary of Significant Accounting Policies [Line Items]
Impairment of acquired intangible assets											3,189,000
In-place leases | Tenant Of Healthcare Property
Summary of Significant Accounting Policies [Line Items]
Impairment of acquired intangible assets							$ 1,484,000				$ 20,000
Above-market leases
Summary of Significant Accounting Policies [Line Items]
Number of impaired acquired intangible assets | lease											1
Impairment of acquired intangible assets											$ 344,000
Impaired Real Estate Properties
Summary of Significant Accounting Policies [Line Items]
Real estate assets, carrying amount								40,266,000	30,412,000			30,412,000
Real estate assets, fair value								$ 27,266,000	$ 22,412,000			$ 22,412,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Reconciliation of Cash, Cash Equivalents and Restricted Cash) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Cash and cash equivalents	$ 53,174	$ 69,342	$ 68,360	$ 74,803
Restricted cash	14,735	10,888	11,167	10,944
Cash, cash equivalents and restricted cash	$ 67,909	$ 80,230	$ 79,527	$ 85,747

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Schedule of Estimated Useful Lives of Assets by Class) (Details)	12 Months Ended
	Dec. 31, 2020
Buildings and improvements | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	15 years
Buildings and improvements | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	40 years
Furniture, fixtures, and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Furniture, fixtures, and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years

Internalization Transaction (Na

Internalization Transaction (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Internalization transaction expenses		$ 3,640	$ 0	$ 0
Internalization Transaction
Business Acquisition [Line Items]
Membership interests acquired percentage	100.00%
Internalization transaction, purchase price	$ 40,000
Internalization Transaction, Tranche One, Closing
Business Acquisition [Line Items]
Internalization transaction, cash paid	25,000
Internalization Transaction, Tranche Two, March 31, 2021
Business Acquisition [Line Items]
Internalization transaction, payable	7,500
Internalization Transaction, Tranche Three, March 31, 2022
Business Acquisition [Line Items]
Internalization transaction, payable	$ 7,500

Internalization Transaction (Sc

Internalization Transaction (Schedule of Allocation of Purchase Price) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Goodwill	$ 39,529		$ 0
Deferred internalization transaction purchase price	(14,728)		$ 0
Internalization Transaction
Business Acquisition [Line Items]
Goodwill	39,529	$ 39,529
Right-of-use assets - operating lease	1,205
Total assets acquired	40,734
Operating lease liabilities	(1,060)
Deferred internalization transaction purchase price	(14,674)
Total liabilities acquired	(15,734)
Net assets allocated at acquisition	$ 25,000

Internalization Transaction (_2

Internalization Transaction (Schedule of Pro Forma Financial Information) (Details) - Internalization Transaction - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Revenues	$ 276,536	$ 210,901
Net income attributable to common stockholders	$ 56,083	$ 11,822
Net income per common share attributable to common stockholders:
Basic (in dollars per share)	$ 0.25	$ 0.08
Diluted (in dollars per share)	$ 0.25	$ 0.08

Acquisitions and Dispositions_2

Acquisitions and Dispositions (Narrative) (Details) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020USD ($)	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2020USD ($)property	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Real Estate [Line Items]
Number of real estate properties acquired | property									3
Capitalized acquisition fees and costs									$ 310
Number of real estate properties sold | property									2
Sale price of real estate dispositions	$ 58,000								$ 58,000
Proceeds from real estate dispositions									28,542	$ 2,882	$ 0
Gain on real estate disposition	$ 439	$ 0	$ 2,703	$ 0	$ 79	$ 0	$ 0	$ 0	$ 3,142	$ 79	$ 0
Maximum
Real Estate [Line Items]
Acquisition fees and costs (% of contract purchase price)									6.00%

Acquisitions and Dispositions_3

Acquisitions and Dispositions (Schedule of Consideration Transferred for Properties Acquired) (Details) - USD ($) $ in Thousands	Dec. 22, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Purchase Price		$ 16,135
Payment for construction in process		$ 28,797	$ 12,841	$ 15,583
Grimes Healthcare Facility
Business Acquisition [Line Items]
Ownership Percentage		100.00%
Purchase Price		$ 5,030
Tampa Healthcare Facility
Business Acquisition [Line Items]
Ownership Percentage		100.00%
Purchase Price		$ 11,047
Tucson Healthcare Facility IV
Business Acquisition [Line Items]
Ownership Percentage		100.00%
Purchase Price		$ 58
Payment for construction in process	$ 849

Acquisitions and Dispositions_4

Acquisitions and Dispositions (Schedule of Allocation of Acquisitions) (Details) - USD ($) $ in Thousands	Dec. 22, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Payment for construction in process		$ 28,797	$ 12,841	$ 15,583
Capitalized acquisition fees and costs		310
2020 Acquisitions
Business Acquisition [Line Items]
In-place leases		1,748
Right-of-use assets - finance lease		2,534
Total assets acquired		19,100
Finance lease liabilities		(2,854)
Below-market leases		(169)
Total liabilities acquired		(3,023)
Net assets acquired		16,077
Tucson Healthcare Facility IV
Business Acquisition [Line Items]
Payment for construction in process	$ 849
Capitalized acquisition fees and costs	$ 58
Land | 2020 Acquisitions
Business Acquisition [Line Items]
Property, plant and equipment acquired		831
Buildings and improvements | 2020 Acquisitions
Business Acquisition [Line Items]
Property, plant and equipment acquired		13,524
Tenant improvements | 2020 Acquisitions
Business Acquisition [Line Items]
Property, plant and equipment acquired		$ 463

Acquisitions and Dispositions_5

Acquisitions and Dispositions (Schedule of Dispositions) (Details) - USD ($) $ in Thousands	May 28, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Real Estate [Line Items]
Sale Price		$ 58,000
Net Proceeds		28,542	$ 2,882	$ 0
Notes receivable, principal amount outstanding		$ 30,700	$ 2,700
San Antonio Healthcare Facility II
Real Estate [Line Items]
Ownership Percentage		100.00%
Sale Price		$ 35,000
Net Proceeds		$ 6,125
Sale price of real estate disposition in cash	$ 7,000
Notes receivable, principal amount outstanding	$ 28,000
Dallas Healthcare Facility II
Real Estate [Line Items]
Ownership Percentage		100.00%
Sale Price		$ 23,000
Net Proceeds		$ 22,417

Acquired Intangible Assets, N_3

Acquired Intangible Assets, Net (Narrative) (Details)	12 Months Ended
	Dec. 31, 2020USD ($)lease	Dec. 31, 2019USD ($)lease	Dec. 31, 2018USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average remaining useful life of intangible assets	9 years 9 months 18 days	10 years 4 months 24 days
Amortization of acquired intangible assets	$ 37,637,000	$ 26,699,000	$ 19,919,000
Impairment of acquired intangible assets			$ 0
In-place leases
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average remaining useful life of intangible assets	9 years 9 months 18 days	10 years 4 months 24 days
Impairment of acquired intangible assets	$ 4,693,000	$ 3,195,000
Number of impaired acquired intangible assets | lease	3	2
In-place and above-market leases
Acquired Finite-Lived Intangible Assets [Line Items]
Impairment of acquired intangible assets	$ 5,037,000
Above-market leases
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted average remaining useful life of intangible assets	9 years 10 months 24 days	10 years 6 months
Impairment of acquired intangible assets	$ 344,000
Number of impaired acquired intangible assets | lease	1

Acquired Intangible Assets, N_4

Acquired Intangible Assets, Net (Schedule of Acquired Intangible Assets, Net) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired intangible asset, net of accumulated amortization	$ 246,761	$ 285,459
Acquired intangible assets, accumulated amortization	$ 90,730	$ 64,164
Weighted average remaining useful life of intangible assets	9 years 9 months 18 days	10 years 4 months 24 days
In-place leases
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired intangible asset, net of accumulated amortization	$ 231,200	$ 266,856
Acquired intangible assets, accumulated amortization	$ 86,728	$ 62,252
Weighted average remaining useful life of intangible assets	9 years 9 months 18 days	10 years 4 months 24 days
Above-market leases
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired intangible asset, net of accumulated amortization	$ 15,561	$ 18,603
Acquired intangible assets, accumulated amortization	$ 4,002	$ 1,912
Weighted average remaining useful life of intangible assets	9 years 10 months 24 days	10 years 6 months

Acquired Intangible Assets, N_5

Acquired Intangible Assets, Net (Schedule of Estimated Future Amortization Expense of Acquired Intangible Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets, Net [Abstract]
2021	$ 30,597
2022	29,159
2023	28,076
2024	26,001
2025	23,018
Thereafter	109,910
Acquired intangible assets, net	$ 246,761	$ 285,459

Acquired Intangible Liabiliti_3

Acquired Intangible Liabilities, Net (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Intangible Lease Liabilities, Net [Abstract]
Amortization of below-market leases	$ 7,147,000	$ 5,261,000	$ 4,832,000
Accelerated amortization of below-market leases	$ 1,974,000	$ 212,000	$ 0

Acquired Intangible Liabiliti_4

Acquired Intangible Liabilities, Net (Schedule of Acquired Intangible Liabilities, Net) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Intangible Lease Liabilities, Net [Abstract]
Below-market leases, net of accumulated amortization of $13,924 and $12,332, respectively (with a weighted average remaining life of 16.2 years and 16.1 years, respectively)	$ 52,560	$ 59,538
Accumulated amortization of below-market leases	$ 13,924	$ 12,332
Weighted average remaining life of below-market leases	16 years 2 months 12 days	16 years 1 month 6 days

Acquired Intangible Liabiliti_5

Acquired Intangible Liabilities, Net (Schedule of Estimated Future Amortization of Acquired Intangible Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Intangible Lease Liabilities, Net [Abstract]
2021	$ 4,385
2022	3,873
2023	3,808
2024	3,706
2025	3,482
Thereafter	33,306
Acquired intangible liabilities, net	$ 52,560	$ 59,538

Leases (Narrative) (Details)

Leases (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)ft²lease	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Lessee, Lease, Description [Line Items]
Number of operating ground leases | lease	17
Number of operating office leases | lease	1
Number of operating ground leases without corresponding operating lease liabilities | lease	4
Operating lease liability	$ 32,050	$ 31,004
Operating lease costs	2,567	1,388	$ 134
Sublease income	$ 1,604	$ 781	94
Operating lease, weighted average incremental borrowing rate, percent	5.70%
Operating lease, weighted average remaining lease term	48 years 1 month 6 days	50 years 8 months 12 days
Number of finance ground leases | lease	1
Right-of-use assets in exchange for lease liability - finance lease	$ 2,854	$ 0	0
Reduction in the carrying amount of right-of-use assets - finance lease, net	7	$ 0	$ 0
Interest on finance lease liability	$ 47
Finance lease, weighted average incremental borrowing rate, percent	5.30%
Finance lease, weighted average remaining lease term	43 years 4 months 24 days
Minimum
Lessee, Lease, Description [Line Items]
Operating lease, weighted average incremental borrowing rate, percent	3.50%
Maximum
Lessee, Lease, Description [Line Items]
Operating lease, weighted average incremental borrowing rate, percent	6.60%
Corporate Lease
Lessee, Lease, Description [Line Items]
Operating lease liability	$ 1,060
Leased area of real estate property | ft²	24,555
Operating lease costs	$ 264

Leases (Schedule of Future Mini

Leases (Schedule of Future Minimum Rent to Lessor from Operating Leases) (Details) $ in Thousands	Dec. 31, 2020USD ($)leaseproperty
Leases [Abstract]
2021	$ 224,764
2022	233,130
2023	235,913
2024	232,177
2025	223,136
Thereafter	1,434,582
Total	2,583,702
Value of underlying operating lease asset, leases not yet commenced	$ 59,171
Number of executed leases, operating leases not yet commenced | lease	2
Number of development properties, operating leases not yet commenced | property	2

Leases (Schedule of Future Mi_2

Leases (Schedule of Future Minimum Rent from Lessee for Operating Leases) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
2021	$ 2,464
2022	1,682
2023	1,638
2024	1,687
2025	1,688
Thereafter	135,031
Total undiscounted rental payments	144,190
Less imputed interest	(112,140)
Total operating lease liabilities	$ 32,050	$ 31,004

Leases (Schedule of Future Mi_3

Leases (Schedule of Future Minimum Rent from Lessee for Finance Lease) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
2021	$ 147
2022	147
2023	147
2024	152
2025	154
Thereafter	7,110
Total undiscounted rental payments	7,857
Less imputed interest	(5,014)
Total finance lease liabilities	$ 2,843	$ 0

Notes Receivable, Net (Narrativ

Notes Receivable, Net (Narrative) (Details)	Jan. 06, 2021USD ($)	May 28, 2020USD ($)	Dec. 31, 2020USD ($)noteReceivable	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of notes receivable outstanding | noteReceivable			2
Notes receivable, net			$ 31,262,000	$ 2,700,000
Investment in note receivable, principal amount			30,700,000	2,700,000
Amortization of loan origination fee			166,000	0	$ 0
Estimated credit losses for notes receivable			0
Note Receivable Due June 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable, net			$ 28,562,000	0
Investment in note receivable, principal amount		$ 28,000,000
Interest rate			7.00%
Loan origination fee incurred		$ 560,000
Amortization of loan origination fee			$ 166,000
Interest income on notes receivable			1,187,000
Unamortized loan origination fee			394,000
Note Receivable Due June 2022 | Note Receivable, Period One
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest rate		7.00%
Note Receivable Due June 2022 | Note Receivable, Period Two
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest rate		8.00%
Note Receivable Due November 2021
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable, net			2,700,000	$ 2,700,000
Investment in note receivable, principal amount			$ 2,700,000
Interest rate			6.00%
Note Receivable Due November 2021 | Subsequent Event
Accounts, Notes, Loans and Financing Receivable [Line Items]
Amendment fee received	$ 50,000
Principal amount repaid	$ 500,000

Notes Receivable, Net (Schedule

Notes Receivable, Net (Schedule of Notes Receivable Balance) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable, net	$ 31,262	$ 2,700
Note Receivable Due November 2021
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable, net	$ 2,700	2,700
Interest Rate	6.00%
Note Receivable Due June 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable, net	$ 28,562	$ 0
Interest Rate	7.00%

Other Assets, Net (Narrative) (

Other Assets, Net (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)tenant	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Line of Credit Facility [Line Items]
Amortization of deferred financing costs	$ 3,884	$ 2,825	$ 2,810
Amortization of leasing commissions	598	158	76
Lease Modifications
Line of Credit Facility [Line Items]
Amortization of leasing commissions	$ 12
Number of impaired leasing commissions | tenant	2
Revolving Line of Credit
Line of Credit Facility [Line Items]
Amortization of deferred financing costs	$ 1,206	$ 1,010	$ 1,260

Other Assets, Net (Schedule of

Other Assets, Net (Schedule of Other Assets, Net) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Other Assets [Abstract]
Deferred financing costs, related to the revolver portion of the credit facility, net of accumulated amortization of $6,902 and $5,696, respectively	$ 1,634	$ 2,623
Leasing commissions, net of accumulated amortization of $811 and $240, respectively	11,421	10,288
Restricted cash	14,735	10,888	$ 11,167	$ 10,944
Tenant receivables	5,541	6,116
Straight-line rent receivable, net	69,687	48,526
Prepaid and other assets	5,443	4,709
Derivative assets	0	884
Total other assets, net	108,461	84,034
Deferred financing costs, related to the revolver portion of the credit facility, accumulated amortization	6,902	5,696
Leasing commissions, accumulated amortization	$ 811	$ 240

Accounts Payable and Other Li_3

Accounts Payable and Other Liabilities (Details) $ in Thousands	Dec. 31, 2020USD ($)	Sep. 30, 2020employee	Sep. 29, 2020employee	Dec. 31, 2019USD ($)
Payables and Accruals [Abstract]
Accounts payable and accrued expenses	$ 14,033			$ 11,448
Accrued interest expense	4,269			5,185
Accrued property taxes	2,511			3,537
Accrued personnel costs	1,202			0
Distribution and servicing fees	3,128			0
Distributions payable to stockholders	9,117			9,093
Tenant deposits	1,047			1,500
Deferred rental income	9,767			9,003
Deferred internalization transaction purchase price	14,728			0
Derivative liabilities	20,444			5,588
Total accounts payable and other liabilities	$ 80,246			$ 45,354
Number of employees | employee		76	0

Notes Payable (Schedule of Debt

Notes Payable (Schedule of Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Notes payable, principal amount outstanding	$ 453,422	$ 457,345
Unamortized deferred financing costs related to notes payable	(1,805)	(2,500)
Total notes payable, net of deferred financing costs	$ 451,617	454,845
Weighted Average
Debt Instrument [Line Items]
Interest Rates: Range and Weighted Average	4.40%
Fixed Rate
Debt Instrument [Line Items]
Notes payable, principal amount outstanding	$ 218,415	219,567
Fixed Rate | Minimum
Debt Instrument [Line Items]
Interest Rates: Range and Weighted Average	4.00%
Fixed Rate | Maximum
Debt Instrument [Line Items]
Interest Rates: Range and Weighted Average	4.80%
Fixed Rate | Weighted Average
Debt Instrument [Line Items]
Interest Rates: Range and Weighted Average	4.30%
Variable Rate, Subject to Interest Rate Swap
Debt Instrument [Line Items]
Notes payable, principal amount outstanding	$ 235,007	$ 237,778
Variable Rate, Subject to Interest Rate Swap | Minimum
Debt Instrument [Line Items]
Interest Rates: Range and Weighted Average	3.70%
Variable Rate, Subject to Interest Rate Swap | Maximum
Debt Instrument [Line Items]
Interest Rates: Range and Weighted Average	5.10%
Variable Rate, Subject to Interest Rate Swap | Weighted Average
Debt Instrument [Line Items]
Interest Rates: Range and Weighted Average	4.50%

Notes Payable (Schedule of Futu

Notes Payable (Schedule of Future Principal Payments Due on Debt) (Details) - Notes Payable $ in Thousands	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
2021	$ 146,026
2022	166,209
2023	2,710
2024	27,360
2025	2,195
Thereafter	108,922
Total	$ 453,422

Credit Facility (Narrative) (De

Credit Facility (Narrative) (Details)	12 Months Ended
	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Jul. 01, 2020USD ($)instrument	Jan. 01, 2020USD ($)instrument
Line of Credit Facility [Line Items]
Proceeds from credit facility	$ 140,000,000	$ 605,000,000	$ 155,000,000
Payments on credit facility	110,000,000	52,000,000	$ 20,000,000
Credit facility, principal amount outstanding	938,000,000	908,000,000
Credit facility, maximum increase	$ 1,600,000,000
Daily amount outstanding less than lenders' commitments percentage	0.50
Daily amount outstanding greater than or equal to lenders' commitments percentage	0.50
Minimum
Line of Credit Facility [Line Items]
Fee for unused portion of lenders' commitment, percentage	0.15%
Maximum
Line of Credit Facility [Line Items]
Fee for unused portion of lenders' commitment, percentage	0.25%
Credit Facility
Line of Credit Facility [Line Items]
Weighted average interest rate, variable	2.40%
Credit Facility | London Interbank Offered Rate (LIBOR) | Minimum
Line of Credit Facility [Line Items]
Margin range	1.75%
Credit Facility | London Interbank Offered Rate (LIBOR) | Maximum
Line of Credit Facility [Line Items]
Margin range	2.25%
Credit Facility | Prime Rate | Minimum
Line of Credit Facility [Line Items]
Margin range	0.75%
Credit Facility | Prime Rate | Maximum
Line of Credit Facility [Line Items]
Margin range	1.25%
Credit Facility | Interest rate swaps
Line of Credit Facility [Line Items]
Number of interest rate swap agreements | instrument				2	3
Weighted average interest rate, fixed	3.77%
Property Acquisition and Share Repurchases
Line of Credit Facility [Line Items]
Proceeds from credit facility	$ 20,000,000
Economic Uncertainty
Line of Credit Facility [Line Items]
Proceeds from credit facility	75,000,000
Property Acquisition And Internalization Transaction
Line of Credit Facility [Line Items]
Proceeds from credit facility	45,000,000
Variable Rate, Fixed Through Interest Rate Swaps
Line of Credit Facility [Line Items]
Credit facility, principal amount outstanding	400,000,000	250,000,000
Variable Rate, Fixed Through Interest Rate Swaps | Interest rate swaps
Line of Credit Facility [Line Items]
Credit facility, principal amount outstanding				$ 100,000,000	$ 150,000,000
Variable Rate Debt
Line of Credit Facility [Line Items]
Credit facility, principal amount outstanding	$ 538,000,000	$ 658,000,000

Credit Facility (Schedule of Cr

Credit Facility (Schedule of Credit Facility) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Line of Credit Facility [Line Items]
Credit facility, principal amount outstanding	$ 938,000	$ 908,000
Unamortized deferred financing costs related to the term loan credit facility	(5,900)	(7,385)
Credit facility, net of deferred financing costs of $5,900 and $7,385, respectively	932,100	900,615
Variable Rate Debt
Line of Credit Facility [Line Items]
Credit facility, principal amount outstanding	538,000	658,000
Variable Rate, Fixed Through Interest Rate Swaps
Line of Credit Facility [Line Items]
Credit facility, principal amount outstanding	400,000	250,000
Revolving Line of Credit | Variable Rate Debt
Line of Credit Facility [Line Items]
Credit facility, principal amount outstanding	138,000	108,000
Term Loan | Variable Rate Debt
Line of Credit Facility [Line Items]
Credit facility, principal amount outstanding	400,000	550,000
Term Loan | Variable Rate, Fixed Through Interest Rate Swaps
Line of Credit Facility [Line Items]
Credit facility, principal amount outstanding	$ 400,000	$ 250,000

Credit Facility (Schedule of Pr

Credit Facility (Schedule of Principal Payments Due on Credit Facility) (Details) - Credit Facility $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)extensionPeriod
Line of Credit Facility [Line Items]
2022	$ 138,000
2023	280,000
2024	520,000
Total	$ 938,000
Number of extension periods | extensionPeriod	1
Extension period	12 months

Related-Party Transactions an_3

Related-Party Transactions and Arrangements (Narrative) (Details) - employee	Sep. 30, 2020	Jul. 28, 2020	Sep. 30, 2020	Sep. 29, 2020
Related Party Transaction [Line Items]
Number of employees	76		76	0
Special limited partnership interest, shareholder annual return			8.00%
Maximum
Related Party Transaction [Line Items]
Disposition fee (% of contract sales price)			6.00%
Carter Validus Advisors II, LLC and its affiliates
Related Party Transaction [Line Items]
Acquisition fee (% of contract purchase price of each property or asset acquired)		2.00%
Acquisition fee (% of amount advanced with respect to loans and similar assets)		2.00%
Acquisition expenses reimbursed (% of purchase price of each property or real estate-related investment)	0.01%
Carter Validus Advisors II, LLC and its affiliates | Maximum
Related Party Transaction [Line Items]
Disposition fee (% of contract sales price)			1.00%
Disposition fee (% of third party brokerage commission)			50.00%
Carter Validus Advisors II, LLC
Related Party Transaction [Line Items]
Monthly asset management fee (% of aggregate asset value)			0.0625%
Carter Validus Advisors II, LLC | Maximum
Related Party Transaction [Line Items]
Operating expense reimbursement (% of average invested assets)			2.00%
Operating expense reimbursement ( % of net income)			25.00%
Carter Validus Real Estate Management Services II, LLC
Related Party Transaction [Line Items]
Property management fee (% of gross revenues from properties managed)			3.00%
Oversight fee (% of gross revenues from properties managed)			1.00%
Carter Validus Real Estate Management Services II, LLC | Maximum
Related Party Transaction [Line Items]
Construction management fee (% of project costs)			5.00%

Related-Party Transactions an_4

Related-Party Transactions and Arrangements (Schedule of Related Party Transactions) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Incurred	$ 29,141	$ 53,396	$ 25,577
Payable	0	9,759
SC Distributors, LLC | Distribution and Servicing Fees
Related Party Transaction [Line Items]
Incurred	(65)	(563)
Incurred			368
Payable	0	6,210
Carter Validus Advisors II, LLC and its affiliates | Acquisition fees and costs
Related Party Transaction [Line Items]
Incurred	97	26,072	4,272
Carter Validus Advisors II, LLC and its affiliates | Asset management fees
Related Party Transaction [Line Items]
Incurred	17,914	16,475	13,114
Payable	0	2,100
Carter Validus Advisors II, LLC and its affiliates | Operating expense reimbursement
Related Party Transaction [Line Items]
Incurred	3,966	4,492	2,692
Payable	0	518
Carter Validus Advisors II, LLC and its affiliates | Disposition fees
Related Party Transaction [Line Items]
Incurred	350	0	0
Carter Validus Advisors II, LLC and its affiliates | Loan origination fees
Related Party Transaction [Line Items]
Incurred	560	0	0
Carter Validus Real Estate Management Services II, LLC | Property management fees
Related Party Transaction [Line Items]
Incurred	5,290	5,403	4,391
Payable	0	433
Carter Validus Real Estate Management Services II, LLC | Leasing commission fees
Related Party Transaction [Line Items]
Incurred	594	1,241	497
Payable	0	299
Carter Validus Real Estate Management Services II, LLC | Construction management fees
Related Party Transaction [Line Items]
Incurred	435	276	$ 243
Payable	$ 0	$ 199

Segment Reporting (Narrative) (

Segment Reporting (Narrative) (Details)	3 Months Ended								12 Months Ended
	Dec. 31, 2020USD ($)	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2020USD ($)segment	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Segment Reporting Information [Line Items]
Number of reportable business segments | segment									2
Goodwill	$ 39,529,000				$ 0				$ 39,529,000	$ 0
Rental revenue	67,809,000	$ 70,667,000	$ 68,875,000	$ 69,185,000	$ 69,434,000	$ 48,063,000	$ 46,937,000	$ 46,467,000	276,536,000	210,901,000	$ 177,333,000
Internalization Transaction
Segment Reporting Information [Line Items]
Goodwill	$ 39,529,000	$ 39,529,000							39,529,000
Intersegment Elimination
Segment Reporting Information [Line Items]
Rental revenue									$ 0	$ 0	$ 0

Segment Reporting (Schedule of

Segment Reporting (Schedule of Information for Reportable Segments) (Details) - USD ($) $ in Thousands	Nov. 08, 2019	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Information [Line Items]
Rental revenue		$ 67,809	$ 70,667	$ 68,875	$ 69,185	$ 69,434	$ 48,063	$ 46,937	$ 46,467	$ 276,536	$ 210,901	$ 177,333
Rental expenses										(43,533)	(40,984)	(37,327)
General and administrative expenses										(16,681)	(8,421)	(5,396)
Internalization transaction expenses										(3,640)	0	0
Asset management fees										(17,914)	(16,475)	(13,114)
Depreciation and amortization										(105,483)	(74,104)	(58,258)
Impairment loss on real estate - healthcare	$ (13,000)					(8,000)				0	(21,000)	0
Gain on real estate dispositions		439	0	2,703	0	79	0	0	0	3,142	79	0
Income from operations		27,597	18,548	25,294	20,988	17,353	2,290	16,157	14,196	92,427	49,996	63,238
Interest and other expense, net		(12,849)	(13,284)	(14,199)	(15,319)	(15,566)	(11,920)	(9,893)	(9,835)	(55,651)	(47,214)	(34,365)
Net income attributable to common stockholders		$ 14,748	$ 5,264	$ 11,095	$ 5,669	$ 1,787	$ (9,630)	$ 6,264	$ 4,361	36,776	2,782	28,873
Operating Segments
Segment Reporting Information [Line Items]
Rental revenue										276,536	210,901	177,333
Rental expenses										(43,533)	(40,984)	(37,327)
Segment net operating income										233,003	169,917	140,006
Operating Segments | Data Centers
Segment Reporting Information [Line Items]
Rental revenue										110,755	109,689	103,226
Rental expenses										(28,346)	(30,270)	(27,289)
Segment net operating income										82,409	79,419	75,937
Operating Segments | Healthcare Facilities
Segment Reporting Information [Line Items]
Rental revenue										165,781	101,212	74,107
Rental expenses										(15,187)	(10,714)	(10,038)
Segment net operating income										$ 150,594	$ 90,498	$ 64,069

Segment Reporting (Schedule o_2

Segment Reporting (Schedule of Assets by Reportable Segments) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Assets by segment [Line Items]
Total assets	$ 3,205,289		$ 3,239,534
Goodwill	39,529		0
Operating Segments | Data centers
Assets by segment [Line Items]
Total assets	979,222		989,953
Goodwill		$ 15,574
Operating Segments | Healthcare
Assets by segment [Line Items]
Total assets	2,147,389		2,184,450
Goodwill		$ 23,955
All other
Assets by segment [Line Items]
Total assets	$ 78,678		$ 65,131

Segment Reporting (Schedule o_3

Segment Reporting (Schedule of Capital Additions, Acquisitions, Dispositions and Goodwill by Reportable Segments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Capital additions and acquisitions by segment [Line Items]
Capital additions by segment:	$ 28,797	$ 12,841	$ 15,583
Acquisitions by segment:	16,135	528,259	217,332
Proceeds from Dispositions by segment:	(28,542)	(2,882)	0
Net cash outflows from capital additions, acquisitions and dispositions	16,390	538,218	232,915
Goodwill allocated by segment:	39,529	0	0
Operating Segments | Data centers
Capital additions and acquisitions by segment [Line Items]
Capital additions by segment:	3,945	7,004	2,763
Acquisitions by segment:	0	0	112,181
Proceeds from Dispositions by segment:	0	0	0
Goodwill allocated by segment:	15,574	0	0
Operating Segments | Healthcare
Capital additions and acquisitions by segment [Line Items]
Capital additions by segment:	24,852	5,837	12,820
Acquisitions by segment:	16,135	528,259	105,151
Proceeds from Dispositions by segment:	(28,542)	(2,882)	0
Goodwill allocated by segment:	$ 23,955	$ 0	$ 0

Fair Value (Narrative) (Details

Fair Value (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Fair Value [Line Items]
Notes payable, principal amount outstanding	$ 453,422	$ 457,345
Credit facility, principal amount outstanding	938,000	908,000
Notes receivable, principal amount outstanding	30,700	2,700
Fixed Rate
Fair Value [Line Items]
Notes payable, principal amount outstanding	218,415	219,567
Variable Rate, Fixed Through Interest Rate Swaps
Fair Value [Line Items]
Notes payable, principal amount outstanding	235,007	237,778
Credit facility, principal amount outstanding	400,000	250,000
Variable Rate Debt
Fair Value [Line Items]
Credit facility, principal amount outstanding	538,000	658,000
Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Fixed Rate
Fair Value [Line Items]
Notes payable, fair value disclosure	229,999	222,816
Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Variable Rate, Fixed Through Interest Rate Swaps
Fair Value [Line Items]
Notes payable, fair value disclosure	234,554	237,974
Credit facility, fair value disclosure	398,563	250,472
Estimate of Fair Value Measurement | Significant Other Observable Inputs (Level 2) | Variable Rate Debt
Fair Value [Line Items]
Credit facility, fair value disclosure	$ 536,329	$ 659,691

Fair Value (Schedule of Fair Va

Fair Value (Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Assets:
Derivative assets	$ 0	$ 884
Liabilities:
Derivative liabilities	20,444	5,588
Recurring basis
Assets:
Derivative assets		884
Total assets at fair value		884
Liabilities:
Derivative liabilities	20,444	5,588
Total liabilities at fair value	20,444	5,588
Quoted Prices in Active Markets for Identical Assets (Level 1) | Recurring basis
Assets:
Derivative assets		0
Total assets at fair value		0
Liabilities:
Derivative liabilities	0	0
Total liabilities at fair value	0	0
Significant Other Observable Inputs (Level 2) | Recurring basis
Assets:
Derivative assets		884
Total assets at fair value		884
Liabilities:
Derivative liabilities	20,444	5,588
Total liabilities at fair value	20,444	5,588
Significant Unobservable Inputs (Level 3) | Recurring basis
Assets:
Derivative assets		0
Total assets at fair value		0
Liabilities:
Derivative liabilities	0	0
Total liabilities at fair value	$ 0	$ 0

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities (Narrative) (Details) $ in Thousands	Dec. 31, 2020USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Additional loss expected to be reclassified from AOCI into earnings during next twelve months	$ 9,486
Derivatives in a net liability position	$ 21,901

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities (Schedule of the Notional Amount and Fair Value of Derivative Instruments) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Derivatives, Fair Value [Line Items]
Fair Value of Asset		$ 884
Fair Value of (Liability)	$ (20,444)	(5,588)
Interest rate swaps | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Outstanding Notional Amount	635,007	637,778
Interest rate swaps | Designated as Hedging Instrument | Asset
Derivatives, Fair Value [Line Items]
Fair Value of Asset	0	884
Interest rate swaps | Designated as Hedging Instrument | (Liability)
Derivatives, Fair Value [Line Items]
Fair Value of (Liability)	$ (20,444)	$ (5,588)

Derivative Instruments and He_5

Derivative Instruments and Hedging Activities (Schedule of Income and Losses Recognized on Derivative Instruments) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Amount of (Loss) Income Recognized in Other Comprehensive (Loss) Income on Derivatives									$ (23,583)	$ (9,305)	$ 3,208
Amount of (Loss) Income Reclassified From Accumulated Other Comprehensive (Loss) Income to Net Income									(7,843)	1,602	818
Total Amount of Interest and Other Expense, Net Presented in Statements of Comprehensive Income (Loss)	$ 12,849	$ 13,284	$ 14,199	$ 15,319	$ 15,566	$ 11,920	$ 9,893	$ 9,835	55,651	47,214	34,365
Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of (Loss) Income Reclassified From Accumulated Other Comprehensive (Loss) Income to Net Income									(7,843)	1,602	818
Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Amount of (Loss) Income Recognized in Other Comprehensive (Loss) Income on Derivatives									$ (23,583)	$ (9,305)	$ 3,208

Derivative Instruments and He_6

Derivative Instruments and Hedging Activities (Schedule of Offsetting of Derivative Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Gross Amounts of Recognized Assets		$ 884
Gross Amounts Offset in the Balance Sheet		0
Net Amounts of Assets Presented in the Balance Sheet	$ 0	884
Gross Amounts Not Offset in the Balance Sheet, Financial Instruments Collateral		(5)
Gross Amounts Not Offset in the Balance Sheet, Cash Collateral		0
Net Amount		$ 879

Derivative Instruments and He_7

Derivative Instruments and Hedging Activities (Schedule of Offsetting of Derivative Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Gross Amounts of Recognized Liabilities	$ 20,444	$ 5,588
Gross Amounts Offset in the Balance Sheet	0	0
Net Amounts of Liabilities Presented in the Balance Sheet	20,444	5,588
Gross Amounts Not Offset in the Balance Sheet, Financial Instruments Collateral	0	(5)
Gross Amounts Not Offset in the Balance Sheet, Cash Collateral	0	0
Net Amount	$ 20,444	$ 5,583

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive (Loss) Income (Schedule of Amounts Recognized in Accumulated Other Comprehensive (Loss) Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, beginning	$ 1,738,419	$ 1,047,385	$ 990,551
Other comprehensive (loss) income	(15,740)	(10,907)	2,390
Balance, ending	1,653,873	1,738,419	1,047,385
Cumulative Effect, Period of Adoption, Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, beginning		0
Balance, ending			0
Unrealized Income (Loss) on Derivative Instruments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, beginning	(4,704)	6,100	3,710
Other comprehensive (loss) income before reclassification	(23,583)	(9,305)	3,208
Amount of loss (income) reclassified from accumulated other comprehensive (loss) income to net income	7,843	(1,602)	(818)
Other comprehensive (loss) income	(15,740)	(10,907)	2,390
Balance, ending	$ (20,444)	(4,704)	6,100
Unrealized Income (Loss) on Derivative Instruments | Cumulative Effect, Period of Adoption, Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, beginning		103
Balance, ending			103
Unrealized Income (Loss) on Derivative Instruments | Cumulative Effect, Period of Adoption, Adjusted Balance
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, beginning		$ 6,203
Balance, ending			$ 6,203

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive (Loss) Income (Schedule of Reclassifications Out of Accumulated Other Comprehensive (Loss) Income) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest and other expense, net	$ 12,849	$ 13,284	$ 14,199	$ 15,319	$ 15,566	$ 11,920	$ 9,893	$ 9,835	$ 55,651	$ 47,214	$ 34,365
Interest rate swap contracts | Amounts Reclassified from Accumulated Other Comprehensive Loss (Income) to Net Income | Reclassification out of Accumulated Other Comprehensive (Loss) Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest and other expense, net									$ 7,843	$ (1,602)	$ (818)

Stock-based Compensation (Narra

Stock-based Compensation (Narrative) (Details) - USD ($)	Jan. 08, 2021	Oct. 01, 2020	Jul. 01, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Mar. 06, 2020	May 06, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation				$ 437,000	$ 89,000	$ 90,000
Restricted Stock, 2021 Award | Mr Seton
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value				1,800,000
Restricted Stock, 2021 Award | Ms Neely
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value				$ 700,000
Restricted Stock, Performance-Based
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period under plan				3 years
Restricted Stock, Performance-Based | Mr Seton
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value, percentage				50.00%
Restricted Stock, Performance-Based | Ms Neely
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value, percentage				50.00%
Restricted Stock, Time-Based
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period under plan				4 years
Restricted Stock, Time-Based | Mr Seton
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value, percentage				50.00%
Restricted Stock, Time-Based | Ms Neely
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value, percentage				50.00%
Class A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of authorized and reserved shares of common stock under plan (in shares)							5,000,000	300,000
Class A | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense				$ 4,921,000	215,000
Unrecognized compensation expense, weighted average period of recognition				3 years 9 months 7 days
Fair value of nonvested shares of restricted common stock				$ 5,326,336	$ 240,038
Class A | Restricted Stock | Independent Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value		$ 7,500	$ 60,000	$ 70,000
Award vesting period under plan		1 year	3 years	1 year
Award vesting under plan, percentage per annum			33.34%
Grant date fair value (in dollars per share)		$ 8.65	$ 8.65
Class A | Restricted Stock, Time-Based | Mr Seton
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value		$ 2,000,000
Grants in period (in shares)		231,214
Class A | Restricted Stock, Time-Based | Mr Seton | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period (in shares)	103,567
Class A | Restricted Stock, Time-Based | Ms Neely
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value		$ 1,000,000
Grants in period (in shares)		115,607
Class A | Restricted Stock, Time-Based | Ms Neely | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period (in shares)	40,276
Class A | Restricted Stock, One-Time | Certain Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value (in dollars per share)		$ 8.65
Grants in period (in shares)		206,936

Stock-based Compensation (Sched

Stock-based Compensation (Schedule of Nonvested Shares of Restricted Common Stock Activity) (Details) - Class A - Restricted Stock	12 Months Ended
	Dec. 31, 2020shares
Summary of Restricted Common Stock Activity, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares)	27,750
Vested (in shares)	(10,500)
Granted (in shares)	595,677
Ending balance (in shares)	612,927

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Impact related to uncertain tax positions from the results of operations	$ 0	$ 0	$ 0
Interest expense or penalties related to unrecognized tax benefits	$ 0

Income Taxes (Schedule of Chara

Income Taxes (Schedule of Characterization of Distributions Paid to Stockholders) (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Class A
Income Taxes [Line Items]
Ordinary dividends (as a percent)	0.00%	17.93%	41.38%
Capital gain distributions (as a percent)	0.00%	0.38%	0.00%
Nontaxable distributions (as a percent)	100.00%	81.69%	58.62%
Total (as a percent)	100.00%	100.00%	100.00%
Class I
Income Taxes [Line Items]
Ordinary dividends (as a percent)	0.00%	17.93%	41.38%
Capital gain distributions (as a percent)	0.00%	0.38%	0.00%
Nontaxable distributions (as a percent)	100.00%	81.69%	58.62%
Total (as a percent)	100.00%	100.00%	100.00%
Class T
Income Taxes [Line Items]
Ordinary dividends (as a percent)	0.00%	4.79%	33.01%
Capital gain distributions (as a percent)	0.00%	0.43%	0.00%
Nontaxable distributions (as a percent)	100.00%	94.78%	66.99%
Total (as a percent)	100.00%	100.00%	100.00%
Class T2
Income Taxes [Line Items]
Ordinary dividends (as a percent)	0.00%	4.79%	33.01%
Capital gain distributions (as a percent)	0.00%	0.43%	0.00%
Nontaxable distributions (as a percent)	100.00%	94.78%	66.99%
Total (as a percent)	100.00%	100.00%	100.00%

Commitments and Contingencies (

Commitments and Contingencies (Details)	Dec. 31, 2020legalProceeding
Commitments and Contingencies Disclosure [Abstract]
Number of pending legal proceedings to which the company is a party	0

Selected Quarterly Financial _3

Selected Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Selected Quarterly Financial Information [Abstract]
Total revenue	$ 67,809	$ 70,667	$ 68,875	$ 69,185	$ 69,434	$ 48,063	$ 46,937	$ 46,467	$ 276,536	$ 210,901	$ 177,333
Total expenses	(40,651)	(52,119)	(46,284)	(48,197)	(52,160)	(45,773)	(30,780)	(32,271)	(187,251)	(160,984)	(114,095)
Gain on real estate dispositions	439	0	2,703	0	79	0	0	0	3,142	79	0
Income from operations	27,597	18,548	25,294	20,988	17,353	2,290	16,157	14,196	92,427	49,996	63,238
Interest and other expense, net	(12,849)	(13,284)	(14,199)	(15,319)	(15,566)	(11,920)	(9,893)	(9,835)	(55,651)	(47,214)	(34,365)
Net income (loss) attributable to common stockholders	$ 14,748	$ 5,264	$ 11,095	$ 5,669	$ 1,787	$ (9,630)	$ 6,264	$ 4,361	$ 36,776	$ 2,782	$ 28,873
Net income (loss) per common share attributable to common stockholders:
Basic (in dollars per share)	$ 0.07	$ 0.02	$ 0.05	$ 0.03	$ 0.01	$ (0.07)	$ 0.05	$ 0.03	$ 0.17	$ 0.02	$ 0.22
Diluted (in dollars per share)	$ 0.07	$ 0.02	$ 0.05	$ 0.03	$ 0.01	$ (0.07)	$ 0.05	$ 0.03	$ 0.17	$ 0.02	$ 0.22
Weighted average number of common shares outstanding:
Basic (in shares)	221,863,141	221,346,730	220,992,009	221,540,890	218,928,165	137,063,509	136,135,710	136,179,343	221,436,617	157,247,345	131,040,645
Diluted (in shares)	222,475,926	221,406,461	221,029,409	221,570,975	218,955,915	137,063,509	136,161,037	136,204,843	221,622,444	157,271,668	131,064,388

Subsequent Events (Distribution

Subsequent Events (Distributions) (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 18, 2021	Mar. 02, 2021	Feb. 25, 2021	Feb. 01, 2021	Jan. 25, 2021	Jan. 04, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Subsequent Event [Line Items]
Cash							$ 76,517	$ 49,494	$ 40,296
Issuance of common stock under the distribution reinvestment plan							$ 30,553	$ 39,934	$ 40,938
Distributions declared per common share (in dollars per share)							$ 0.48	$ 0.58	$ 0.63
Subsequent Event
Subsequent Event [Line Items]
Cash		$ 5,983		$ 6,612		$ 6,574
Issuance of common stock under the distribution reinvestment plan		2,293		2,541		2,543
Distributions payable		8,276		9,153		9,117
Class A | Subsequent Event
Subsequent Event [Line Items]
Cash		4,992		5,520		5,489
Issuance of common stock under the distribution reinvestment plan		1,432		1,586		1,587
Distributions payable		6,424		7,106		7,076
Distributions declared per common share (in dollars per share)	$ 0.001369863		$ 0.001369863		$ 0.001369863
Annualized distribution per share (in dollars per share)	0.50		0.50		0.50
Class I | Subsequent Event
Subsequent Event [Line Items]
Cash		298		328		325
Issuance of common stock under the distribution reinvestment plan		191		211		212
Distributions payable		489		539		537
Distributions declared per common share (in dollars per share)	0.001369863		0.001369863		0.001369863
Annualized distribution per share (in dollars per share)	0.50		0.50		0.50
Class T | Subsequent Event
Subsequent Event [Line Items]
Cash		642		708		704
Issuance of common stock under the distribution reinvestment plan		613		679		679
Distributions payable		1,255		1,387		1,383
Distributions declared per common share (in dollars per share)	0.001131781		0.001131781		0.001131781
Annualized distribution per share (in dollars per share)	0.41		0.41		0.41
Class T2 | Subsequent Event
Subsequent Event [Line Items]
Cash		51		56		56
Issuance of common stock under the distribution reinvestment plan		57		65		65
Distributions payable		$ 108		$ 121		$ 121
Distributions declared per common share (in dollars per share)	0.001131781		0.001131781		0.001131781
Annualized distribution per share (in dollars per share)	$ 0.41		$ 0.41		$ 0.41
Class A, I, T and T2 shares | Subsequent Event
Subsequent Event [Line Items]
Number of days, distribution calculation	365 days		365 days		365 days

SCHEDULE III - REAL ESTATE AS_2

SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION (SCHEDULE OF REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	$ 453,422
Initial Cost, Land	336,437
Initial Cost, Buildings and Improvements	2,468,824
Cost Capitalized Subsequent to Acquisition	85,697
Gross Amount Carried at Close of Period, Land	335,678
Gross Amount Carried at Close of Period, Buildings and Improvements	2,555,280
Gross Amount Carried at Close of Period, Total	2,890,958	$ 2,896,766	$ 1,758,326	$ 1,551,194
Accumulated Depreciation	197,134	$ 128,304	$ 84,594	$ 45,789
Houston Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	762
Initial Cost, Buildings and Improvements	2,970
Cost Capitalized Subsequent to Acquisition	106
Gross Amount Carried at Close of Period, Land	762
Gross Amount Carried at Close of Period, Buildings and Improvements	3,076
Gross Amount Carried at Close of Period, Total	3,838
Accumulated Depreciation	653
Cincinnati Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	356
Initial Cost, Buildings and Improvements	3,167
Cost Capitalized Subsequent to Acquisition	89
Gross Amount Carried at Close of Period, Land	356
Gross Amount Carried at Close of Period, Buildings and Improvements	3,256
Gross Amount Carried at Close of Period, Total	3,612
Accumulated Depreciation	604
Winston-Salem Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	684
Initial Cost, Buildings and Improvements	4,903
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	684
Gross Amount Carried at Close of Period, Buildings and Improvements	4,903
Gross Amount Carried at Close of Period, Total	5,587
Accumulated Depreciation	882
Stoughton Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	4,049
Initial Cost, Buildings and Improvements	19,991
Cost Capitalized Subsequent to Acquisition	2,342
Gross Amount Carried at Close of Period, Land	4,049
Gross Amount Carried at Close of Period, Buildings and Improvements	22,333
Gross Amount Carried at Close of Period, Total	26,382
Accumulated Depreciation	3,601
Fort Worth Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	8,297
Initial Cost, Buildings and Improvements	35,615
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	8,297
Gross Amount Carried at Close of Period, Buildings and Improvements	35,615
Gross Amount Carried at Close of Period, Total	43,912
Accumulated Depreciation	5,641
Fort Worth Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	367
Initial Cost, Buildings and Improvements	1,587
Cost Capitalized Subsequent to Acquisition	164
Gross Amount Carried at Close of Period, Land	367
Gross Amount Carried at Close of Period, Buildings and Improvements	1,751
Gross Amount Carried at Close of Period, Total	2,118
Accumulated Depreciation	481
Winter Haven Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	2,805
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	2,805
Gross Amount Carried at Close of Period, Total	2,805
Accumulated Depreciation	464
Overland Park Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,558
Initial Cost, Buildings and Improvements	20,549
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,558
Gross Amount Carried at Close of Period, Buildings and Improvements	20,549
Gross Amount Carried at Close of Period, Total	22,107
Accumulated Depreciation	3,174
Indianapolis Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	524
Initial Cost, Buildings and Improvements	6,422
Cost Capitalized Subsequent to Acquisition	37
Gross Amount Carried at Close of Period, Land	524
Gross Amount Carried at Close of Period, Buildings and Improvements	6,459
Gross Amount Carried at Close of Period, Total	6,983
Accumulated Depreciation	961
Clarion Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	462
Initial Cost, Buildings and Improvements	5,377
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	462
Gross Amount Carried at Close of Period, Buildings and Improvements	5,377
Gross Amount Carried at Close of Period, Total	5,839
Accumulated Depreciation	1,008
Webster Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,858
Initial Cost, Buildings and Improvements	20,140
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,858
Gross Amount Carried at Close of Period, Buildings and Improvements	20,140
Gross Amount Carried at Close of Period, Total	21,998
Accumulated Depreciation	2,927
Eagan Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	768
Initial Cost, Buildings and Improvements	5,037
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	768
Gross Amount Carried at Close of Period, Buildings and Improvements	5,037
Gross Amount Carried at Close of Period, Total	5,805
Accumulated Depreciation	861
Houston Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	8,329
Initial Cost, Buildings and Improvements	36,297
Cost Capitalized Subsequent to Acquisition	(17,360)
Gross Amount Carried at Close of Period, Land	8,329
Gross Amount Carried at Close of Period, Buildings and Improvements	18,937
Gross Amount Carried at Close of Period, Total	27,266
Accumulated Depreciation	753
Augusta Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	556
Initial Cost, Buildings and Improvements	14,401
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	556
Gross Amount Carried at Close of Period, Buildings and Improvements	14,401
Gross Amount Carried at Close of Period, Total	14,957
Accumulated Depreciation	2,224
Cincinnati Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,812
Initial Cost, Buildings and Improvements	24,382
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,812
Gross Amount Carried at Close of Period, Buildings and Improvements	24,382
Gross Amount Carried at Close of Period, Total	26,194
Accumulated Depreciation	3,881
Cincinnati Healthcare Facility III
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	446
Initial Cost, Buildings and Improvements	10,239
Cost Capitalized Subsequent to Acquisition	4
Gross Amount Carried at Close of Period, Land	446
Gross Amount Carried at Close of Period, Buildings and Improvements	10,243
Gross Amount Carried at Close of Period, Total	10,689
Accumulated Depreciation	1,487
Florence Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	650
Initial Cost, Buildings and Improvements	9,919
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	650
Gross Amount Carried at Close of Period, Buildings and Improvements	9,919
Gross Amount Carried at Close of Period, Total	10,569
Accumulated Depreciation	1,434
Oakland Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	229
Initial Cost, Buildings and Improvements	5,416
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	229
Gross Amount Carried at Close of Period, Buildings and Improvements	5,416
Gross Amount Carried at Close of Period, Total	5,645
Accumulated Depreciation	904
Wyomissing Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,504
Initial Cost, Buildings and Improvements	20,193
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,504
Gross Amount Carried at Close of Period, Buildings and Improvements	20,193
Gross Amount Carried at Close of Period, Total	21,697
Accumulated Depreciation	2,978
Luling Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	824
Initial Cost, Buildings and Improvements	7,530
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	824
Gross Amount Carried at Close of Period, Buildings and Improvements	7,530
Gross Amount Carried at Close of Period, Total	8,354
Accumulated Depreciation	1,104
Minnetonka Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,085
Initial Cost, Buildings and Improvements	15,099
Cost Capitalized Subsequent to Acquisition	119
Gross Amount Carried at Close of Period, Land	1,999
Gross Amount Carried at Close of Period, Buildings and Improvements	15,304
Gross Amount Carried at Close of Period, Total	17,303
Accumulated Depreciation	2,862
Omaha Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,259
Initial Cost, Buildings and Improvements	9,796
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,259
Gross Amount Carried at Close of Period, Buildings and Improvements	9,796
Gross Amount Carried at Close of Period, Total	11,055
Accumulated Depreciation	1,341
Sherman Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,679
Initial Cost, Buildings and Improvements	23,926
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,679
Gross Amount Carried at Close of Period, Buildings and Improvements	23,926
Gross Amount Carried at Close of Period, Total	25,605
Accumulated Depreciation	3,186
Sherman Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	214
Initial Cost, Buildings and Improvements	3,209
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	214
Gross Amount Carried at Close of Period, Buildings and Improvements	3,209
Gross Amount Carried at Close of Period, Total	3,423
Accumulated Depreciation	431
Fort Worth Healthcare Facility III
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	3,120
Initial Cost, Buildings and Improvements	9,312
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	3,120
Gross Amount Carried at Close of Period, Buildings and Improvements	9,312
Gross Amount Carried at Close of Period, Total	12,432
Accumulated Depreciation	1,235
Oklahoma City Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	21,760
Initial Cost, Land	4,626
Initial Cost, Buildings and Improvements	30,509
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	4,626
Gross Amount Carried at Close of Period, Buildings and Improvements	30,509
Gross Amount Carried at Close of Period, Total	35,135
Accumulated Depreciation	4,177
Oklahoma City Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	991
Initial Cost, Buildings and Improvements	8,366
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	991
Gross Amount Carried at Close of Period, Buildings and Improvements	8,366
Gross Amount Carried at Close of Period, Total	9,357
Accumulated Depreciation	1,218
Waco Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	873
Initial Cost, Buildings and Improvements	8,233
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	873
Gross Amount Carried at Close of Period, Buildings and Improvements	8,233
Gross Amount Carried at Close of Period, Total	9,106
Accumulated Depreciation	1,050
Edmond Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	796
Initial Cost, Buildings and Improvements	3,199
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	796
Gross Amount Carried at Close of Period, Buildings and Improvements	3,199
Gross Amount Carried at Close of Period, Total	3,995
Accumulated Depreciation	467
Oklahoma City Healthcare Facility III
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	452
Initial Cost, Buildings and Improvements	1,081
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	452
Gross Amount Carried at Close of Period, Buildings and Improvements	1,081
Gross Amount Carried at Close of Period, Total	1,533
Accumulated Depreciation	162
Oklahoma City Healthcare Facility IV
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	368
Initial Cost, Buildings and Improvements	2,344
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	368
Gross Amount Carried at Close of Period, Buildings and Improvements	2,344
Gross Amount Carried at Close of Period, Total	2,712
Accumulated Depreciation	342
Alpharetta Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	3,395
Initial Cost, Buildings and Improvements	11,081
Cost Capitalized Subsequent to Acquisition	25
Gross Amount Carried at Close of Period, Land	3,395
Gross Amount Carried at Close of Period, Buildings and Improvements	11,106
Gross Amount Carried at Close of Period, Total	14,501
Accumulated Depreciation	1,488
Flint Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	111
Initial Cost, Buildings and Improvements	7,001
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	111
Gross Amount Carried at Close of Period, Buildings and Improvements	7,001
Gross Amount Carried at Close of Period, Total	7,112
Accumulated Depreciation	925
Newcastle Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	412
Initial Cost, Buildings and Improvements	1,173
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	412
Gross Amount Carried at Close of Period, Buildings and Improvements	1,173
Gross Amount Carried at Close of Period, Total	1,585
Accumulated Depreciation	174
Oklahoma City Healthcare Facility V
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	541
Initial Cost, Buildings and Improvements	12,445
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	541
Gross Amount Carried at Close of Period, Buildings and Improvements	12,445
Gross Amount Carried at Close of Period, Total	12,986
Accumulated Depreciation	1,790
Rancho Mirage Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,724
Initial Cost, Buildings and Improvements	7,626
Cost Capitalized Subsequent to Acquisition	29,844
Gross Amount Carried at Close of Period, Land	2,726
Gross Amount Carried at Close of Period, Buildings and Improvements	37,468
Gross Amount Carried at Close of Period, Total	40,194
Accumulated Depreciation	2,224
Oklahoma City Healthcare Facility VI
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	896
Initial Cost, Buildings and Improvements	3,684
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	896
Gross Amount Carried at Close of Period, Buildings and Improvements	3,684
Gross Amount Carried at Close of Period, Total	4,580
Accumulated Depreciation	536
Franklin Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	6,624
Initial Cost, Buildings and Improvements	10,971
Cost Capitalized Subsequent to Acquisition	135
Gross Amount Carried at Close of Period, Land	6,624
Gross Amount Carried at Close of Period, Buildings and Improvements	11,106
Gross Amount Carried at Close of Period, Total	17,730
Accumulated Depreciation	1,439
Oklahoma City Healthcare Facility VII
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	23,988
Initial Cost, Land	3,203
Initial Cost, Buildings and Improvements	32,380
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	3,203
Gross Amount Carried at Close of Period, Buildings and Improvements	32,380
Gross Amount Carried at Close of Period, Total	35,583
Accumulated Depreciation	3,859
Las Vegas Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,614
Initial Cost, Buildings and Improvements	639
Cost Capitalized Subsequent to Acquisition	22,091
Gross Amount Carried at Close of Period, Land	2,895
Gross Amount Carried at Close of Period, Buildings and Improvements	22,449
Gross Amount Carried at Close of Period, Total	25,344
Accumulated Depreciation	1,801
Somerset Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	906
Initial Cost, Buildings and Improvements	10,466
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	906
Gross Amount Carried at Close of Period, Buildings and Improvements	10,466
Gross Amount Carried at Close of Period, Total	11,372
Accumulated Depreciation	1,373
Oklahoma City Healthcare Facility VIII
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,002
Initial Cost, Buildings and Improvements	15,384
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	2,002
Gross Amount Carried at Close of Period, Buildings and Improvements	15,384
Gross Amount Carried at Close of Period, Total	17,386
Accumulated Depreciation	1,809
Hawthorne Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	39,749
Initial Cost, Land	16,498
Initial Cost, Buildings and Improvements	57,312
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	16,498
Gross Amount Carried at Close of Period, Buildings and Improvements	57,312
Gross Amount Carried at Close of Period, Total	73,810
Accumulated Depreciation	6,254
McLean Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	23,460
Initial Cost, Land	31,554
Initial Cost, Buildings and Improvements	4,930
Cost Capitalized Subsequent to Acquisition	330
Gross Amount Carried at Close of Period, Land	31,554
Gross Amount Carried at Close of Period, Buildings and Improvements	5,260
Gross Amount Carried at Close of Period, Total	36,814
Accumulated Depreciation	616
McLean Data Center II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	27,540
Initial Cost, Land	20,392
Initial Cost, Buildings and Improvements	22,727
Cost Capitalized Subsequent to Acquisition	105
Gross Amount Carried at Close of Period, Land	20,392
Gross Amount Carried at Close of Period, Buildings and Improvements	22,832
Gross Amount Carried at Close of Period, Total	43,224
Accumulated Depreciation	2,473
Marlton Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	30,471
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	57,154
Cost Capitalized Subsequent to Acquisition	5
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	57,159
Gross Amount Carried at Close of Period, Total	57,159
Accumulated Depreciation	5,896
Andover Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	6,566
Initial Cost, Buildings and Improvements	28,072
Cost Capitalized Subsequent to Acquisition	514
Gross Amount Carried at Close of Period, Land	6,566
Gross Amount Carried at Close of Period, Buildings and Improvements	28,586
Gross Amount Carried at Close of Period, Total	35,152
Accumulated Depreciation	3,299
Grand Rapids Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	21,381
Initial Cost, Land	2,533
Initial Cost, Buildings and Improvements	39,487
Cost Capitalized Subsequent to Acquisition	95
Gross Amount Carried at Close of Period, Land	2,533
Gross Amount Carried at Close of Period, Buildings and Improvements	39,582
Gross Amount Carried at Close of Period, Total	42,115
Accumulated Depreciation	4,940
Corpus Christi Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	975
Initial Cost, Buildings and Improvements	4,963
Cost Capitalized Subsequent to Acquisition	698
Gross Amount Carried at Close of Period, Land	1,002
Gross Amount Carried at Close of Period, Buildings and Improvements	5,634
Gross Amount Carried at Close of Period, Total	6,636
Accumulated Depreciation	621
Chicago Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,329
Initial Cost, Buildings and Improvements	29,940
Cost Capitalized Subsequent to Acquisition	(545)
Gross Amount Carried at Close of Period, Land	1,358
Gross Amount Carried at Close of Period, Buildings and Improvements	29,366
Gross Amount Carried at Close of Period, Total	30,724
Accumulated Depreciation	3,024
Blythewood Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	612
Initial Cost, Buildings and Improvements	17,714
Cost Capitalized Subsequent to Acquisition	27
Gross Amount Carried at Close of Period, Land	634
Gross Amount Carried at Close of Period, Buildings and Improvements	17,719
Gross Amount Carried at Close of Period, Total	18,353
Accumulated Depreciation	1,842
Tempe Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,997
Initial Cost, Buildings and Improvements	11,991
Cost Capitalized Subsequent to Acquisition	132
Gross Amount Carried at Close of Period, Land	2,997
Gross Amount Carried at Close of Period, Buildings and Improvements	12,123
Gross Amount Carried at Close of Period, Total	15,120
Accumulated Depreciation	1,262
Aurora Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	973
Initial Cost, Buildings and Improvements	9,632
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	973
Gross Amount Carried at Close of Period, Buildings and Improvements	9,632
Gross Amount Carried at Close of Period, Total	10,605
Accumulated Depreciation	986
Norwalk Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	33,400
Initial Cost, Land	10,125
Initial Cost, Buildings and Improvements	43,360
Cost Capitalized Subsequent to Acquisition	94
Gross Amount Carried at Close of Period, Land	10,125
Gross Amount Carried at Close of Period, Buildings and Improvements	43,454
Gross Amount Carried at Close of Period, Total	53,579
Accumulated Depreciation	4,207
Allen Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	12,974
Initial Cost, Land	857
Initial Cost, Buildings and Improvements	20,582
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	857
Gross Amount Carried at Close of Period, Buildings and Improvements	20,582
Gross Amount Carried at Close of Period, Total	21,439
Accumulated Depreciation	2,101
Austin Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	20,603
Initial Cost, Land	1,368
Initial Cost, Buildings and Improvements	32,039
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,368
Gross Amount Carried at Close of Period, Buildings and Improvements	32,039
Gross Amount Carried at Close of Period, Total	33,407
Accumulated Depreciation	3,270
Beaumont Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	5,791
Initial Cost, Land	946
Initial Cost, Buildings and Improvements	8,372
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	946
Gross Amount Carried at Close of Period, Buildings and Improvements	8,372
Gross Amount Carried at Close of Period, Total	9,318
Accumulated Depreciation	859
Charlotte Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	372
Initial Cost, Buildings and Improvements	17,131
Cost Capitalized Subsequent to Acquisition	3,382
Gross Amount Carried at Close of Period, Land	372
Gross Amount Carried at Close of Period, Buildings and Improvements	20,513
Gross Amount Carried at Close of Period, Total	20,885
Accumulated Depreciation	2,096
Atlanta Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	116,200
Initial Cost, Land	19,159
Initial Cost, Buildings and Improvements	129,778
Cost Capitalized Subsequent to Acquisition	8,435
Gross Amount Carried at Close of Period, Land	19,159
Gross Amount Carried at Close of Period, Buildings and Improvements	138,213
Gross Amount Carried at Close of Period, Total	157,372
Accumulated Depreciation	17,357
Sunnyvale Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	10,013
Initial Cost, Buildings and Improvements	24,709
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	10,013
Gross Amount Carried at Close of Period, Buildings and Improvements	24,709
Gross Amount Carried at Close of Period, Total	34,722
Accumulated Depreciation	2,252
San Antonio Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	10,360
Initial Cost, Land	1,813
Initial Cost, Buildings and Improvements	11,706
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,813
Gross Amount Carried at Close of Period, Buildings and Improvements	11,706
Gross Amount Carried at Close of Period, Total	13,519
Accumulated Depreciation	1,124
Cincinnati Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,556
Initial Cost, Buildings and Improvements	8,966
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,556
Gross Amount Carried at Close of Period, Buildings and Improvements	8,966
Gross Amount Carried at Close of Period, Total	10,522
Accumulated Depreciation	887
Silverdale Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,530
Initial Cost, Buildings and Improvements	7,506
Cost Capitalized Subsequent to Acquisition	15
Gross Amount Carried at Close of Period, Land	1,530
Gross Amount Carried at Close of Period, Buildings and Improvements	7,521
Gross Amount Carried at Close of Period, Total	9,051
Accumulated Depreciation	776
Silverdale Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,542
Initial Cost, Buildings and Improvements	4,981
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,542
Gross Amount Carried at Close of Period, Buildings and Improvements	4,981
Gross Amount Carried at Close of Period, Total	6,523
Accumulated Depreciation	550
King of Prussia Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	11,671
Initial Cost, Land	1,015
Initial Cost, Buildings and Improvements	17,413
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,015
Gross Amount Carried at Close of Period, Buildings and Improvements	17,413
Gross Amount Carried at Close of Period, Total	18,428
Accumulated Depreciation	1,482
Tempe Data Center II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	15,803
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	15,803
Gross Amount Carried at Close of Period, Total	15,803
Accumulated Depreciation	1,361
Houston Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	48,607
Initial Cost, Land	10,082
Initial Cost, Buildings and Improvements	101,051
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	10,082
Gross Amount Carried at Close of Period, Buildings and Improvements	101,051
Gross Amount Carried at Close of Period, Total	111,133
Accumulated Depreciation	8,011
Saginaw Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,251
Initial Cost, Buildings and Improvements	15,878
Cost Capitalized Subsequent to Acquisition	235
Gross Amount Carried at Close of Period, Land	1,251
Gross Amount Carried at Close of Period, Buildings and Improvements	16,113
Gross Amount Carried at Close of Period, Total	17,364
Accumulated Depreciation	1,747
Elgin Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	5,467
Initial Cost, Land	1,067
Initial Cost, Buildings and Improvements	7,861
Cost Capitalized Subsequent to Acquisition	(421)
Gross Amount Carried at Close of Period, Land	1,067
Gross Amount Carried at Close of Period, Buildings and Improvements	7,440
Gross Amount Carried at Close of Period, Total	8,507
Accumulated Depreciation	602
Oklahoma City Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,868
Initial Cost, Buildings and Improvements	44,253
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,868
Gross Amount Carried at Close of Period, Buildings and Improvements	44,253
Gross Amount Carried at Close of Period, Total	46,121
Accumulated Depreciation	3,460
Rancho Cordova Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,760
Initial Cost, Buildings and Improvements	32,109
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,760
Gross Amount Carried at Close of Period, Buildings and Improvements	32,109
Gross Amount Carried at Close of Period, Total	33,869
Accumulated Depreciation	2,282
Rancho Cordova Data Center II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,943
Initial Cost, Buildings and Improvements	10,340
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,943
Gross Amount Carried at Close of Period, Buildings and Improvements	10,340
Gross Amount Carried at Close of Period, Total	12,283
Accumulated Depreciation	750
Carrollton Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,995
Initial Cost, Buildings and Improvements	5,870
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,995
Gross Amount Carried at Close of Period, Buildings and Improvements	5,870
Gross Amount Carried at Close of Period, Total	7,865
Accumulated Depreciation	441
Katy Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,443
Initial Cost, Buildings and Improvements	12,114
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,443
Gross Amount Carried at Close of Period, Buildings and Improvements	12,114
Gross Amount Carried at Close of Period, Total	13,557
Accumulated Depreciation	799
San Jose Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	12,205
Initial Cost, Buildings and Improvements	34,309
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	12,205
Gross Amount Carried at Close of Period, Buildings and Improvements	34,309
Gross Amount Carried at Close of Period, Total	46,514
Accumulated Depreciation	2,240
Indianola Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	330
Initial Cost, Buildings and Improvements	5,698
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	330
Gross Amount Carried at Close of Period, Buildings and Improvements	5,698
Gross Amount Carried at Close of Period, Total	6,028
Accumulated Depreciation	357
Indianola Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	709
Initial Cost, Buildings and Improvements	6,061
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	709
Gross Amount Carried at Close of Period, Buildings and Improvements	6,061
Gross Amount Carried at Close of Period, Total	6,770
Accumulated Depreciation	392
Canton Data Center
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	345
Initial Cost, Buildings and Improvements	8,268
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	345
Gross Amount Carried at Close of Period, Buildings and Improvements	8,268
Gross Amount Carried at Close of Period, Total	8,613
Accumulated Depreciation	473
Benton Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	19,048
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	19,048
Gross Amount Carried at Close of Period, Total	19,048
Accumulated Depreciation	1,142
Benton Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	1,647
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	1,647
Gross Amount Carried at Close of Period, Total	1,647
Accumulated Depreciation	110
Bryant Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	930
Initial Cost, Buildings and Improvements	3,539
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	930
Gross Amount Carried at Close of Period, Buildings and Improvements	3,539
Gross Amount Carried at Close of Period, Total	4,469
Accumulated Depreciation	234
Hot Springs Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	384
Initial Cost, Buildings and Improvements	2,077
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	384
Gross Amount Carried at Close of Period, Buildings and Improvements	2,077
Gross Amount Carried at Close of Period, Total	2,461
Accumulated Depreciation	142
Clive Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	336
Initial Cost, Buildings and Improvements	22,332
Cost Capitalized Subsequent to Acquisition	61
Gross Amount Carried at Close of Period, Land	336
Gross Amount Carried at Close of Period, Buildings and Improvements	22,393
Gross Amount Carried at Close of Period, Total	22,729
Accumulated Depreciation	1,490
Valdosta Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	659
Initial Cost, Buildings and Improvements	5,626
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	659
Gross Amount Carried at Close of Period, Buildings and Improvements	5,626
Gross Amount Carried at Close of Period, Total	6,285
Accumulated Depreciation	376
Valdosta Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	471
Initial Cost, Buildings and Improvements	2,780
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	471
Gross Amount Carried at Close of Period, Buildings and Improvements	2,780
Gross Amount Carried at Close of Period, Total	3,251
Accumulated Depreciation	189
Bryant Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	647
Initial Cost, Buildings and Improvements	3,364
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	647
Gross Amount Carried at Close of Period, Buildings and Improvements	3,364
Gross Amount Carried at Close of Period, Total	4,011
Accumulated Depreciation	132
Laredo Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	12,137
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	12,137
Gross Amount Carried at Close of Period, Total	12,137
Accumulated Depreciation	425
Laredo Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	23,677
Cost Capitalized Subsequent to Acquisition	83
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	23,760
Gross Amount Carried at Close of Period, Total	23,760
Accumulated Depreciation	838
Poplar Bluff Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	13,515
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	13,515
Gross Amount Carried at Close of Period, Total	13,515
Accumulated Depreciation	475
Tucson Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	5,998
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	5,998
Gross Amount Carried at Close of Period, Total	5,998
Accumulated Depreciation	212
Akron Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	3,503
Initial Cost, Buildings and Improvements	38,512
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	3,503
Gross Amount Carried at Close of Period, Buildings and Improvements	38,512
Gross Amount Carried at Close of Period, Total	42,015
Accumulated Depreciation	1,240
Akron Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,085
Initial Cost, Buildings and Improvements	10,277
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,085
Gross Amount Carried at Close of Period, Buildings and Improvements	10,277
Gross Amount Carried at Close of Period, Total	11,362
Accumulated Depreciation	398
Akron Healthcare Facility III
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,206
Initial Cost, Buildings and Improvements	26,044
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	2,206
Gross Amount Carried at Close of Period, Buildings and Improvements	26,044
Gross Amount Carried at Close of Period, Total	28,250
Accumulated Depreciation	811
Alexandria Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	5,076
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	5,076
Gross Amount Carried at Close of Period, Total	5,076
Accumulated Depreciation	158
Appleton Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	414
Initial Cost, Buildings and Improvements	1,900
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	414
Gross Amount Carried at Close of Period, Buildings and Improvements	1,900
Gross Amount Carried at Close of Period, Total	2,314
Accumulated Depreciation	79
Austin Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	3,229
Initial Cost, Buildings and Improvements	7,534
Cost Capitalized Subsequent to Acquisition	(2,807)
Gross Amount Carried at Close of Period, Land	2,195
Gross Amount Carried at Close of Period, Buildings and Improvements	5,761
Gross Amount Carried at Close of Period, Total	7,956
Accumulated Depreciation	184
Bellevue Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	567
Initial Cost, Buildings and Improvements	1,269
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	567
Gross Amount Carried at Close of Period, Buildings and Improvements	1,269
Gross Amount Carried at Close of Period, Total	1,836
Accumulated Depreciation	55
Bonita Springs Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,199
Initial Cost, Buildings and Improvements	4,373
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,199
Gross Amount Carried at Close of Period, Buildings and Improvements	4,373
Gross Amount Carried at Close of Period, Total	5,572
Accumulated Depreciation	140
Bridgeton Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	39,740
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	39,740
Gross Amount Carried at Close of Period, Total	39,740
Accumulated Depreciation	1,232
Covington Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,238
Initial Cost, Buildings and Improvements	16,635
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	2,238
Gross Amount Carried at Close of Period, Buildings and Improvements	16,635
Gross Amount Carried at Close of Period, Total	18,873
Accumulated Depreciation	513
Crestview Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	400
Initial Cost, Buildings and Improvements	1,536
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	400
Gross Amount Carried at Close of Period, Buildings and Improvements	1,536
Gross Amount Carried at Close of Period, Total	1,936
Accumulated Depreciation	55
Dallas Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	6,072
Initial Cost, Buildings and Improvements	27,457
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	6,072
Gross Amount Carried at Close of Period, Buildings and Improvements	27,457
Gross Amount Carried at Close of Period, Total	33,529
Accumulated Depreciation	833
De Pere Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	615
Initial Cost, Buildings and Improvements	1,596
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	615
Gross Amount Carried at Close of Period, Buildings and Improvements	1,596
Gross Amount Carried at Close of Period, Total	2,211
Accumulated Depreciation	66
Denver Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	3,586
Initial Cost, Buildings and Improvements	32,363
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	3,586
Gross Amount Carried at Close of Period, Buildings and Improvements	32,363
Gross Amount Carried at Close of Period, Total	35,949
Accumulated Depreciation	1,012
El Segundo Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,659
Initial Cost, Buildings and Improvements	9,016
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	2,659
Gross Amount Carried at Close of Period, Buildings and Improvements	9,016
Gross Amount Carried at Close of Period, Total	11,675
Accumulated Depreciation	282
Fairlea Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	139
Initial Cost, Buildings and Improvements	1,910
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	139
Gross Amount Carried at Close of Period, Buildings and Improvements	1,910
Gross Amount Carried at Close of Period, Total	2,049
Accumulated Depreciation	63
Fayetteville Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	485
Initial Cost, Buildings and Improvements	24,855
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	485
Gross Amount Carried at Close of Period, Buildings and Improvements	24,855
Gross Amount Carried at Close of Period, Total	25,340
Accumulated Depreciation	766
Fort Myers Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,153
Initial Cost, Buildings and Improvements	2,387
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	2,153
Gross Amount Carried at Close of Period, Buildings and Improvements	2,387
Gross Amount Carried at Close of Period, Total	4,540
Accumulated Depreciation	93
Fort Myers Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	3,557
Initial Cost, Buildings and Improvements	11,064
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	3,557
Gross Amount Carried at Close of Period, Buildings and Improvements	11,064
Gross Amount Carried at Close of Period, Total	14,621
Accumulated Depreciation	400
Fort Walton Beach Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	385
Initial Cost, Buildings and Improvements	3,182
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	385
Gross Amount Carried at Close of Period, Buildings and Improvements	3,182
Gross Amount Carried at Close of Period, Total	3,567
Accumulated Depreciation	104
Frankfort Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	342
Initial Cost, Buildings and Improvements	950
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	342
Gross Amount Carried at Close of Period, Buildings and Improvements	950
Gross Amount Carried at Close of Period, Total	1,292
Accumulated Depreciation	35
Frisco Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	22,114
Cost Capitalized Subsequent to Acquisition	4,653
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	26,767
Gross Amount Carried at Close of Period, Total	26,767
Accumulated Depreciation	1,009
Goshen Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	383
Initial Cost, Buildings and Improvements	5,355
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	383
Gross Amount Carried at Close of Period, Buildings and Improvements	5,355
Gross Amount Carried at Close of Period, Total	5,738
Accumulated Depreciation	182
Grapevine Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,726
Initial Cost, Buildings and Improvements	26,849
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,726
Gross Amount Carried at Close of Period, Buildings and Improvements	26,849
Gross Amount Carried at Close of Period, Total	28,575
Accumulated Depreciation	834
Hammond Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,693
Initial Cost, Buildings and Improvements	23,750
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	2,693
Gross Amount Carried at Close of Period, Buildings and Improvements	23,750
Gross Amount Carried at Close of Period, Total	26,443
Accumulated Depreciation	760
Hammond Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	950
Initial Cost, Buildings and Improvements	12,147
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	950
Gross Amount Carried at Close of Period, Buildings and Improvements	12,147
Gross Amount Carried at Close of Period, Total	13,097
Accumulated Depreciation	384
Harlingen Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	10,628
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	10,628
Gross Amount Carried at Close of Period, Total	10,628
Accumulated Depreciation	354
Henderson Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	839
Initial Cost, Buildings and Improvements	2,390
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	839
Gross Amount Carried at Close of Period, Buildings and Improvements	2,390
Gross Amount Carried at Close of Period, Total	3,229
Accumulated Depreciation	82
Houston Healthcare Facility III
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	752
Initial Cost, Buildings and Improvements	5,832
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	752
Gross Amount Carried at Close of Period, Buildings and Improvements	5,832
Gross Amount Carried at Close of Period, Total	6,584
Accumulated Depreciation	181
Howard Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	529
Initial Cost, Buildings and Improvements	1,818
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	529
Gross Amount Carried at Close of Period, Buildings and Improvements	1,818
Gross Amount Carried at Close of Period, Total	2,347
Accumulated Depreciation	76
Jacksonville Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,233
Initial Cost, Buildings and Improvements	6,173
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,233
Gross Amount Carried at Close of Period, Buildings and Improvements	6,173
Gross Amount Carried at Close of Period, Total	7,406
Accumulated Depreciation	203
Lafayette Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	4,819
Initial Cost, Buildings and Improvements	35,424
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	4,819
Gross Amount Carried at Close of Period, Buildings and Improvements	35,424
Gross Amount Carried at Close of Period, Total	40,243
Accumulated Depreciation	1,110
Lakewood Ranch Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	636
Initial Cost, Buildings and Improvements	1,784
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	636
Gross Amount Carried at Close of Period, Buildings and Improvements	1,784
Gross Amount Carried at Close of Period, Total	2,420
Accumulated Depreciation	74
Las Vegas Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	651
Initial Cost, Buildings and Improvements	5,323
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	651
Gross Amount Carried at Close of Period, Buildings and Improvements	5,323
Gross Amount Carried at Close of Period, Total	5,974
Accumulated Depreciation	173
Lehigh Acres Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	441
Initial Cost, Buildings and Improvements	2,956
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	441
Gross Amount Carried at Close of Period, Buildings and Improvements	2,956
Gross Amount Carried at Close of Period, Total	3,397
Accumulated Depreciation	101
Lubbock Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	5,210
Initial Cost, Buildings and Improvements	39,939
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	5,210
Gross Amount Carried at Close of Period, Buildings and Improvements	39,939
Gross Amount Carried at Close of Period, Total	45,149
Accumulated Depreciation	1,229
Manitowoc Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	257
Initial Cost, Buildings and Improvements	1,733
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	257
Gross Amount Carried at Close of Period, Buildings and Improvements	1,733
Gross Amount Carried at Close of Period, Total	1,990
Accumulated Depreciation	69
Manitowoc Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	250
Initial Cost, Buildings and Improvements	11,231
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	250
Gross Amount Carried at Close of Period, Buildings and Improvements	11,231
Gross Amount Carried at Close of Period, Total	11,481
Accumulated Depreciation	381
Marinette Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	208
Initial Cost, Buildings and Improvements	1,002
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	208
Gross Amount Carried at Close of Period, Buildings and Improvements	1,002
Gross Amount Carried at Close of Period, Total	1,210
Accumulated Depreciation	41
New Bedford Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,464
Initial Cost, Buildings and Improvements	26,297
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	2,464
Gross Amount Carried at Close of Period, Buildings and Improvements	26,297
Gross Amount Carried at Close of Period, Total	28,761
Accumulated Depreciation	827
New Braunfels Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,568
Initial Cost, Buildings and Improvements	11,386
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	2,568
Gross Amount Carried at Close of Period, Buildings and Improvements	11,386
Gross Amount Carried at Close of Period, Total	13,954
Accumulated Depreciation	356
North Smithfield Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,309
Initial Cost, Buildings and Improvements	14,024
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,309
Gross Amount Carried at Close of Period, Buildings and Improvements	14,024
Gross Amount Carried at Close of Period, Total	15,333
Accumulated Depreciation	463
Oklahoma City Healthcare Facility IX
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,316
Initial Cost, Buildings and Improvements	9,822
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,316
Gross Amount Carried at Close of Period, Buildings and Improvements	9,822
Gross Amount Carried at Close of Period, Total	11,138
Accumulated Depreciation	350
Oshkosh Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	414
Initial Cost, Buildings and Improvements	2,043
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	414
Gross Amount Carried at Close of Period, Buildings and Improvements	2,043
Gross Amount Carried at Close of Period, Total	2,457
Accumulated Depreciation	79
Palm Desert Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	582
Initial Cost, Buildings and Improvements	5,927
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	582
Gross Amount Carried at Close of Period, Buildings and Improvements	5,927
Gross Amount Carried at Close of Period, Total	6,509
Accumulated Depreciation	206
Rancho Mirage Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,286
Initial Cost, Buildings and Improvements	5,481
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	2,286
Gross Amount Carried at Close of Period, Buildings and Improvements	5,481
Gross Amount Carried at Close of Period, Total	7,767
Accumulated Depreciation	187
San Antonio Healthcare Facility III
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,824
Initial Cost, Buildings and Improvements	22,809
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,824
Gross Amount Carried at Close of Period, Buildings and Improvements	22,809
Gross Amount Carried at Close of Period, Total	24,633
Accumulated Depreciation	698
San Antonio Healthcare Facility IV
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	31,694
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	31,694
Gross Amount Carried at Close of Period, Total	31,694
Accumulated Depreciation	970
San Antonio Healthcare Facility V
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	3,273
Initial Cost, Buildings and Improvements	19,697
Cost Capitalized Subsequent to Acquisition	903
Gross Amount Carried at Close of Period, Land	3,273
Gross Amount Carried at Close of Period, Buildings and Improvements	20,600
Gross Amount Carried at Close of Period, Total	23,873
Accumulated Depreciation	636
Santa Rosa Beach Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	741
Initial Cost, Buildings and Improvements	3,049
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	741
Gross Amount Carried at Close of Period, Buildings and Improvements	3,049
Gross Amount Carried at Close of Period, Total	3,790
Accumulated Depreciation	94
Savannah Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	2,300
Initial Cost, Buildings and Improvements	20,186
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	2,300
Gross Amount Carried at Close of Period, Buildings and Improvements	20,186
Gross Amount Carried at Close of Period, Total	22,486
Accumulated Depreciation	622
St. Louis Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,164
Initial Cost, Buildings and Improvements	8,052
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	1,164
Gross Amount Carried at Close of Period, Buildings and Improvements	8,052
Gross Amount Carried at Close of Period, Total	9,216
Accumulated Depreciation	258
Sturgeon Bay Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	248
Initial Cost, Buildings and Improvements	700
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	248
Gross Amount Carried at Close of Period, Buildings and Improvements	700
Gross Amount Carried at Close of Period, Total	948
Accumulated Depreciation	32
Victoria Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	328
Initial Cost, Buildings and Improvements	12,908
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	328
Gross Amount Carried at Close of Period, Buildings and Improvements	12,908
Gross Amount Carried at Close of Period, Total	13,236
Accumulated Depreciation	406
Victoria Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	446
Initial Cost, Buildings and Improvements	12,986
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	446
Gross Amount Carried at Close of Period, Buildings and Improvements	12,986
Gross Amount Carried at Close of Period, Total	13,432
Accumulated Depreciation	405
Webster Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	7,371
Initial Cost, Buildings and Improvements	243,983
Cost Capitalized Subsequent to Acquisition	4,584
Gross Amount Carried at Close of Period, Land	7,371
Gross Amount Carried at Close of Period, Buildings and Improvements	248,567
Gross Amount Carried at Close of Period, Total	255,938
Accumulated Depreciation	7,464
Wilkes-Barre Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	821
Initial Cost, Buildings and Improvements	4,139
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	821
Gross Amount Carried at Close of Period, Buildings and Improvements	4,139
Gross Amount Carried at Close of Period, Total	4,960
Accumulated Depreciation	146
Yucca Valley Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	901
Initial Cost, Buildings and Improvements	4,788
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	901
Gross Amount Carried at Close of Period, Buildings and Improvements	4,788
Gross Amount Carried at Close of Period, Total	5,689
Accumulated Depreciation	175
Tucson Healthcare Facility II
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	0
Cost Capitalized Subsequent to Acquisition	18,325
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	18,325
Gross Amount Carried at Close of Period, Total	18,325
Accumulated Depreciation	0
Tucson Healthcare Facility III
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	1,763
Initial Cost, Buildings and Improvements	0
Cost Capitalized Subsequent to Acquisition	8,349
Gross Amount Carried at Close of Period, Land	1,763
Gross Amount Carried at Close of Period, Buildings and Improvements	8,349
Gross Amount Carried at Close of Period, Total	10,112
Accumulated Depreciation	40
Grimes Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	831
Initial Cost, Buildings and Improvements	3,690
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	831
Gross Amount Carried at Close of Period, Buildings and Improvements	3,690
Gross Amount Carried at Close of Period, Total	4,521
Accumulated Depreciation	93
Tampa Healthcare Facility
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	10,297
Cost Capitalized Subsequent to Acquisition	0
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	10,297
Gross Amount Carried at Close of Period, Total	10,297
Accumulated Depreciation	100
Tucson Healthcare Facility IV
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Encumbrances	0
Initial Cost, Land	0
Initial Cost, Buildings and Improvements	58
Cost Capitalized Subsequent to Acquisition	849
Gross Amount Carried at Close of Period, Land	0
Gross Amount Carried at Close of Period, Buildings and Improvements	907
Gross Amount Carried at Close of Period, Total	907
Accumulated Depreciation	$ 0

SCHEDULE III - REAL ESTATE AS_3

SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION (SCHEDULE OF REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION - NARRATIVE) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)property	Dec. 31, 2019USD ($)
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Number of properties collateralized under line of credit facility | property	130
Credit facility, principal amount outstanding	$ 938,000	$ 908,000
Aggregated cost for federal income tax purposes	3,060,569
Capitalized acquisition fees and costs	310
Tucson Healthcare Facility IV
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Capitalized acquisition fees and costs	$ 58
Minimum
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Life used for depreciation	15 years
Maximum
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]
Life used for depreciation	40 years

SCHEDULE III - REAL ESTATE AS_4

SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION (SCHEDULE OF REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION - ROLLFORWARD) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate [Roll Forward]
Balance at beginning of year	$ 2,896,766	$ 1,758,326	$ 1,551,194
Acquisitions	14,876	1,151,827	195,328
Improvements	31,260	15,084	11,804
Impairment	0	(25,501)	0
Dispositions	(51,944)	(2,807)	0
Other adjustments	0	(163)	0
Balance at end of year	2,890,958	2,896,766	1,758,326
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation [Roll Forward]
Balance at beginning of year	(128,304)	(84,594)	(45,789)
Depreciation	(69,623)	(48,215)	(38,805)
Impairment	0	4,501	0
Dispositions	793	4	0
Balance at end of year	$ (197,134)	$ (128,304)	$ (84,594)